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The polyglutamine disorders are a subgroup of inherited neurodegenerative 
disorders with a common mutation which confers toxicity via a polyglutamine 
tract in the protein leading ultimately to various forms of neurodegeneration. 
One of these disorders, spinocerebellar ataxia 7 (SCA7) exists at a higher 
frequency in South Africa, than elsewhere in the world, and a founder effect 
has been demonstrated in South Africa, such that every patient tested thus far 
is linked to a common ancestor.  
 
The manipulation of RNA interference (RNAi) has been used with increasing 
success to selectively knockdown the expression of disease-causing genes at 
the RNA level. Thus, the possibility of applying this method to SCA7 in South 
Africa was considered. However, the wild-type allele of ataxin-7 is likely to be 
necessary for cellular function therefore a form of allele-specific silencing is 
required, such as a SNP linked to the mutation. Given the less than desirable 
nature of the SNP itself, extensive screens of twenty different RNAi hairpins 
were performed to identify one that might distinguish between the mutant and 
wild-type alleles. Using different reporter genes and target lengths a hairpin 
was identified that showed significant selective knockdown of the mutant 
transcript in a heterozygous full-length assay. Furthermore, this hairpin led to 
the release of wild-type protein from mutant-forming aggregates, suggesting 
an additional benefit of allele-specific silencing over general knockdown. 
Finally, re-structuring of this hairpin in a primary miRNA based format yielded 
the same selectivity at the same position, strongly suggesting that the designs 
and therefore mismatch placement positions were accurate. These findings 
strongly support previous studies that suggest that single nucleotide mismatch 
placement in the 3’ end of the guide strand may lead to strong discrimination. 
 
Most importantly, as SCA7 uniquely presents with a retinal phenotype in 
addition to the classic cerebellar pathology, the relative accessibility of the eye 
lends itself to efficacious assessment of therapy. This study will therefore form 
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In recent years, disorders of the nervous system have been seen to have an 
increasing impact on the global burden of disease (1) for the most part, due 
to the trend towards aging populations (2). While this is currently more of a 
feature in developed countries, improved medical care in developing nations 
will soon lead to a similar phenomenon, with better health care leading to 
increased life expectancy (2). Neurodegenerative diseases encompass a 
group of nervous system disorders presenting with progressive symptoms 
that last decades, placing a significant financial and emotional burden on 
families. The devastating phenotypes and general lack of meaningful 
therapies thus requires a significant effort towards the investigation of novel 
cures. Given the incomplete understanding of neurodegeneration, an ideal 
subgroup to study is that of the dominantly inherited disorders, since the 
disease-causing mutation sheds light on the mechanism of pathogenesis. 
 
The dominantly inherited neurodegenerative disorders include a plethora of 
distinct as well as phenotypically overlapping diseases. Within this group, the 
subset of polyglutamine disorders constitutes a significant area of research. 
Conditions falling within this subset have a common type of mutation; that of 
an expanded CAG repeat, encoding a stretch of polyglutamines within the 
disease-causing protein. To date, nine polyglutamine disorders have been 
identified; Huntington disease (HD), spinobulbar muscular atrophy (SBMA), 
dentatorubral pallidoluysian atrophy (DRPLA) and the following 
spinocerebellar ataxias, 1, 2, 3, 6, 7 and 17 (3). As a result of the common 
type of mutation these disorders share a variety of features including late 
onset of symptoms, anticipation and instability of repeats in transmission 
from parent to child. The common pathogenic number of repeats in each 
polyglutamine disorder vary, but mostly lie in the 40-60 range, with numbers 
extending into the hundreds (4, 5). The polyglutamine disorders share similar 
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conditions results in presentation of neurodegeneration (3). A common 
feature of all these disorders is that of anticipation, whereby the number of 
repeats beyond the threshold level is inversely proportional to the age of 
onset (AOO) of symptoms, such that larger expansions result in earlier and 
often more severe forms of the phenotype. While the mechanism of 
pathogenesis for each disorder has not been fully elucidated, many common 
features have been identified. The toxic gain-of-function caused by the 
mutant protein is a generally accepted view, possibly due to nuclear 
fragmentation and/or cytoplasmic or nuclear aggregation of the mutant 
proteins, of which the implications of the latter is a highly contentious issue 
(6). The context within which the expanded repeat lies is likely to lead to 
different cell-type susceptibilities based on the function of each of the protein 
coding genes. Thus specific disorders show degeneration of various regions 
of the cerebellum and cortex, consequently leading to different phenotypic 
symptoms. It is therefore possible that research conducted on one of these 
disorders may provide information on others. 
 
With this in mind, we wanted to investigate a possible therapeutic approach 
targeting the mutant gene in SCA7. One of the methods showing success 
with other polyglutamine disorders is the manipulation of the RNA 
interference (RNAi) pathway in order to yield decreased expression of the 
disease-causing gene. Thus, in this study an RNAi based approach was 
investigated specifically for SCA7 patients in South Africa.  
 
1.1. Spinocerebellar ataxia 7 
1.1.1. Phenotype 
The significant heterogeneity between and within families with inherited late 
onset ataxia led to the classification of the different forms of the disorder into 
three different subsets of autosomal dominant cerebellar ataxias (ADCA) 
based on the Harding classification (7); ADCAI, II and III. ADCAII was 
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form of pigmentary retinopathy (8). However in the mid-1990s the 
identification of heterogeneous disease-causing mutations in this and other 
types of ADCA led to a reclassification based on the genotype. Although 
ADCAI and III constitute a variety of genetically different SCAs, ADCAII is 
caused by SCA7 alone (8). A single exception to this classification has been 
identified in which a British family presenting with SCA7 symptoms is 
negative for the SCA7 mutation (9). 
 
A more recent description of SCA7 symptoms includes ataxia, dysarthria, 
dysphagia, and exaggerated deep tendon reflexes, as well as a macular 
degeneration of cone-rod dystrophy (10, 11). In adult onset SCA7, cerebellar 
symptoms usually precede the visual phenotype; however other phenotypic 
signs are evident in the earlier onset (childhood or juvenile) forms of the 
disorder, usually with visual degeneration preceding the onset of cerebellar 
symptoms (12). Juvenile onset SCA7 presents with an early onset of 
symptoms and a more rapid progression of the disorder, but is otherwise 
similar to adult onset SCA7. Infantile onset, however, which occurs before 2 
years of age, can be quite distinct phenotypically (13, 14). Features include 
failure to thrive, weight loss, motor regression, cardiac abnormalities, wasting 
and hypotonia with ataxia difficult to recognise; indeed the infantile onset 
cases appear to involve multiple tissues and organs (14, 15). 
 
1.1.2. Genetics 
Identification of linkage to the short arm of chromosome 3 indicated that 
SCA7 was genetically distinct from other ADCAs (16).  Further investigation 
of some SCA7 families using the repeat expansion detection method (used 
to identify expanded repeats without knowledge of the locus of the mutated 
gene) indicated that an expanded triplet repeat co-segregated with the 
disease (4). Refinement of the previously mentioned area of chromosome 3 
(17) and positional cloning techniques (18) resulted in characterisation of the 













  Chapter 1: Introduction 
 
4
as disease-causing in five different French families with SCA7. A schematic 
representation of the atxn7 is indicated in Figure 1.1. 
 
 
Figure 1.1: Representation of the atxn7 transcript in Vega (BCM:ATXN7-001). This 
transcript represents the most common isoform containing 13 exons, 3.940 Kb with 
892 residues over 135.62 Kb of genomic DNA (19). Alternative transcripts have 
subsequently been identified in humans with homologues in mice (20, 21). Numbers 
represent exons shown with approximate distances between each other. 
 
The normal allele of atxn7 contains CAG repeat numbers ranging from 4 to 
35 with the most common normal sized alleles being (CAG)10, (12, 22) 
although this differs in some population groups (23). Allele sizes within the 
range of 28 to 35 are now considered mutable normal alleles (previously 
known as intermediate alleles) because while there are no reports of SCA7 
being associated with these sizes, they have been shown to expand into the 
pathological range in transmission from parent to child (24). The sizes of 
disease-causing expansions are considered to range from 37 to over 400, 
with the largest expansion identified being (CAG)460 (15). The lower threshold 
is not perfectly defined, however, as results from a family study show 
phenotypic presentations in individuals with 36 repeats (25). Repeats in 
SCA7 show the greatest instability in transmission from parent to child than 
any of the polyglutamine disorders, in particular through the paternal line, 
indicating the predisposition of spermatogenic instability (24, 26) such as that 
indicated in Figure 1.2. The bias of instability in  paternal transmission is not 
unique to SCA7 (27, 28) and may be due to the high mitotic turnover of 
spermatocytes in comparison to oocytes (29). However the extreme cases of 
instability far surpass those of the other polyglutamine disorders with a report 
of a (CAG)49 expanding to (CAG)460 in a single transmission (15). A possible 
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explanation may be that the genomic context within which the atxn7 
expansion lies contributes to the instability of the repeat (30). Evidence for 
this has been demonstrated in a mouse model of SCA7 where the removal of 
intronic sequences within and flanking atxn7, leads to reduced instability in 
transmission to offspring (30).  
 
Figure 1.2: A comparison of the number of repeats identified in blood (top panel) 
and sperm (bottom panel) of a SCA7 patient. PCR products were analysed using 
GENESCAN softwar , where the horizontal axis represents the number of repeats 
and the vertical axis, fluorescent units. Taken from David et al. 1998 (22).  
 
1.1.3. Correlations between genotype and phenotype 
Anticipation is the phenomenon of a decreasing AOO in successive 
generations first observed in patients with HD by Heilbronner in 1903 (31). It 
has since been shown to be caused by an increase in the number of repeats 
in transmission from parent to child (32), and is striking in SCA7, due to the 
previously mentioned dramatic instability of the SCA7 (CAG) repeat. The 
strong correlation between the AOO and the number of repeats has been 
examined extensively (12, 22, 24) and indicates that the repeat number 
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relationship. An increase in the number of repeats has also been shown to 
be associated with a more severe and shorter course of disease (22).  
Generally, patients with smaller repeat sizes (less than 60) present with 
classic ataxic symptoms, later followed by progressive macular degeneration 
(12). Indeed, a patient with only 39 repeats and an AOO of 77 years showed 
no gross macular degeneration, reinforcing this observed trend (33). In 
contrast, patients carrying larger expansions (which constitute a smaller 
percentage of SCA7 patients (12, 22)), and therefore presenting with an 
earlier AOO, present with initial symptoms of macular degeneration, followed 
by progressive ataxia or a dual onset of symptoms. 
 
1.1.4. Pathology 
The pathology of SCA7 correlates with the phenotype in that both regions of 
the cerebellum and the retina show marked degeneration. Atrophy of the 
cerebellum and pons in human studies are typical of SCA7, with the latter 
significantly worse in SCA7 patients than for other SCAs, and found to 
precede atrophy of the cerebellum (11). Specifically, atrophy of the cerebellar 
cortex and dentate nucleus, is noted (34). Extensive loss of the Purkinje cells 
with minimal changes to the granular layer of the cerebellum occurs.  In the 
brainstem, olivocerebellar, spinocerebellar, and pyramidal tracts show 
atrophy with the inferior olive showing noticeable neuronal loss with gliosis. 
Pyrimidal pathways and motor neurons in the spinal cord are also affected. 
Degeneration of the subthalamic nucleus, globus pallidus and substantia 
nigra is variable, and seen in some patients (34). Other pathologies include 
neuronal loss in brainstem cranial nerve motor nuclei (III, IV, XII), and 
demyelination of pyramidal tracts and posterior columns of the spinal cord 
(11). Inclusion formation has been reported in affected areas, notably in the 
inferior olive, however they are also found in some areas of the cerebral 
cortex not affected in SCA7 brains, although this study reported an early 
onset case (35). In contrast, cases of severe infantile onset SCA7 show 
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The retinal phenotype occurs as a result of the degeneration of the cone and 
rod photoreceptor neurons in the retina – one of the few disorders 
characterised by cone followed by rod photoreceptor degeneration (36). The 
retinal phenotype appears as macular degeneration, but is caused by 
photoreceptor dysfunction of initially the cones, followed by the rods, leading 
to the disorder being incorporated into the group of cone-rod dystrophies. 
Central vision is initially impaired as indicated by a decrease in colour 
discrimination (37, 38). The loss of vision then proceeds to the entire retina, 
as dysfunction of the rods follows that of the cones, leading to total 
blindness.  
 
1.1.5. Function of the normal protein 
The normal protein has been studied by several groups with some success 
as to the characterisation and the identification of the function of the protein. 
Initial investigations of the atxn7 gene product (ATXN7) indicated that it 
localised to the nucleus due to the presence of an arginine-lysine nuclear 
localisation signal (NLS), whose activity was demonstrated in transfected 
Cos-1 cells (39). In addition the protein was shown to contain a phosphate 
binding site (40). Both of these domains are conserved in the murine 
homologue of ATXN7, which has 88% homology to the human sequence 
(41). In addition, the protein has been found to possess a highly conserved 
nuclear export signal (42) which in addition to the NLS suggests a nuclear-
shuttling role for ATXN7 (43). Immunoreactivity for the 95 kD protein has 
been found the nucleus of Purkinje cells, although both cytoplasmic and 
nuclear staining has been identified in non-cerebellar neurons (44). The 
distribution of the normal protein indicates ubiquitous expression throughout 
the neurons of the nervous system, as well the retina, in addition to 
expression of atxn7 in several non-neuronal tissues (45). The only tissues 
tested that did not show immunoreactivity were the liver and kidney. 
Jonasson and colleagues refined these data by comparing their data with 
that of other studies (46). They indicated that there may be an age-
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individuals, with nuclear staining present earlier followed by cytoplasmic 
staining later in life. However the data for these controls is not conclusive and 
since the studies on the five different controls were performed by four 
different groups, this would need to be verified (46). Subcellular localisation 
shows co-localisation with cytoplasmic organelles such as the endoplasmic 
reticulum and nuclear envelope, but with neither the mitochondria nor the 
golgi (45).  
 
Yeast 2-hybrid studies looking for ATXN7-interacting proteins identified R85, 
a splice variant of Cbl-associated protein as well as an ATPase subunit S4 of 
the 19S proteasomal complex (47, 48). The former suggested a possible role 
for the ubiquitination and degradation of ATXN7, whilst the latter indicated 
proteasome inhibition, which is known to cause aggregation and neuronal 
intranuclear inclusions (NIIs) in in vitro polyglutamine models such as SCA3  
(49).  
 
Subsequently, several studies have proposed that ATXN7 is involved in 
transcriptional regulation. In 2001, a study revealed that ATXN7 interacted 
with the cone-rod homeobox (CRX) protein – a photoreceptor cell-specific 
transcription factor (50). Although the exact function of CRX is unknown, 
mutations in the gene coding for the latter are responsible for retinal 
degenerative disorders (51). Biologically, many of these mutations have been 
shown to result in dysregulated expression of the photoreceptor genes. 
Furthermore a knockout mouse model of Crx (the mus musculus homologue 
of CRX) develops retinal degeneration due to impairment of photoreceptor 
cell development (52). In 2004 interacting domains of CRX and ATXN7 were 
mapped using various deletions and point mutations and indicated that the 
CRX/ATXN7 interaction occurs via their respective polyglutamine tracts 
present in the wild-type proteins (36). It was further indicated that CRX and 
ATXN7 co-occupy a regulatory region of the CRX target genes regulating 
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A second hypothesis for the role of ATXN7 in transcriptional regulation came 
from the identification of a yeast homologue which showed significant 
similarity to a gene identified as a novel subunit of the histone 
acetyltransferase (HAT) Spt/Ada/Gcn5/acetylase (SAGA) complex - 
responsible for approximately 10% of transcription regulation of the yeast 
genome (53). The following year the ATXN7 protein was identified as a 
subunit of GCN5 HAT of the transcriptional co-activator complexes, TATA 
box binding protein (TBP)-free TBP associated factor (TAF) containing 
protein TFTC, and SPT3/TAF9/GCN5 acetyltransferase complex STAGA; the 
mammalian equivalent of the yeast SAGA complex (54). These complexes 
contain several proteins except TBP, making it distinct from the general 
transcription factor TFIID and preferentially acetylate histone H3 and activate 
transcription on chromatin templates (54). Indeed it has since been 
demonstrated that an in vivo interaction between STAGA and ATXN7 exists 
and is functional, based on the HAT activity of GCN5 (55). 
 
1.1.6. Pathogenesis 
A common point of discussion within the area of research of polyglutamine 
disorders is that of the mechanism of pathogenesis; whether it be solely a 
gain-of-function due to the accumulation of toxic protein fragments, or 
alternatively whether loss-of-function of the wild-type allele contributes to 
disease pathogenesis. Certainly, it is generally accepted that the gain-of-
function accrued by the toxic mutant protein contributes towards and results 
in cell death in all the polyglutamine disorders. However, the precise manner 
in which the mutant protein which causes toxicity is unknown. Many studies 
have explored cell-specific vulnerability, expression, aggregate formation and 
other possible mechanisms of pathogenesis without definitive outcomes. In 
addition the extent to which loss of function may contribute towards disease 
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1.1.6.1. Expression and aggregation 
For the most part there has been difficulty identifying a correlation between 
the level of expression, cell-type expression and aggregate formation with 
respect to the neuropathology observed in SCA7 patients. This is most 
strikingly demonstrated by the ubiquitous expression of atxn7 contrasting 
sharply with specific sub-types of neurons affected by the disease process 
(45). Furthermore there is no relationship between levels of expression and 
the degree of degeneration suggested by the strong immunoreactivity of 
ATXN7 in the external pallidum compared with the weak presence of the 
protein in the Purkinje cells, both severely degenerated in SCA7 patient 
brains (see Figure 1.3, page 21, (56)). The only correlating observation made 
was the increase in loss of neurons with nuclear labelling. However this 
hypothesis is weakened due to the lack of a direct relationship between cells 
containing inclusions and cell death. While almost all cells with inclusions 
showed high levels of expression, the converse did not follow in many 
situations such as the lack of inclusions in the putamen and pallidum, which 
had shown high levels of expression.  
 
One of the most controversial areas within the field of polyglutamine 
disorders research is the consequence of aggregate formation within specific 
neuronal cell types, i.e. are the aggregates protective, causative or simply 
associated with neuronal death?  Aggregation in the form of NIIs has been 
identified in multiple neuronal cell types  (35, 39, 44, 46, 56) and these 
inclusions appear large and at the ultra-structural level, filamentous, a feature 
regarded as specific to the glutamine expansion (57). These NIIs have been 
shown to be for the most part, ubiquitinated, indicating that the inclusions are 
recognised by the ubiquitin proteasome system (UPS) but are in some way 
resistant to degradation (35, 56). Interestingly, a patient with 41 repeats (who 
died at 92 years of age) was shown to have no inclusion formation, whilst a 
patient from the same kindred with 42 repeats did show evidence for 
inclusion formation, suggesting other factors were involved in the formation 
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SCA7 spreads to non-neuronal tissues such as the cardiovascular system 
which is known to be a component of the broad systemic phenotype of 
infantile cases (58). These inclusions were shown to be non-ubiquitinated. 
However, strongly ubiquitinated inclusions were identified in the 
hippocampus of the same individual; an area demonstrating a striking lack of 
cellular loss. ATXN7 NIIs have been shown to form in nuclear bodies and 
recruit proteins including those involved in the UPS as well as chaperones 
(47, 48, 59) although the impairment of the UPS was examined in vivo and 
shown not to be involved in disease pathology. Indeed this study strongly 
suggests that NIIs are protective (60).  
 
1.1.6.2. Studies of the mutant protein 
In a study by Zander and colleagues, extensive observations of ATXN7 were 
made using comparisons of in vitro cellular models (42). Using various 
constructs of full-length and truncated, mutant and wild-type atxn7 cDNA 
fused to multiple tags, the authors were able to investigate the localisation 
and interactions of both wild-type and mutant ATXN7. Firstly, they showed 
that the protein in its normal form is predominantly nuclear, confirming a 
functional nuclear localisation signal (NLS) initially identified by Kaytor and 
colleagues (39), and that no aggregates were found in human embryonic 
kidney cells (HEK293) transfected with the normal (CAG)10-containing vector. 
However, nuclear and peri-nuclear inclusions were formed in the same cells 
transfected with the mutant (CAG)100 full-length vector. Interestingly, cells 
sub-cloned from a human neuroblastoma cell line did not show as high 
expression levels of transfected ATXN7, nor as extensive aggregate 
formation. Ultrastructural examination provided evidence for the fact that the 
aggregates formed by ATXN7 were fibrillar in nature. Furthermore, the study 
showed that the aggregate formation in the in vitro cellular model did not 
require cleavage of the protein, in that both terminals of the protein could be 
identified in vitro, however in SCA7 brains, most of the NIIs were only 
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processing of the protein had occurred in vivo. This is not a phenomenon 
unique to SCA7 (61).  
 
Importantly, the study by Zander et al. also examined the proteins recruited 
by the ATXN7 inclusions (42). Experiments using co-transfection of mutant 
and wild-type vectors showed that the mutant ATXN7 recruits its wild-type 
counterpart into the aggregates. Further investigation indicated that several 
other proteins are recruited into the inclusions of SCA7 patient brains, 
mimicked by the in vitro model (42). The first of these, the SCA3 protein 
(ATXN3), reinforces previous studies that proteins containing polyglutamine 
stretches are recruited by inclusions caused by other polyglutamine proteins. 
Other examples include an abundance of heat shock protein (Hsp) -40 and 
ubiquitin, as well as proteasome subunits, although a discrepancy lies in the 
fact that the 19S subunit was detected in the SCA7 brain, whilst the 20S 
subunit is detected only in the transfected cells. The latter aside, the 
aforementioned folding proteins suggest that an effort towards refolding/ 
disaggregation/ degradation of the mutant proteins is made by the cell but is 
none-the-less unsuccessful. Low levels of activated caspase-3 were also 
detected in both models. Indeed comparisons of SCA7 and non-SCA7 brains 
indicated a substantial and statistically significant increase in the level of 
activated caspase-3 in the former, which would suggest the initiation of a 
cell-death pathway. This is pertinent given that mutant ATXN7 has been 
shown to cause apoptotic cell death in primary cultures of cerebellar neurons 
by induction of caspase-3 and -9 (62). However the Zander et al. study (42) 
also noted several morphological changes within cells forming ATXN7 
positive inclusions such as irregular shaped nuclei as well as ultrastructural 
observations such as nuclei with indentations often associated with 
membrane disruption and multiple organelle abnormalities such as swollen 
mitochondria and enlarged cisternae of the Golgi complex associated with 
proximal autophagic vacuoles. These observations indicate early signs of 
cells in distress reminiscent of an autophagic (non-apoptotic) cell death 
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neuronal cell types. Further analysis of these cells showed 10-20 times 
retarded growth, compared to minimal effects by the addition of only the wild-
type vector, suggesting a response of the cell to both expression of the 
mutant protein, as well as the effects of aggregation. 
 
1.1.6.3. Alteration of transcription 
Since the wild-type protein has been shown to be affected by the presence of 
the mutant, there is a suggestion that loss of function of this transcription 
subunit would lead to undesired phenotypic effects. Alternatively transcription 
could be affected by the dominant negative effects of the mutant protein.  
 
Given that ATXN7 has been shown to recruit and interact with retinal-specific 
transcriptional complexes, it follows that disruption of the recruitment would 
lead to dysfunction of retinal-specific genes. Although ATXN7 had been 
shown to be a subunit of the transcriptional activator complex, STAGA (54), 
the introduction of the expansion did not prevent complex formation. 
Experiments in yeast showed that while human ATXN7 could rescue SAGA 
formation in the absence of yeast Sca7, expanded human ATXN7 forms a 
dysfunctional SAGA complex (63). This complex retains its HAT activity, but 
has reduced interactions of crucial proteins, allowing for acetylation of free 
histones, but not nucleosomes, suggesting the alteration of transcription of 
certain genes. In an accompanying paper this mechanism of mutant ATXN7 
pathogenesis was further elucidated as indicated by the ascertainment of 
GCN5 HAT activity which is removed with the addition of atxn7_92Q but not 
a truncated form of atxn7_92Q (55). Furthermore, the authors showed an in 
vitro as well as in vivo association of STAGA and CRX, dependent on the 
presence of ATXN7. Interestingly, knockdown of atxn7 resulted in decreased 
levels of GCN5 and STAF36 (another component of STAGA), and that the 
resultant lack of HAT activity could be rescued by the addition of histone 
deacetylase (HDAC). In vivo experiments showed a discrepancy between 
consistently reduced CRX occupancy on CRX-dependent promoters as 
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substrate of GCN5) on CRX dependent genes. This led the authors to 
suggest that an effect of polyglutamine ATXN7 on CRX could not be solely 
responsible for the transcriptional dysregulation observed. Taken together 
the study contributed not only to the understanding of the normal function of 
ATXN7, but in addition to the complex effect of the polyglutamine protein. 
Indeed the authors suggest that while it is not clear whether expanded 
ATXN7 replaces normal ATXN7, or interferes with the latter’s associations, it 
is clear that it causes a dominant negative effect upon retinal transcription, 
contributing to the understanding of the unique retinal-specific degeneration 
in SCA7.  
 
1.1.6.4. Nuclear localisation and cleavage 
Trafficking into and out of the nucleus appears to be a common theme of 
polyglutamine disorders (64, 65). In their study Taylor and colleagues 
showed that a point mutation in the conserved nuclear export signal (NES) of 
ATXN7 resulted in cellular toxicity, in addition to which the mutant protein 
was shown to have a reduction in its ability to export from the nucleus in a 
polyglutamine-length dependent manner. This lends itself to the hypothesis 
that the accumulation of the mutant protein in the nucleus may lead to mild 
toxicity which is evident over a longer time period – resulting in a late onset 
of symptoms (43).  
 
Cleavage of the mutant protein into truncated N-terminal fragments has been 
suggested as contributing to pathogenesis in other polyglutamine disorders 
(66-69). Hinting at a similar mechanism in SCA7, ATXN7 NIIs in animal 
models show the presence of truncated fragments (70) (Chapter 1.1.7.1). 
Recently it was shown that caspase-7 cleaves ATXN7 (71). Cleavage results 
in increased toxicity in vitro as well as the accumulation of NIIs and 
transcriptional repression. Interestingly though, this cleavage position results 
in the disruption of the NES, creating accumulation of the fragment in the 
nucleus. They further showed that expanded ATXN7 activates caspase-7 in 
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(70) thus indicating that capase-7 would likely act in vivo to create the 
observed fragments. Prevention of this cleavage can result in reduced 
toxicity, as is the case with other polyglutamines suggesting a common 
contributing mechanism of pathogenesis for the polyglutamine diseases (71), 
but as has been previously shown, cleavage does not prevent aggregation in 
vitro (chapter 1.1.6.2), further reinforcing the lack of a correlation between 
aggregation and toxicity.  
 
1.1.6.5. Contribution of larger normal alleles 
While most studies have centred on expanded polyglutamine proteins 
beyond a defined threshold level, one study has investigated the implications 
of larger normal (LN) alleles. Investigation of a cohort from Southern India 
showed that a population of patients with ataxia symptoms (negative for 
expansions in SCA1, 2, 3, 7 and DRPLA) had a significantly higher frequency 
of LN alleles (23). For instance the most common normal allele in this group 
for the SCA7 locus was (CAG)15. Many of these individuals had LN alleles at 
more than three of the aforementioned loci, indeed, over 75% had LN alleles 
at more than two loci, while none of the control individuals had LN alleles at 
more than two loci. G ven that sequestration of transcription factors 
(theorised to give rise to pathogenesis) occurs due to accumulation of 
polyglutamine proteins, the authors suggest that a possible mechanism of 
disease could be caused by not one polyglutamine protein in the traditional 
defined expanded range, but by many LN polyglutamine proteins. While 
these results are intriguing, this study is the only investigation to hypothesise 
such a mechanism and has yet to be validated experimentally or by other 
studies of polyglutamine disorders.  
 
1.1.7. Lessons from in vivo models 
In an elegant paper in 2004, Helmlinger and colleagues posed the following, 
“It remains to be determined at which stage polyglutamine expansions induce 













  Chapter 1: Introduction 
 
16
strategies interfering with polyglutamine protein expression. Finally, it is not 
known whether neurons can recover from the toxicity of full-length mutant 
proteins and whether these results can be extended to other polyglutamine 
disorders” (72). Hence it is of utmost importance to be aware of the detailed 
phenotype of animal models of the disease, in order that we might be able to 
assess the efficacy of interventions as well as gain a deeper understanding 
of the mechanism of disease. 
 
1.1.7.1. Mouse models 
Three groups have created transgenic mouse models in an attempt to mimic 
the SCA7 phenotype. The first designed several transgenic lines created 
using full-length human atxn7 cDNA containing 10 or 90 (CAG) repeats 
expressed off either the photoreceptor-specific rhodopsin promoter (R7N/E) 
or the Purkinje cell-specific (pcp-2) promoter (P7N/E) (73). Mice expressing 
the expanded sequence from these two promoters developed retinal and 
locomotor deficient phenotypes respectively. R7E mice showed several 
manifestations of retinal pathology including severe disorganisation of the 
outer nuclear layer (ONL), and a reduction in the percentage of 
photoreceptor cells. Interestingly, in addition to demonstrating progressive 
retinal degeneration as well as profuse NII formation, the mice showed 
morphological changes in interneurons (postsynaptic to the targeted 
neurons) suggesting a possible explanation for a trans degeneration of 
neurons with minimal atxn7 expression. In the P7E mice, Purkinje cells 
showed NIIs after eight months, and by 16 months, almost all these cells 
contained NIIs. The phenotype was less obvious, in that there were no visible 
abnormalities in the mice after 1 year possibly due to the low expression 
level of the transgene under the pcp-2 promoter. However, a rotarod 
performance test showed that P7E mice performed significantly worse than 
their wild-type littermates. The pathological changes in these mice were also 
less noticeable than those in the R7E mice, however, reduced dendritic 
arbour – indicative of unhealthy neurons - and a decreased Purkinje cell 
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be positive only for the N-terminal ATXN7 antibody, and not the C-terminal 
antibody, suggesting that some form of proteolytic cleavage of the mutant 
protein may be occurring as is the case in SCA7 brains (42). Redesigning the 
transgene construct to incorporate 128 repeats expressed off a stronger 
promoter resulted in. the mice developing ataxia a few months after birth, 
with death within 3 months of the onset of symptoms (74). It was shown that 
localisation and processing - including N-terminal fragment accumulation and 
stabilisation of ATXN7 by the expansion resulting in decreased turnover of 
the mutant protein - was the same through spared and unspared areas of 
neurodegeneration. Finally it was noted that NIIs sequestered many proteins 
of the transcriptional pathway confirming findings from a previous in vitro 
study (42).  
 
The R7E mouse model was also used to investigate the involvement of 
chaperones in the pathogenesis of SCA7. Previous studies of drosophila 
models of polyglutamine disorders and in vitro cellular models (75, 76) had 
shown that increased expression of specific heat shock proteins has 
beneficial effects. However, although increased expression of Hsp40 and 70 
reduced aggregate formation in vitro, no reduction occurred in vivo (77). The 
authors suggest that while the expression of specific chaperones may not 
ameliorate pathogenesis, indication of a global heat shock response may be 
more successful. This data is intriguing in light of the fact that a later study 
showed decreased protein levels of Hsp27 and 70 in patient lymphoblasts 
(78). Given the lack of correlation between in vivo mouse models and in vitro 
human cell lines, this aspect of SCA7 pathogenesis warrants further study.  
 
A second study (72) adapting the aforementioned mouse model (74) 
investigated at which point irreversible neuronal damage occurs after 
exposure to polyglutamine proteins, using double transgenic mice, R7N-R7E. 
These mice expressed both full-length normal (R7N) and expanded (R7N) 
human atxn7 specifically in the retina under the transcriptional control of the 
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phenotype was caused by a general polyglutamine effect due to the 
observation of retinopathy in an HD mouse model. Experiments using this 
mouse model showed that the disappearance of normal recombinant atxn7, 
when expressed in combination with R7E was not due to recruitment of 
normal ATXN7 by the expanded polyglutamine protein. Rather, given an 
associated decrease in normal atxn7 mRNA levels, the presence of 
polyglutamine proteins appears to cause transcriptional dysregulation of the 
Rho promoter. Moreover it was shown that expression of the mutant atxn7 
was also reduced; indeed they noted a reduction in expression to minimal 
levels of 1% after just 9 weeks without alleviation of retinopathy and eventual 
but not complete clearance of aggregate formation.  
 
Given that CRX is involved in the transcription of photorecepter specific 
genes such as Rho, and that HD polyglutamine can also suppress Rho 
promoter activity, this study suggests that retinal dysfunction in SCA7 cannot 
be completely explained by the ATXN7/CRX interaction reported by La 
Spada and colleagues (50). It follows that mutant ATXN7 may cause 
irreversible transcriptional dysregulation, and this in conjunction with the 
comparatively slow removal of aggregates results in continued disease 
progression.  
 
The R7E mouse has been used in other studies in comparison to the 
transcriptional changes that occur in the SCA1 knock-in mouse model. In 
2006, a study demonstrated that the neuronal differential programme of 
photoreceptors in SCA7 and HD mice was altered due to transcriptional 
alterations of certain rod-specific genes (80). This is in addition to the 
investigation of the effect of SCA7 pathogenesis leading to altered neuronal 
fate and function by way of activation of the JNK/c-Jun stress pathway (81). 
A third study proposed that since there are significant overlaps between 
SCA1 and 7 in phenotype and pathology, there may be a common 
pathogenic mechanism contributing to disease (82). Using microarray 
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like growth factor (IGF) pathway in a response likely due to neuronal injury. 
Because this down-regulation occurred in the cerebellar granular layer, it is 
suggested that non-cell-autonomous degeneration of the Purkinje cells might 
occur due to this change in the granule neurons. While this is acknowledged 
not to be the primary cause of disease, the commonality between the two 
models may represent a common pathogenetic result, a finding important in 
the context of other polyglutamine disorders.  
 
The second group to create a SCA7 mouse was La Spada and colleagues 
(50). Using a neuron-specific promoter, they were able to create transgenic 
mice expressing the full-length human atxn7 containing either 24 (Prp-SCA7-
c24Q) or 92 (Prp-SCA7-c92Q) repeats directed specifically to allow high 
levels of expression in neurons. The authors noted that the mice showed 
ATXN7 NIIs in the retina and demonstrated a specific con-rod dystrophy 
phenotype as well as a complex neurological phenotype including gait ataxia 
and involuntary movements. Progressive thinning of the ONL with significant 
loss of cone photoreceptors was observed, as well as activation of Muller 
cells (the retinal counterparts of the astrocytes in the central nervous system 
(CNS)) indicating that some injury was taking place resulting in dysfunctional 
neurotransmission in the retina. Positive TUNEL staining indicated that 
apoptosis may also contribute towards the reported ONL thinning. In 
summary, it is suggested that the loss of photoreceptor cells cannot 
completely account for this severe retinal phenotype, and hence it is 
suggested that cellular dysfunction is the primary cause of the complete 
blindness in these SCA7 mice.  
 
The neurological examinations of these mice (70) indicated little to no 
expression of ATXN7 protein in the Purkinje cell layer although these cells 
were seen to degenerate rapidly. This suggests a possible non-cell-
autonomous degeneration whereby deficits in neighbouring cells result in 
degeneration of the Purkinje cell layer (Figure 1.3, page 21). Furthermore, 
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present in the NIIs. Interestingly, the appearance of these NIIs coincided with 
the presentation of ataxic gait symptoms in the mice indicating a possible 
pathogenic role for the nuclear localisation of a truncated fragment.  
 
Given that the cell bodies of Bergmann glia surround Purkinje cells, the 
aforementioned transgenic mice were manipulated in order to express the 
full-length mutant and wild-type human atxn7 genes only in the former cells 
(83). Remarkably, these mice developed ataxia and neurodegeneration. 
Since Bergmann glia are known to remove glutamate from Purkinje cells, the 
authors investigated the effects of GLAST (the Bergmann glia-specific 
glutamate transporter). A significant reduction in GLAST was noted in mutant 
mice, which impaired glutamate transport in Bergmann glia cells, cerebellar 
slices and cerebellar synaptosomes. In addition, the Purkinje cell 
degeneration that was evident suggested excitotoxic injury. This study has 
greatly contributed to the understanding of the degeneration of Purkinje cells 



















Figure 1.3: Purkinje cell degeneration in SCA7. (a) Immunohistochemistry with anti-
ATXN7 (magenta), calbindin (green) and DAPI (blue) antibodies. Note the reduced 
dendritic arborisation and displaced Purkinje cells in the SCA7 mouse compared to the 
control.  Neurons in the granule cell layer (GCL) and the molecular layer (ML) contain 
aggregates of ATXN7, while mutant ATXN7 is not present in degenerating Purkingje 
cells; thus indicating a non cell-autonomous process. (b) Expression of mutant ATXN7 is 
sufficient to induce Purkinje cell degeneration. Immunohistochemistry analysis 
performed using anti-ATXN7 (green) and anti-calbindin (red) antibodies. Note that both 
non-transgenic (NT) mice and mice transgenic for atxn7 containing only 10 repeats 
(10Q) have normal cerebellar cytoarchitecture; whereas mice transfected with atxn7 
containing 92 repeats (92Q) have reduced ML thickness, misaligned Purkinje cell layer 
(PCL) and tortuous Purkinje cell dendrites. ATXN7 expression is diffuse in 10Q PCL, 
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The third group to create a SCA7 mouse is that led by Huda Zoghbi. The 
only knock-in mouse created thus far, incorporated 266 CAG repeats in the 
murine Sca7 gene, which normally contains 5 repeats (84). Repeat sizes 
over 200 generally result in infantile onset of SCA7 symptoms and the 
Sca7266Q/5Q mouse recapitulates many of the human infantile symptoms, a 
broad, rapidly progressive and severe form of the late onset disorder. The 
progressive cone-rod dystrophy phenotype includes a decrease in several 
retinal-specific genes; indeed, Rho knockout mice have a similar retinal 
pathology (85). However cell loss is not as extensive as has been reported in 
other transgenic models (50, 73). Expression analysis indicated that not all 
downregulated genes corresponded with those affected by CRX removal, 
further evidence that CRX may not be the sole factor involved in the specific 
retinal degeneration. Further experiments reiterated the stabilisation of - and 
thus inability of the cellular machinery to degrade - the mutant protein also 
observed by Yvert and colleagues (74). Finally the study indicates that the 
NIIs are unlikely to be required for pathogenesis, but rather observations of 
accumulated mutant protein tagged by ubiquitin and Hsp70, and precursors 
of NIIs, correspond with increased neuronal sensitivity and death.  
 
Using the same mouse model Bowman and colleagues examined the 
impairment of the UPS in vulnerable neuronal cell populations because 
aggregates had previously been shown to be resistant to degradation (60). 
The Sca7266Q/5Q mouse was crossed with a well documented UPS reporter 
mouse. High levels of the reporter gene (fused to green fluorescent protein; 
GFP) in the latter model indicated a dysfunctional UPS, whilst low levels 
presented functional UPS by way of the high degradation of the reporter 
protein. Although high levels of GFP were noted in the adapted knock-in 
model, these levels were shown to correlate with a dramatic increase in 
mRNA, thus exempting a dysfunctional UPS. Interestingly, the increase in 
transcription of the gene correlated with vulnerable neurons and the 
expression was shown to be directly proportional to cell specific 
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reporter of neuropathology was inversely related to NII formation 
strengthening the hypothesis that NIIs are neuroprotective, until such time as 
the toxicity overwhelms the cells and causes cell death.  
 
1.1.7.2. Drosophila model 
Latouche and colleagues assessed a drosophila SCA7 model in which they 
induced expression of expanded atxn7 only within the neuronal cells (86), in 
order to distinguish between developmental defects caused by ubiquitous 
over-expression and specific neuronal effects. The dual aims of the study 
were to identify potential modifying genes affecting the SCA7 phenotype, as 
well as to assess the effect of inducing repression of the toxic protein in order 
to determine whether a normal phenotype could be restored. To allow for 
quicker and increased levels of expression, the study used a truncated form 
of atxn7 in the fly model. The model demonstrated a reduced lifespan as well 
as locomotor dysfunction and limited cell death. Due to the latter, the authors 
suggested that the formation of NIIs (which co-immnoprecipitated with the 
same proteins previously linked to NIIs) may be the cause of the cell 
dysfunction. Removal of induction of the expanded ATXN7 protein, showed a 
significant time dependent increase in the life span of the flies as well as a 
decrease in the number of NIIs. Although it was removed after day two, this 
apparent clearance of NIIs only occurred after 14 to 20 days after induction, 
and although these flies died later than their continuously expressing 
counterparts and showed significant improvement in motor function, the data 
reiterates Helmlinger’s study (72) that irreversible pathogenic events had 
taken place.  
 
While this study addressed many aspects of the mechanism of degeneration, 
it should be noted that a model expressing a truncated form of a mutant 
polyglutamine protein yields only the ability to assess the effects of a toxic 
gain-of-function effect. The most accurate model of any disorder would be 
that of a transgenic model mimicking the natural situation and thus allowing 
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effects of a possible loss-of-function due to alteration of the protein’s 
secondary structure as is the case with the Zoghbi mouse model (84). 
 
1.1.8. SCA7 in South Africa 
Globally, SCA7 represents one of the rarer polyglutamine disorders with a 
prevalence of less than 1:100 000, in comparison to the other dominantly 
inherited ataxias (87, 88). However the situation in South Africa is different, 
such that SCA7 constitutes one of the more prevalent forms of the disorders 
(Figure 1.4), as is the case in Scandinavia (89). While it remains a rare 
disorder in comparison to infectious diseases, the SCA7 situation in South 
Africa has further unique attributes in that it is only found in the Black African 
population group (Figure 1.4) (90). This is in contrast to the rest of the world 
where most SCA7 patients reported are of Caucasian, Arabic or North 
African (non-Black) descent (24). Only one family of black African descent 
outside of South Africa has been reported (13). The allele sizes of South 
African SCA7 patients range from 6 – 15 in the normal range and 42 – 92 in 
the expanded range in line with those documented globally (90). The mean 
age of onset in South Africa is 20.3 years (S.D. = 11.84, r = 5–39 years) (90). 
 
Following the study by Bryer and colleagues, a second study in South Africa 
indicated that all the families with SCA7 shared a common ancestor (91). 
The presence of founder effects in South Africa is not uncommon, indeed, 
the variegate porphyria gene is considered one of the classic founder effects 
(92). Recently, another polyglutamine gene, which had previously been 
hypothesized to have a founder mutation in South Africa, was proved using 
molecular marker analysis (93). However these founder effects were 
identified in the Cape, a region known to have a significant sudden migrant 
influx in the 1600’s thus explaining the presence of the common ancestor 
theory. In contrast, the founder effect identified for SCA7 showed that the 
families were from different geographical origins within the country (91). 
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remains that all the patient samples available in the UCT database to date 


































Figure 1.4: Ethnic distribution of the families in SA that tested positive for one of the 
five SCA expansions tested for at the UCT/NHLS laboratory in January, 2007. B = 
black African, MA = Mixed ancestry, C = aucasian. I = Indian, U = Unknown. Data 
compiled using the University of Cape Town Human Genetics Laboratory database 
from de-identified and coded samples.   
 
 
1.2. RNAi  
RNA interference (RNAi) is a powerful endogenous gene silencing 
mechanism triggered by double-stranded RNAs (dsRNA) which are present 
in various forms including small interfering RNAs (siRNAs) and 
endogenously encoded microRNAs (miRNAs). These small, 19 – 25 
nucleotide (nt) RNAi effectors trigger silencing in a sequence specific manner 
resulting in knockdown of the target mRNA. While siRNAs have traditionally 
been exploited for use by investigators to ascertain the functions of specific 
genes and as a therapeutic method to silence disease genes, miRNAs are a 
crucial component of the endogenous pathway responsible for the fine-tuning 
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1.2.1. History of discovery 
While the focus of this thesis is not the endogenous RNAi pathway, the 
context in which RNAi-based therapy falls requires a thorough understanding 
of this mechanism. In the years leading up to the discovery of RNAi, a 
mechanism of ‘co-suppression’ was identified in plants. Puzzling to 
researchers at the time, the introduction of transgenes coding for the purple 
pigment in flowers yielded reduced rather than increased levels of 
pigmentation (94, 95). This was reiterated in drosophila with the adh gene 
(96). Baulcombe and colleagues then made the important discovery that 
RNA was the common target inducing a similar mechanism between viral-
induced gene silencing and transgene silencing, even suggesting that 
dsRNA may be required (97). Studies prior to 1998 had shown that antisense 
RNA could be used to specifically suppress levels of expression of 
endogenous genes but required high levels of expression themselves in 
order to be efficient (98). Conversely, others had shown that introducing the 
sense RNA strand also resulted in suppression (99). It was the Nobel 
laureates, Andrew Fire and Craig Mello who were able to show that gene-
specific knockdown was triggered by dsRNA in animals (C. elegans) and that 
the mechanism was catalytic in nature such that the presence of only a few 
copies of dsRNA resulted in significant and specific knockdown that was 
transferred to the first generation progeny (100). As a result of the noted 
catalytic or amplificatory mode of action, they further suggested that 
“Whatever their target, the mechanisms underlying RNA interference 
probably exist for a biological purpose.” However, the same long dsRNA 
triggered an antiviral immune response in mammals resulting in non-specific 
mRNA destruction and inhibition of protein synthesis (101). The suggestion 
that RNAi might be guided by short 21-25 nt dsRNA species (102) led to the 
discovery that short 21-23 nt dsRNA fragments could be used to initiate RNAi 
in mammals (103) and that chemically synthesized siRNAs could be used to 
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1.2.2. Mechanism of action 
The RNAi pathway is triggered by the following mechanisms; exogenous 
double-stranded RNA, including viral RNA, endogenous dsRNA and selfish 
genetic elements such as transposons. As such there are many different 
small non-coding dsRNAs responsible for these different functions. For the 
purpose of this review, the following discussion will centre on the small 
dsRNAs relevant to this investigation; small interfering RNAs (siRNAs), 
microRNAs (miRNAs) and short hairpin RNAs (shRNAs). The differences 
between these two are vitally important (extensively reviewed in Rana 2007 
(105). Figure 1.5 shows an example of the endogenous miRNA pathway 
coupled with the various points of introduction of exogenous siRNAs.  
 
Primary miRNA (pri-miRNA) transcripts are expressed off RNA polymerase II 
(Pol II) promoters (although Pol III promoter driven expression has been 
identified (106)) from various regions of the genomic DNA, occasionally 
occurring in clusters (105). These transcripts resolve into a folded secondary 
structure, resembling a hairpin formation with a stem of approximately 33 nt 
with flanking single-stranded sequences. This relatively conserved general 
structure is then associated with the microprocessor complex, Drosha-
DGCR-8 (DiGeorge critical region-8). DGCR-8 is a co-factor that recognises 
and binds the pri-miRNA while Drosha (an RNase III enzyme) cleaves the 
structure approximately 11 bases from the junction of the stem and the 
flanking ssRNA (107, 108). It is this precise anchoring of DGCR8 at the 
junction between the flanking ssRNA and dsRNA stem rather than the 
relative position of the terminal loop that has been shown to determine the 
site of cleavage by Drosha (107). 
 
The resultant precursor miRNA (pre-miRNA) with a two nt overhang is 
transported across the nuclear membrane by exportin-5 (109, 110). At this 
point, a second RNase III enzyme, Dicer cleaves the loop approximately 22 
nts from the base of the stem, resulting in a small RNA duplex with 
characteristic two nucleotide overhangs on the 3’ ends (111). The exact 

















Figure 1.5: Various entry points of manipulation of RNAi in mammalian cells. The 
diagram shows how to manipulate the RNAi pathway in order to achieve knock 
down. 1. Viral or DNA plasmid vectors can be introduced into the cell nucleus to 
result in stable expression of hairpin structures. These can be designed to mimic pri-
miRNA based hairpins which are processed by the Drosha-DGCR8 complex into 
pre-miRNA based hairpins expressed off Pol II promoter. Alternatively, shRNAs can 
be designed to resemble the pre-miRNA structure and are usually expressed off Pol 
III promoters. 2. Processed structures are exported into the cytoplasm and 3. 
processed by TRBP-dicer to yield siRNAs, which can alternatively be directly 
introduced into the cell. 4. The guide strand is incorporated by RISC and leads to 
translational repression or target mRNA cleavage. Adapted from Gonzalez-Allegre 
and Paulson 2007 (112).  
 
of Dicer acting as a molecular ruler, binding the 3’ overhang, resulting in the 
placement of the pre-miRNA stem at the precise position of cleavage (113). 
The mature miRNA/siRNA is then incorporated by the RNA-induced silencing 
complex (RISC) (114, 115). In humans, RISC is composed of Dicer, 
Argonaute proteins, TAR RNA binding protein (TRBP) and a dsRNA binding 
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releases one of the strands (referred to as the ‘passenger’ or antiguide 
strand) and retains the guide (or sense) strand (116). The functional 
asymmetry of the duplex determines which strand is incorporated into the 
RISC loading complex (RLC) whereby the strand with the more unstable 5’ 
end is selectively retained, referred to as the “characteristic thermodynamic 
signature” of the duplex (117, 118).  
 
The suggestion by Schwarz and colleagues that degradation of the 
passenger strand rather than separation of the duplex occurs was confirmed 
using drosophila and human cells (119, 120). Indeed, Matranga and 
colleagues suggest a model whereby Argonaute 2 (Ago2) receives the 
siRNA duplex, and cleaves the passenger strand, releasing the guide for 
formation of mature RISC (siRISC) (119). This cleavage has been confirmed 
in other studies where it has been shown that modification of the passenger 
strand can prevent the formation of a functional RISC, and that in addition, 
the cleavage occurs at position 10 of the passenger strand (121). This 
process is altered in mature miRNA RISC (miRISC) formation due to the 
characteristic mismatches between an miRNA guide strand and its 
passenger counterpart; such that the mismatches prevent Ago2 from 
cleaving the passenger strand, which instead is removed by a slower bypass 
mechanism not requiring Ago2 (119).  
 
The mature miRISC/siRISC is then directed in an as yet, unknown manner, 
to a complimentary mRNA transcript, where RISC facilitates binding of the 
guide to the mRNA leading to translational inhibition or cleavage of the target 
mRNA (extensively reviewed in (122)). It is known however, that both 
sequence specificity as well as target site accessibility play an important role 
in the ability of activated RISC to exert knockdown. In the first instance, it has 
been shown that the ‘seed’ region (considered the first eight nucleotides of 
the 5’ end of the guide strand) is enough to allow for target site recognition by 
the miRNA (123); and secondly, that sites with significant secondary 
structure formations are inaccessible and therefore prevent RISC associated 
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1.2.3. Comparing siRNAs and miRNAs 
One of the distinguishing aspects between siRNAs and miRNAs is that the 
former are generally perfectly complementary to the mRNA target. This exact 
match results in cleavage of the mRNA by the Ago2 component of RISC, 
yielding a transcript recognised by cellular machinery as being aberrant, and 
hence degraded, preventing translation (122). Ago2 has been referred to as 
the “catalytic engine of mammalian RNAi” (125) and is essential for 
mammalian development. Indeed, it was shown that Ago2 is distinct from 
other Ago proteins in being the only species with the ability to cleave mRNA. 
In one of their most interesting experiments, the authors show that Ago2 
knockout mammalian cells are unable to knock down exactly matched 
targets, but that they can reduce expression of mismatched targets 
reinforcing the essential role of Ago2 as a component of a cleavage complex, 
but not in mismatched-target knockdown. Furthermore they showed that 
murine Ago2 knockouts resulted in embryonic lethality. These observations 
raise the issue of the importance of target cleavage in mammals, considering 
the presence of such an evolutionally conserved protein. Indeed it has been 
shown that miRNAs fully complementary to their targets, and siRNAs 
mismatched to their targets can result in cleavage and translational 
repression respectively (126); indeed miRNA directed cleavage has been 
reported in mammalian cells (127). 
 
However, this dramatic mechanism of gene knockdown is seldom utilised by 
the endogenous RNAi pathway in mammals. In this scenario, mature 
miRNAs accompanied by RISC bind to mismatched mRNA targets. The 
degree of mismatched nucleotides varies, but it yields a more subtle form of 
regulation, in that Ago2 is prevented from cleaving the target, but the binding 
itself prevents the translational machinery from processing the transcript. 
Some studies have shown that the complex associated with the target, can 
be escorted to the cells’ processing bodies or p-bodies, where the mature 
miRNA/RISC associated complex can be re-used, as well as maintain 
translational suppression. Extensive studies have examined the mechanism 
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1.2.4. Manipulation of the endogenous pathway 
The purpose of this chapter is to understand how RNAi can be manipulated 
for therapeutic benefit. As can be seen in Figure 1.5 (page 28) there are 
several points of entry of the miRNA pathway that can be used to induce a 
specific gene silencing response, which is required for studying effects of 
loss-of-function, as well as for use in therapeutic investigations. As has been 
previously mentioned, Tuschl and colleagues demonstrated that siRNAs 
could be synthetically produced to exact such a response (104). However, 
this response is transient; thus a mechanism for the introduction of stable 
inducers of RNAi was required. Hairpin RNA structures include a stem of 19-
21 bases separated by a loop sequence of a few nucleotides, expressed off 
strong Pol III promoters which can lead to long-term expression of effectors, 
ideal for many applications in therapeutic approaches (128, 129). Indeed 
Brummelkamp and colleagues designed these short hairpins to resemble the 
pre-miRNA let-7, with 3’ two nucleotide U overhangs, which result from the 
cleavage by Drosha and the polyT transcription stop signal (128); in addition, 
due the short nature of the dsRNA species, they are able to evade the 
mammalian immune response, which had prevented long dsRNAs from 
allowing a specific RNAi response. Whilst these RNAi effectors have been 
used with great efficiency to result in strong knockdown an improvement was 
made in the development of shRNAs While traditional shRNAs mimic pre-
miRNAs in structure, modified hairpins were designed to incorporate features 
of pri-miRNAs (130-132). As a result, they have been shown to be up 12 
times more effective (133). Furthermore, the use of Pol II promoters results in 
pri-miRNA based hairpins being more amenable to regulation e.g. tissue 
specificity can be achieved (134). A further advantage has been recently 
revealed in gene therapy studies, whereby traditional shRNAs can over-
saturate the endogenous miRNA pathway and therefore cause toxicity in vivo 
(135, 136). The limiting factor in this over-saturation was shown to be 
exportin-5 (135) although ongoing studies indicate that due to the sequence 
specificity of the interaction, Ago2 also appears to be a limiting factor (137). 













  Chapter 1: Introduction 
 
32
1.5 (page 28) and illustrates the complexity of the RNAi pathway, in addition 
to the importance of knowledge of the endogenous pathway.  
 
1.3. RNAi-based gene therapy for dominantly 
inherited disorders 
Gene therapy has been studied as a potential treatment for inherited and 
other disorders. However, delivery of large sequences of recombinant DNA, 
with issues such as efficiency, tissue specificity and long-term expression 
has slowed the advancement of this sphere of study (138). More recently, the 
investigation of small nucleic acids in suppression of genes causing a toxic 
gain-of-function has spurred this field. Small molecules such as antisense 
oligonucleotides (139), and ribozymes (140) have been investigated 
therapeutically to reduce gene expression in a sequence specific manner. 
The most recent addition to the field of therapeutic gene silencing are RNAi 
effectors. The major advantage of these over the previously mentioned gene 
suppression molecules lies in that they can be virally delivered for long-term 
expression off tissue specific promoters.  
 
The potential of RNAi in the treatment of many different disorders was 
recognised soon after the publication of the Fire and Mello paper (100). 
However, the manner in which to transfer this sequence specific knockdown 
to mammalian cells remained an obstacle until Tuschl and colleagues 
demonstrated that siRNAs could trigger RNAi without inducing an immune 
response in mammalian cells (141). It then became clear that it would be 
feasible to treat a broad range of disorders including cancer, infectious 
disease and genetic conditions, where partial, temporal or complete removal 
of the disease-causing mRNA would likely result in amelioration of the 
phenotype (142). Since then, a plethora of studies targeting various diseases 
using various mechanisms in vitro and in vivo have been investigated with 
encouraging results (143). In particular, the group of neurodegenerative 
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Given the extensive research on these disorders, many pathogenic genetic 
(not necessarily inherited) defects have been identified which can be 
targeted using RNAi. The focus of this chapter, however, will centre on 
dominantly inherited disorders of neurodegeneration, with special emphasis 
on the polyglutamine disorders. 
 
Studies have shown success using RNAi-based gene therapies in mouse 
models of neurodegenerative disorders (reviewed in (112, 144)). However, 
studies of some dominantly inherited conditions demonstrate that evidence of 
a loss of wild-type function leads to pathogenic effects due to the 
requirement of the normal protein in cellular functioning. As such general 
knockdown of both alleles would likely result in phenotypic abnormalities, 
thus allele-specific silencing of the mutant and not the wild-type transcript 
may be desirable (145, 146).  
 
Given that the impact of losing SCA7 function is not well understood, the 
importance of preserving the normal SCA7 allele in a knockdown strategy is 
unknown. Thus, in order to review the likelihood of this requirement, studies 
of other diseases in this group have been incorporated in this chapter to infer 
mechanisms of action of the expanded protein on the wild-type, in addition to 
the importance of the wild-type protein in cellular function i.e. whether 
general knockdown of both alleles would be sufficient as an RNAi-based 
therapy, or whether allele-specific knockdown resulting in the partial 
expression of wild-type protein is required. The toxic gain-of-function caused 
by the polyglutamine tract is for the most part common to each and has been 
reviewed extensively (6). However, additional contributions to disease 
pathology have been shown to include loss-of-function of the specific wild-
type protein; and the importance of this effect requires consideration when 
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1.3.1. Effect of loss of wild-type function: 
Ultimately the decision to apply knockdown of both mutant and wild-type 
versus allele-specific knockdown will depend to some extent on how well the 
total loss of wild-type function is tolerated. Thus the identification and 
assessment of wild-type function using in vivo studies such as knockout 
models is invaluable. The function of the normal gene product in 
polyglutamine disorders is mostly unknown. However, studies that indicate 
essential function, especially in late development, would be strong indicators 
of a requirement for allele-specificity. Some of these issues are summarised 
in Table 1.1.   
 
Table 1.1: Assessment of the importance of the wild-type function in 
polyglutamine disorders 
Polyglutamine 
disorder* Gene Function of the wild-type Knockout model severity  
SCA6 cacna1α 
Calcium channels involved 
in neurotransmitter release 
(147) 
Severe phenotype (148) 
HD htt 
Possibly involved in 
transcription; trafficking and 
endocytosis; signalling; 
metabolism (149), transport 
of Brain-derived 
neurotrophic factor (BDNF) 
and post-Golgi-trafficking 
(150)  




SCA3 MJD1/ atxn3 Unknown Behavioural changes (153) 
SCA1 atxn1 Unknown Mild neurobehavioural abnormalities (154) 
SCA7 atxn7 
Increasing evidence as a 
co-factor in retinal gene 
expression  (50, 54) 
- 
SCA17 TBP Transcription initiation (155) - 
SCA2 atxn2 Unknown, possible RNA processing (156) 
Mild phenotype including 
increased body weight and 
fatty acid changes in the 
liver (157); possible 
developmental vulnerability 
*The disorders have been ordered starting with the strongest candidates for allele-
specificity, leading to those which may not require such intervention. Since SBMA is 
an X-linked disorder, it has not been included in this summary, nor in the text, 
however loss-of-function has been implicated in SBMA (158). Furthermore, analysis 













  Chapter 1: Introduction 
 
35
In assessing SCA7 for the requirement of allele-specific silencing, the 
following must be considered; will reduction of the mutant whilst retaining the 
remaining single wild-type allele lead to a significantly better phenotype than 
general knockdown of both alleles? An important distinction made here is 
that while loss-of-function may not contribute significantly to disease 
pathogenesis, complete removal of the wild-type allele may lead to 
detrimental defects, hence the importance of knockout models of disease.  
 
Studies on the function of ATXN7 have been reviewed in this chapter 
(chapter 1.1.5, page 7). Briefly, while the toxicity caused by the mutant gene 
in SCA7 is well documented in vivo (50, 72, 84), less evidence for the 
importance of the wild-type is available in that no knockout models have 
been generated unlike for the causative genes of SCA1, 2, 3, 6 and HD 
(Table 1.1). Indeed Dragatis and colleagues have shown that a conditional 
knockout mouse model of HD results in a neurological phenotype suggesting 
the importance of the normal allele late in development (152). Conditional 
knockout models are invaluable, as therapy is likely to occur post-natally, 
therefore defects due to a lack of the protein during early development can 
be eliminated. Importantly in HD, evidence of a balanced translocation in a 
non-symptomatic individual provides the perfect evidence in a ‘human model’ 
for the fact that the remaining single allele is sufficient for normal 
development and function (159). This is the only reported case of a balanced 
translocation in a polyglutamine gene. In contrast the mild phenotype 
exhibited by the knockout model of SCA2 suggests that allele-specificity may 
not be required as the phenotype can be rescued on a low fat diet (157). This 
supports the idea that while the type of mutation is common to the 
polyglutamine diseases, the therapeutic approach may not be the same. The 
interaction of wild-type ATXN7 with the transcriptional activator complex 
TFTC/STAGA and CRX, both of which are known to regulate the expression 
of retinal genes suggests a dominant negative effect of the mutant protein on 
the wild-type leading to the distinct macular degeneration seen in SCA7 (50, 
55). Furthermore, as is the case with SCA3 (160, 161) the wild-type protein is 
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normal function may contribute to pathogenesis. This indicates that retention 
of the wild-type is likely to be desirable.  
 
Even with a knockout model, the impact of total loss-of-function in 
conjunction with a significant amount of mutant expression prior to treatment 
cannot be fully ascertained. Such is the case in SCA1 where a 
neuroprotective role for the wild-type was shown such that transgenic mutant 
mice lacking the wild-type allele showed an exacerbated phenotype (162). 
Since null Sca1 mice show no signs of ataxia and have a normal life span 
(154), it is likely that the wild-type protects against effects of the mutant, and 
may be required to limit the damage caused by the mutant. Alternatively, the 
removal of the mutant protein may negate the neuroprotective effects of the 
wild-type. The distinction between loss-of-function caused by a dominant-
negative effect and neuroprotective effects of the wild-type could result in 
very different approaches to allele-specificity. However, the issue of minimum 
threshold levels of mutant verse wild-type protein tolerated by the cell can 
only be answered in vivo. With regard to SCA7, although extensive data has 
not been published, Yoo et al. have commented that mice homozygous for 
the expanded allele (i.e. lacking the wild-type allele) showed no exacerbated 
phenotype, suggesting neuroprotection is unlikely to be an issue in SCA7 
(84).  
 
Another facet to consider is the importance of the function of the wild-type 
ATXN7 protein. SCA7 is one of the few polyglutamine disorders for which the 
function of the wild-type has been partly elucidated and its importance as a 
transcription factor may indicate its essential cellular function. For example, 
the wild-type protein in SCA17, TBP, and its function as a part of eukaryotic 
transcription is well described (163); thus the importance of the protein as a 
ubiquitous transcription factor may pre-empt the requirement of extensive 
evidence obtained from knockout models, i.e. it is likely that knockout models 
would show embryonic lethality. Similarly, the role of ATXN7 in retinal gene 
transcription and the loss-of-function created by the disruption of the 
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defects at least. What this additional impact would have in cerebellar neurons 
is unknown without any knockout models. Furthermore there is little evidence 
to suggest a redundant protein may rescue the lost ATXN7, as is likely to be 
the case in SCA2 with the ATXN2 related protein 1 (A2RP1) (164). Taken 
together, it is likely that the function of the wild-type protein is required in 
order to prevent undesired effects caused by general knockdown and that 
allele-specific knockdown would be beneficial.  
  
1.3.2. RNAi studies in polyglutamine disorders 
1.3.2.1. Studies using general knockdown 
There have been studies using general RNAi knockdown to treat 
polyglutamine disorders; specifically SBMA, SCA1 and HD (165-167). 
Caplen and colleagues (165) were one of the first groups to show sequence 
specific knockdown in invertebrates and mammalian cells. They 
demonstrated that by using small dsRNAs, this could be obtained without 
invoking the non-specific immune response of mammalian cells to dsRNA. 
Thus they importantly showed evidence for the use of RNAi as a therapeutic 
reverse genetics tool.  
 
In 2004, this was further by investigated by assessing whether viral vectors 
expressing hairpins directed against a human transgene could reduce 
pathology in a SCA1 mouse model (167). After screening hairpins targeting 
10 different regions of the full-length myc-tagged atxn1 sequence, one 
showed efficient knockdown in vitro. Transferring this knockdown to neuronal 
cells by adopting a viral vector with cytomegalovirus (CMV; a Pol II) instead 
of an H1 (Pol III) promoter resulted in more efficient expression of the hairpin 
as well as successful knockdown. Using this effector plasmid in vivo, the 
study noted significantly improved motor performance, with no effects of 
toxicity cause by the expression of the hairpin. Furthermore, SCA1 specific 
pathology improved in that thickenings of the molecular layer was noted 
(thinning of this layer is indicative of SCA1 pathogenesis in humans and 
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expression of the AAV1 vector resulted in a reduction of ATXN1 levels only a 
week after injection as well as the complete resolution of inclusions – 
characteristic of SCA1 and other polyglutamine disorders. Notably, 
accessibility to the target was clearly shown to be an issue in that over 10 
constructs had to be tested before an efficacious hairpin could be identified. 
The following year the same group performed an equivalent study on an HD 
mouse model (166). This HD mouse contained an N-terminal truncated 
huntington gene (htt) fragment containing the expansion. Various hairpins 
were tested in vitro against the short N-terminal myc-tagged transgenes and 
full-length sequences. The most efficient hairpin was incorporated within an 
adeno-associated viral (AAV) vector driven off the Pol II U6 promoter for in 
vivo studies. This showed the same strong sustained hairpin expression and 
consequent knockdown (up to five months) as the previous study. Benefits 
included the absence of inclusions reactive for htt compared to abundance in 
the disease model, corresponding to reduced levels of soluble htt protein and 
mRNA. Although there was no improvement in the weight loss of the mice 
(also a characteristic of the human phenotype), significant improvements in 
stride length and rotarod tests were observed. These studies are important in 
the study of RNAi-based therapy for polyglutamine disorders in that removal 
of the mutant protein was shown to result in amelioration of the phenotype.  
 
However, the shRNAs used targeted only the human transcript leaving the 
endogenous wild-type for the most part, intact; therefore the studies were 
unable to address the issue of expected knockdown of the wild-type gene in 
a therapeutic system. Currently, investigations into general but partial RNAi 
knockdown of murine htt in a knock-in HD mouse model are being assessed 
to create partial reduction (approximately 50%) of both mutant and wild-type 
protein (168).  
 
1.3.2.2. Therapeutic benefits of allele-specific studies 
There are few studies of the polyglutamine disorders which have investigated 
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associated with creating allele-specific silencing for the polyglutamine 
disorders is that one cannot use the difference in size between the 
polyglutamine tracts as a distinguishing factor, as most effectors are only 19-
24 bp in length resulting in the targeting of all CAG repeat motifs (165, 169). 
This is in contrast with disorders such as the Swedish mutations in 
Alzheimers disease (AD) and the small deletion in DYT1 dystonia which 
allow for relatively simple designs for allele-specific selection (170-172). As 
such, one needs to identify another distinguishing factor between the two 
alleles of polyglutamine genes. One way would be to use single nucleotide 
polymorphisms (SNPs). This was first shown in 2003 against a SNP linked to 
the mutant allele of atxn3 (169). To date, phenotypic effects of allele-specific 
silencing have only been reported in one polyglutamine disorder; using this 
SNP linked to atxn3 (169, 173).  
 
The study by Miller and colleagues in 2003 investigated the possibility of 
discriminating between the two alleles of atxn3, in vitro (169). Various 
siRNAs were tested including one targeting the CAG repeat itself in the hope 
that the expansion might lend to this transcript accessibility not achievable 
against the shorter repeat in the wild-type target. The results indicated that 
the repeat length could not be used to discriminate between the two alleles. 
However, a SNP linked to the mutant gene, was successful, in that many of 
the siRNAs tested, varying the position of the mismatch within the siRNA, 
showed significant selective knockdown of the full-length mutant target with 
minimal effects on the wild-type. This selectivity was maintained in a 
heterozygous assay, in which both transgenes were expressed, as well using 
hairpin constructs of the most selective siRNA expressed off a U6 promoter 
in an adenovirus backbone transfected in a neuronal cell line. That selectivity 
could be achieved was important. Further investigations used siRNAs 
targeting the red fluorescent protein (RFP) and GFP tagged reporter genes 
of the mutant and wild-type transcripts respectively. This experiment 
demonstrated that the selective removal of the mutant, released the wild-type 
to a normal dispersed expression from recruitment into aggregates. Although 
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strongly suggests that this would be an additional phenotypic advantage of 
allele-specific silencing.  
 
This study has further implications in that if one can identify a SNP which is 
not only linked to the mutant allele, but also has a significant heterozygosity; 
presumably a significant number of the individuals with the disorder could 
theoretically be treated with the same effector. This therapeutic avenue can 
be especially targeted towards populations in which the disease shows 
evidence of a founder effect. 
 
A study published just a few months later targeting the same SNP outlined 
above, indicated similar success in selectivity of siRNAs, as well in a 
significant decrease in cell death in a neuronal cell line caused by toxicity of 
the mutant gene (173). However, this study did produce interesting data on 
secondary structure, indicating that the repeat size (using 22 and 79 repeats) 
could significantly affect the accessibility of the target to knockdown. 
Although this was a comparison of normal versus the expanded repeat size, 
it suggests that large differences in repeat sizes between different 
expansions may result in differential selectivity, and should be taken into 
account when assessing the effects in patients with different repeats. This 
may be particularly pertinent to SCA7 which has the largest difference in 
repeat sizes. In essence, these studies provide evidence that allele-specific 
silencing is a feasible and desirable approach for therapy for the 
polyglutamine disorders which should be further investigated. 
 
The only in vivo study using an allele-specific approach in a neurological 
disorder showed that modest selectivity of the mutant allele delayed onset of 
disease symptoms in a mouse model of ALS (174). The importance of this 
study lies in the fact that complete discrimination between the two alleles is 
not essential for beneficial phenotypes, suggesting that even moderate 
discrimination of the two alleles may lead to phenotypic advantages. To date 
there has been no allele-specific study investigated for polyglutamine 

















Given the fact that even moderate discrimination is not always feasible for 
some single nucleotide differences, Kubodera et al. have investigated a 
different approach of allele-specific repression (175). Using SCA6 as a model 
system, they were able to show strong knockdown of both mutant and wild-
type alleles of SCA6 in vitro. The siRNA was co-transfected with a vector 
expressing a modified version of wild-type cacna1α, which was resistant to 
siRNA repression. This was achieved by incorporating specific synonymous 
nucleotide changes in the region targeted by the siRNA such that the siRNA 
guide sequence would not be complementary to and thus would not 
knockdown the replacement wild-type transcript. This method has several 
advantages and disadvantages such as bypassing the numerous mutations 
in genes such as SOD1 and presenilin; however the level of expression of 
the modified wild-type gene would have to be assessed and carefully 
controlled, although this may be said to be the case in any gene 
supplementation therapy. Given that these issues are being assessed in 
other disorders (176) this method represents a potential alternative strategy 
to the more canonical allele-specific silencing method.  
 
1.3.2.3. Mechanistic aspects to consider 
Initial studies investigated the sequence specificity of the guide strand to the 
target with opposing results. Whereas some results showed single mismatch 
specificity – the ability of an effector to discriminate between two sequences 
based on a single nucleotide difference – (177-179), others indicated that 
single nucleotide changes could be easily accommodated (177, 180) (Table 
1.2, page 43). There have been several publications showing effective 
discrimination based on single nucleotide discrimination against a variety of 
genes involved in neurodegenerative disorders including the acetylcholine 
receptor (AchR) in slow-channel congenital myasthenic syndrome (SCCMS) 
(181), the London mutation in AD (170) and the SOD1 mutations that cause 
ALS (174, 182, 183) and HD (183). Aspects of these studies are included in 

















In addition several mechanistic issues remain to be considered. Most 
importantly strand bias, while not a concern exclusive to allele-specific 
studies, must be addressed. As has been discussed in the previous section, 
the RISC complex can retain either strand of the siRNA duplex, and this is 
largely determined by the thermodynamic profile of the duplex (118). It has 
been shown that RISC incorporates the strand with greater thermodynamic 
instability at its 5’ end. Thus, subtle changes within the 3’ end of the 
antiguide/passenger strand can be introduced to this effect, such as those 
that produce G:U wobbles with the 5’ end of the guide strand, which do not 
interfere too much with duplex structure (118). The extent of off-target effects 
which result from undesired strand bias can be measured using simple 
reporter assays (171). This is an important consideration bearing in mind that 
off-target effects can result from incorporation of the passenger strand by 
RISC as even limited sequence similarity (e.g. less than 11 continuous 
complementary bases) allows for silencing (184). Indeed, off-target effects 
should be considered for the guide strand as even double mismatched 
sequences may have an effect on non-specific transcripts (185). Thus it is 
possible that even if the correct guide strand is incorporated; it may lead to 
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Table 1.2: Summary of allele-specific studies  





Notch gene in drosophila (177) siRNA Central positions, using single and double mismatches various 
Decreased but not completely 
abrogated knockdown 
Luciferase (178) siRNA Various, including multiple mismatches Various 
Knockdown abrogated when the 
mismatches were placed centrally and 
in the 3’ region of the guide strand. 
Human tissue factor (180) siRNAs Centrally placed Purine:purine Moderate selectivity 
GFP (179) siRNAs/shRNAs Centrally placed double mismatches Various 
Double mismatches could confer 















U:C and U:G 
respectively 
First papers to show single nucleotide 
specificity for therapeutic purposes; 
Showed that it was feasible to create 
expression cassettes producing 








Showed that different types of 
mismatches within the same sequence 
context and placed at the same position 
showed different efficacies of 
knockdown. 
SCCMS (181) shRNAs Tested positions 12 and 13, 12 most effective A:C All positions showed some selectivity. 
SCA3, Tau (169) siRNAs/ shRNAs
Positions 11; 16; double 
mismatches P16P15; latter 
most effective 
Positions 14; double 




Targeting the CAG repeat had no effect 
Targeted a linked SNP; Double 
mismatch most efficient 
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SCA3, atxn3 (173) siRNAs Positions 6; 9; 12; and 15 with 9 the most effective G:G 
Targeted the same linked SNP as 
above; Found sequence independent 
knockdown likely due to 2o structure 
causing disruption of accessibility. 
CD46 (189) siRNAs Central and 3’ positions†  Various 
A:C and G:U mismatches (in particular 
the latter) are well tolerated; Centrally 
placed positions better for 
discrimination 
AD (170) shRNAs 
Positions 10, 11, 12, 13 with 
the latter working the best 
against the London mutation. 
G:U 
Additional double mismatches (placed 
in the 3’ end) added to an initial 
centrally placed mismatch may aid 
discrimination 
sickle cell anaemia (190) siRNAs Position 10 Multiple 
Showed that bulky purine:purine 
residues were most effective for single 
nucleotide discrimination 
ALS (174) shRNA Position 11 G:G Low selectivity required for significant improvement using in vivo phenotype 
ALS, SOD1 
HD, htt (183) siRNAs 




Positions 3’ to the centre showed the 
greatest discrimination, in particular 
position 16. Showed limited selectivity 
using a G:U mismatch. 
CD46 (185) siRNAs Positions 1- 19 Various 
Double mismatches better tolerated in 
the 3’ region of the siRNA than the 5’ 
region 
pachyonychia congenita (191) siRNAs Positions 1 to 19 with P4 and 12 working most efficiently U:C 
Mismatches at positions both 3’ and 5’ 
of the centre can result in selectivity 
*In the analysis of publications where a different nomenclature has been used, the positions have been changed to correspond with Schwarz 
et al. 2006, where the position of the mismatch is given according to the first nucleotide of the 5’ end of the predicted guide strand. †This is 
extrapolated because the target site was changed, not the siRNA itself. The allele-specific study on DYT1 Dystonia (171) has not been 
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In 2001 and 2002 investigations of the tolerance of mismatches to the target 
sequences noted abrogation of knockdown in the presence of mismatches (177-
180). This led to the hypothesis that it may be possible to distinguish between 
two alleles for therapeutic purposes. However the rules that govern single base 
pair allele-specific silencing are not strongly defined. With specific reference to 
allele-specific studies, the following are important aspects to consider: strength 
of the mismatch, position of the mismatch and accessibility of the target site.  
 
The strength of the mismatch formed against the wild-type allele can differ 
resulting in effective or minimal levels of discrimination (183, 190) shown by 
different mismatches in the same sequence context at the same position 
yielding different selectivity (182). Those cases where the mismatch conferred 
against the wild-type is predicted to be a strong destabiliser (such as bulky 
purine:purine mismatches) will show the greatest discrimination (190). In 
comparison, weaker mismatches such as purine:pyrimidine. In particular the 
G:U wobble pair is generally well tolerated (169, 183, 188, 189), although, one 
study has indicated that strong selectivity can be achieved (186). This can be 
modified with the addition of secondary mismatches such that the guide has two 
mismatches against the wild-type but only one against the mutant target (169, 
170).  
 
The position of the mismatch relative to the proposed cleavage site of Ago2 is 
also important in the design, as early studies suggested that given that Ago2 
cleavage occurred at centrally at positions 10 and 11 (178), placing the 
mismatch at this position would yield the most selectivity. Numerous studies 
have examined centrally placed mismatches (Table 1.2) but these have been 
shown to not always be the most successful. Of mismatches at positions 16, 15 
and 9, a double mismatch of the former was shown to be the most selective 
(169); with position 13 (170) and positions 12 and 4 (191) also showing the 
strong selectivity. A recent study has indicated that those placed 3’ to the centre 
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because it used two identical and consistent screens of siRNAs defining 
placement of the mismatch exactly and that mismatches placed at position 16 
appear to consistently show the greatest selectivity.  
 
Secondary structure of the target region can be an issue for siRNA accessibility 
(180). The target region containing the SNP should be taken into consideration 
rather than modified since the presence of the SNP dictates limited mobility of 
the placement of the effector. Furthermore, since predicting software is limited, it 
may not be possible to effectively predict the accessibility of a certain region. 
However this may alter discrimination in polyglutamine disorders since the large 
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   1. 4. Aims and Objectives 
 
In the same way that allele-specific silencing was used to specifically target a 
linked SNP in SCA3 (169), it is proposed that SCA7 too would benefit from such 
an approach. The function of the wild-type protein in SCA7, although not 
definitive, indicates that it is likely to be essential for cellular function. Thus a 
method of retaining the normal protein is desirable. In South Africa, it has been 
shown that a founder effect exists in the cohort of SCA7 patients (91). As such, 
there is a well-characterised SNP (rs3774729) located in exon 12 of atxn7, 
linked to the mutant allele in 100% of the patients studied to date. In addition, 
over 50% of these patients are heterozygous for this SNP, which provides a 
single nucleotide disparity with which to discriminate between the wild-type and 
mutant alleles, containing the G and A alleles respectively. Finally, SCA7 is the 
only polyglutamine disorder that has a retinal degenerative phenotype in 
addition to the progressive neurological symptoms, thus providing a more 
accessible tissue to measure the efficacy of the treatment in vivo. In addition, 
age-related macular degeneration is currently being tested as a potential 
therapeutic target for RNAi (192) and most recently, successful human trials for 
Leber’s congenital amaurosis have been performed (193) providing a 
therapeutic testing ground for gene therapy based approaches in the eye.  
 
The aim of this project was to identify expressed RNAi effectors in order to 
specifically suppress expression of the mutant allele of the atxn-7 gene in 
heterozygous mammalian cell lines, such that this effector has the potential to 
be used for an RNAi based gene therapy for SCA7 patients in South Africa.     
 
In order to do this the following objectives were identified: 
1. Design stably expressing RNAi effectors incorporating mismatches at multiple 
positions.  
2. Screen these hairpins against the wild-type and mutant targets in a 
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which selectively reduces mutant protein levels without significantly affecting the 
levels of the wild-type protein.  
2. Screen the aforementioned effectors in a cellular assay which more closely 
resembles the natural state using full-length targets in both hemizygous and 
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2. Materials and Methods 
 
2.1. RNA isolation 
RNA was isolated from mammalian cells using the RNeasy mini kit (Qiagen, 
Southern Cross Biotechnology, Republic of South Africa (RSA)) as per 
manufacturer’s instructions. Following each method the quality and 
concentration of each sample was determined by spectrophotometry (NanoDrop 
ND-1000 spectrophotometer, NanoDrop Technologies, Inqaba, RSA). Samples 
indicating an A260/A280 of 1.8 to 2.0 were stored at -80C for further experiments.  
 
2.2. PCR 
Amplification of the G>A SNP polymerase chain reaction (PCR) was performed 
according to basic conditions outlined in the Appendix (A1, page 134) with the 
modification of an annealing temperature (TA) of 60oC. Primers used for the 
PCR are indicated in Table A2 in the Appendix (page 134). 
 
2.3. Sequencing 
Total PCR product was resolved on a 1% agarose gel at 120 volts for 30 
minutes (min). The bands were excised using a scalpel, placed in pre-weighed 
1.5 ml tubes (Eppendorf, Merck, RSA) and weighed. The DNA was extracted as 
per the instructions in the QIAquick Gel Extraction kit (Qiagen, Southern Cross 
Biotechnology, RSA). After the clean-up, 5 μl of recovered amplicon was 
resolved by agarose gel electrophoresis to confirm the presence of extracted 
PCR product. The cycle sequencing reaction was performed in a total volume of 
20 μl containing 5 μl of the PCR product, 8 pmol of primer, 1 μl of the BigDyeTM 
termination mix (Applied Biosystems, RSA), 1 x BigDyeTM Buffer (Applied 
Biosystems, RSA), made up with distilled H2O (dH2O). The cycling conditions 
were performed as follows on a Hybaid Touchdown Thermocycler:  
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30 cycles of   96oC – 30 seconds (sec) 
50oC – 15 sec 
60oC – 4 min 
Unincorporated nucleotides and salts were subsequently removed from 
sequencing products using columns (CENTRI-SEP, Princeton Separations, 
RSA), as per the manufacturer’s instructions. Sequencing analysis was 
performed using capillary based electrophoresis on the ABI 3100 Genetic 
Analyzer and analysed using the Sequence Analysis version 3.7 software 
(Applied Biosystems, RSA).  
 
2.4. cDNA synthesis 
2.4.1. DNase treatment 
RNA was treated with AmbionTurbo DNAse (Ambion, UK) to remove remaining 
genomic and/or plasmid DNA contamination. The reaction was performed using 
a maximum of 10 μg of RNA; 1x TURBO buffer; 2 units of TURBO DNase made 
up to a final volume of 50 μl with RNAse-free dH2O and incubated for 30 min at 
37oC. DNase was inactivated using 3μl of DNase Inactivation reagent (Ambion, 
UK), incubated at room temperature for two to three min, vortexing during 
incubation. The sample was centrifuged at 10 000 x g for two min, after which 
the supernatant was transferred to a fresh tube.  
 
2.4.2. cDNA synthesis 
cDNA synthesis was performed according to the PrimerDesign protocol 
(PrimerDesign, UK). 
 
2.5. Real time PCR 
PCR was performed using custom made primers (PrimerDesign, UK). The 
following reaction conditions were used to perform real time PCR; 10 μl of 
Precision Mastermix (PrimerDesign, UK); 10 pmol of each primer 
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standard curve consisting of the following dilution was made using multiple 
aliquots of test samples; 100 ng, 50 ng, 25 ng, 10 ng, 5 ng. The cycling 
conditions used were: 
1 cycle of   95oC – 10 min 
40 cycles of   95oC – 15 sec 
56oC– 30 sec 
72oC – 30 sec 
PCR was performed using an Applied Biosystems 7000. Each sample was 
quantified in duplicate and a negative control was used in each experiment to 
control for contamination. Relative expression levels were normalised to GAPDH 
(Table A2, page 134).  
 
2.6. Effector design  
2.6.1. shRNA 
2.6.1.1. General design 
shRNA effectors were designed based on the original expression vector system 
by Brummelkamp and colleagues (128). The design included the use of a Pol III 
promoter which produces small transcripts with a well-defined start site and a 
five thymidine termination signal. In this study the Pol III promoter from the 
pTZU6+1 vector was used for small transcript production (194). The effectors 
were then designed with 19 nt of sequence matching the target sequence 
representing the sense strand followed by 19 nt of reverse complementary 
sequence representing the antisense strand. This semi-palindromic sequence 
was interrupted by a short nine nt spacer or loop sequence. Finally the 
antisense sequence was followed by five thymidines which results in a two nt 3’ 
overhang because termination site cleavage occurs after the second uracil 
(195). The favoured thermodynamics of the transcript thus predict the formation 
of a short hairpin loop structure. Cleavage of this dsRNA product by Dicer has 
been shown to yield 21 and 22 nt sense and antisense products (128). 
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creating G:U mis-pairings in the 3’ end of the anti-guide strand as has been 
shown previously (118) in order to bias guide strand incorporation by RISC.  
 
2.6.1.2. Mismatch placement 
Based on the predicted guide strand, mismatches to the wild-type G allele were 
placed consecutively from position 10 to position 16 where position 1 is the first 
nt of the guide strand assuming a 21 nt duplex (Figure 2.1). Further shRNA 
mismatch designs incorporated a secondary mismatch immediately 3’ to the 
primary mismatch (Figure 2.2). Finally, shRNAs with alternative secondary 
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Figure 2.1. Single mismatch guide strands in shRNA format. Convention for the 
diagram follows Schwarz and colleagues (183). Sequences of expected single 
mismatch guide strands (underlined) processed from a shRNA format indicating the site 
of the primary mismatch to the G allele of the wild-type atxn7 target. Sequence context 
of both the wild-type and mutant targets are shown. G:U mis-pairings are highlighted in 
bold. The shRNAs were labelled according to the position of the primary mismatch 
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Figure 2.2. Double mismatch guide strands in shRNA format. Convention for the 
diagram follows Schwarz and colleagues (183). Sequences of expected double 
mismatch guide strands (underlined) processed from a shRNA format indicating the site 
of the primary mismatch to the G allele of the wild-type atxn7 target. Sequence context 
of both the wild-type and mutant targets are shown. G:U mis-pairings are highlighted in 
bold. The shRNAs were labelled according to the position of the primary mismatch 
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Figure 2.3. Additional mismatch guide strands in shRNA format. Convention for the 
diagram follows Schwarz and colleagues (183). Sequences of expected double and 
tertiary mismatch guide strands (underlined) processed from a shRNA format indicating 
the site of the primary mismatch to the G allele of the wild-type atxn7 target. Sequence 
context of both the wild-type and mutant targets are shown. G:U mis-pairings are 
highlighted in bold. The shRNAs were labelled according to the position of the primary 




2.6.2.1. general design 
The design of the pri-miRNA-based constructs was adapted from Ely and 
colleagues (196). The reported miR-122 structure from miRBase, 
http://microrna.sanger.ac.uk/cgi-bin/sequences/mirna_entry.pl?acc=MI0000442, 
was used as a template for the design of the constructs seen in Figure 2.4 (page 
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sequences without modifying the overall secondary structure of the pri-miRNA 
and inserted within an exon of a CMV immediate early promoter enhancer 
expression cassette. The predicted guide sequence was designed to be 
perfectly complementary to the target unlike most miRNAs and thus should 
trigger Ago2 directed cleavage of the target. Furthermore, the bulges caused by 
single mismatches in the stem loop were maintained wherever possible; in terms 
of both position as well as mismatch strength.  
 
2.6.2.2. Mismatch placement 
Given that the pri-miR based hairpins are based on a naturally occurring and 
experimentally confirmed guide sequence, constructs were designed to place 
the mismatch at position 16. However, since Dicer processing of shRNA 
constructs may yield heterogeneous products, variations of the shRNA based 
P16 construct were accommodated by creating multiple pri-miRNA based 
hairpins one or two nt up and down of the predicted Drosha and Dicer cleavage 
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Figure 2.4. Guide strands in miRNA format. Sequences of mismatch guide strands 
processed from a miRNA format indicating the site of the primary mismatch to the G 
allele of the wild-type atxn7 target. Sequence context of both the wild-type and mutant 
targets are shown. The miRNAs were labelled according to the position of the primary 
mismatch relative to the 5’ end of the guide strand. Major species refers to the strand 
most likely to be incorporated by RISC, while the minor species indicates the strand 
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2.7. Plasmid construction/ cloning 
2.7.1. shRNA 
Construction of shRNA-expressing vectors has been previously described (197) 
in which the pTZU6+1 vector (194) is used as a template to create U6/shRNA 
cassettes. This method was modified by using a single step PCR step. 
U6/shRNA cassettes (Figure 2.5) were constructed as follows; A PCR cocktail of 
200 μg of pTZU6+1 vector, 10 pmol U6 universal forward primer (Table A3, 
Appendix, page 135), 10 pmol long reverse primer (Table A3), 0.2 mM dNTPs, 1 
x Gotaq Buffer (Promega, Whitehead Scientific, RSA), 2 units of GoTaq 
(Promega, Whitehead Scientific, RSA), was made up to a final volume of 25 μl 
with dH2O. The cycling conditions were the same as th se for standard PCR as 
indicated in the Appendix (A1, page 134). PCR products were electrophoresed 
on a 2% agarose gel. The expected product size of 300 nt was excised under 
low Ultra violet (UV) light and cleaned using the Qiagen Gel Extraction kit 
according to manufacturers’ instructions (Qiagen, Southern Cross 
Biotechnology, RSA). The PCR products were quantified using a NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Inqaba, RSA. A total of 100 
ng of PCR product was ligated to the TA cloning vector pGEMTeasy (Promega, 
Whitehead Scientific, RSA) according to manufacturers’ instructions including 
ligation and background control reactions, and incubated at 4oC overnight. Five 
μl of the ligation product was then used to transform competent DH5α 
Esherichia coli cells and grown on ampicillin selective agar plates. Blue/white 
screening was used to identify potentially positive clones. White colonies were 
screened using PCR with T7 and SP6 primers (Integrated DNA Technologies, 
Whitehead Scientific, RSA) according to the standard method in the Appendix 
(A1). Colonies producing the correct band size were selected and transformed 
using a miniprep kit (Qiagen, Southern Cross Biotechnology, RSA). Plasmid 
preparations were sequenced using both SP6 and T7 primers to confirm the 
correct sequence. It should be noted that some of the colonies representing the 
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Correct sequences were confirmed by manual screening as well as using 
Bioedit (Tom Hall, Ibis Biosciences, USA). Plasmid integrity was verified by 
performing either EcoRIII or NotI (Promega, Whitehead Scientific, RSA) 
restriction endonuclease reactions and electrophoresed on a 2% agarose gel. 
 
 
Figure 2.5. Schematic representation of the shRNA cassette. U6/shRNA expression 
plasmids were constructed using cassettes constructed as shown schematically where 
L indicates the loop.  
 
2.7.2. miRNA 
Pri-miRNA based hairpin constructs (Figure 2.6) were created by performing 
PCR-based primer extension of partially overlapping complementary long 
oligonucleotides (Table A4, 132); followed by a secondary PCR using partially 
flanking outer primers with XhoI and NotI restriction sites. PCR products were 
gel excised (Qiagen, Southern Cross Biotechnology, RSA), and ligated to the 
pGEMTeasy TA cloning vector (Promega, Whitehead Scientific, RSA). Positive 
clones were co firmed by sequencing and restriction enzyme digestion. These 
were then digested with XhoI and NotI restriction enzymes and ligated to 
complementary overhangs of the pCI_neo vector (Promega, Whitehead 





















Figure 2.6. Schematic representation of the miRNA cassette. U6/shRNA expression 
plasmids were constructed using cassettes constructed as shown schematically where 
L indicates the loop.  
 
2.7.3. Construction of luciferase targets 
Short target sequences of atxn7 were cloned into psiCHECK (Promega, 
Whitehead Scientific, RSA) that expresses the Renilla luciferase reporter gene 
(Figure 2.7). Seventy four bp of annealed DNA oligonucleotides harbouring each 
of the target sequences and NotI and XhoI sticky ends were ligated into the 
psiCHECK plasmids upstream of the Renilla reporter gene (Oligonucleotide 
sequences are found in Table A5, 133). 
 
 
Figure 2.7. Schematic of the dual luciferase reporter targets. atx7-G-luc and atx7-A-luc 
are the wild-type and mutant reporter siCHECK plasmids used in the luciferase assay, 
and included a short region of 60bp of atxn7 target sequence spanning the G>A SNP 
fused to the Renilla luciferase reporter gene.  
 
2.7.4. Construction of full-length targets 
Full-length atxn7 cDNA constructs (wild-type (CAG)10 and mutant (CAG)100) 
were fused to the N-terminus of the reporter gene, enhanced green fluorescent 
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modified to replace the G residue of the SNP with the mutant A allele. Long 
oligonucleotides (Table A5, Appendix, page 137) were annealed and subjected 
to an initial primer extension with taq polymerase; this was followed by a 
secondary primer extension to produce XhoI and HindIII sticky ends. The 
resultant 150 nt dsDNA cassette harbouring the A allele with XhoI and HindIII 
ends was cloned into the mutant vector (CAG)100 linearised with XhoI and 
HindIII. The generated A allele (atx7-100-A-eGFP) was confirmed by DNA 
sequencing. For the heterozygous assay, the mutant atx7-100-A-eGFP was 
modified to substitute the eGFP with the red fluorescent protein pdsRED-
monomer-N1 vector (Clontech, Takara Bio, USA). The dsRED-monomer-N1 
plasmid was linearised with HpaI and Age and the resulting dsRED fragment 
was cloned into the atx7-100-A-eGFP vector which had been linearised with the 
same restriction endonucleases to remove the eGFP gene. The sequence of the 
mutant vector (atx7-100-A-dsRED) was confirmed. pdsRED-monomer-N1 was 
chosen because it does not result in aggregate formation as other dsRED 
protein  has been shown to do, therefore any aggregate formation is as a result 
of the fused target protein (198). Schematic diagrams of the expression 


















Figure 2.8. Schematic of the full-length target reporter constructs. atx7-10-G-eGFP, 
atx7-100-A-eGFP, atx7-100-A-dsRED are the 3 reporter plasmids used in the full-length 
hemi- and heterozygous assays and consist of the full-length atxn7 cDNA. The wild-
type construct (atx7-10-G-eGFP) has a CAG repeat length of 10 incorporating the G 
allele of the SNP, fused to eGFP. The two mutant constructs (atx7-100-A-eGFP, atx7-
100-A-dsRED) have CAG repeat lengths of 100, as well as the A allele of the SNP, and 
are fused to eGFP and dsRED respectively. (Figure drawn by M. Weinberg) 
 
2.8. Transfections 
2.8.1. Maintenance of cell line 
All the transfection experiments of this project were performed in HEK293 cell 
lines. This is a well known and commonly used cell line for artificial in vitro 
experiments (199). Cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% Fetal Calf Serum (FCS; Sigma, UK); L-
glutamine (4 mM; Sigma, UK), penicillin (50 U/ml; Sigma, UK), and streptomycin 
(50 mg/ml; Sigma, UK). Cells were maintained in a 37oC incubator and medium 
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amenable to transfection of the fusion construct plasmids obtained (42), 
HEK293s were used in all the transfection experiments. In addition, an antibody 
targeting ATXN7 had indicated no detectable levels of the protein in mock 
transfected HEK293 cell lines (42). However, a concern regarding the effect of 
endogenous levels of the ubiquitous atxn7 transcript seen in other studies (55) 
was addressed by performing real-time PCR. Atxn7 levels in cells transfected 
with full-length transcript plasmids were quantified relative to non-transfected 
cells. As can be seen in Figure 2.9, there was a 500 fold increase in the former 
indicating that endogenous levels of the transcript would have insignificant 
effects on the quantitative nature of the assay.  
 
Figure 2.9. Relative abundance of atxn7 transcript. Fold change in levels of atxn7 
between endogenous levels of transcript and transfection of 1 μg of the full-length wild-
type target as indicated. Each experiment was performed in triplicate, and the data is 
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2.8.2. Validation of cellular assay 
All transfection experiments were normalised to a non-specific control 
shR/miRNA expression plasmid. In order to confirm that these sequences had 
no effect on the target sequence, they were compared to expression plasmids 
containing only the corresponding promoter with no effector sequences. The 
results confirm that the non-specific effectors have no effect on the target 
sequences, and thus can be accurately used for normalisation purposes (Figure 
2.10). In each assay, miRNA and shRNA effectors were always normalised to 
miR-NS and shR-NS respectively, in order to take into account any effects of the 
different promoters and background vector sequence. 
 
Figure 2.10: Effect of non-specific effectors on the target relative to empty vectors a full-
length hemizygous assay. Quantitation of fluorescence in HEK293 cells transfected with 
wild-type (atx7-10-G-eGFP) or mutant (atx7-100-A-eGFP) expression plasmids and the 
indicated effector. Each experiment was performed in triplicate and the data is relative 
to that measured using a non-specific effector, NS. Average ± standard deviation is 
shown. Wild-type and mutant targets are represented by red and blue bars respectively. 
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Further validation of this assay was demonstrated by the similar levels of 
knockdown achieved using E19 (Figure 2.11; kind gift from Y. Yokobayashi 
(200)); the eGFP-specific hairpin. In each experiment using the full-length assay, 
this hairpin was used, and demonstrated that a) knockdown of the transcript was 
feasible, and b) similar levels of knockdown were achieved against the mutant 
and wild-type sequences indicating that this assay was an accurate 
measurement of transfected target knockdown.   
 
 
Figure 2.11: Effect of eGFP specific effector on the target in a full-length hemizygous 
assay. Quantitation of fluorescence in HEK293 cells transfected with wild-type (atx7-10-
G-eGFP) or mutant (atx7-100-A-eGFP) expression plasmids and shR-E19. Each 
experiment was performed in triplicate and the data is relative to that measured using a 
non-specific effector, NS. Average ± standard deviation is shown. Wild-type and mutant 
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2.8.3. Hemizyous assays 
Plasmid transfections using the luciferase targets were performed using 
Lipofectamine 2000 (Invitrogen, RSA), according to manufacturer’s instructions 
with a total of 1μg of DNA in a 1:1 ratio of target:shRNA vector. Transfections for 
the hemizygous full-length target fluorescence assays were performed using 
jetPEI (Polyplus, Autogen Bioclear, UK) with a Nitrogen to Phosphate ratio (N/P) 
of 5, using a total of 2 μg of DNA in a 1:1 ratio of target:shRNA vector. All 
hemizygous assays were performed by seeding 1 x 105 cells in each well of a 
24-well plate.  
 
2.8.4. Heterozygous assays 
2.8.4.1. shRNA transfections 
The heterozygous assays were performed as above except for the following 
changes; 6-well plates were seeded with 2.5 x 105 cells per well with a total of 
6μg of DNA. In cases where target vectors were transfected separately for 
comparison in the heterozygous experiments, pU6TZ+1 was included to equate 
the total amount of DNA transfected to that in the co-transfections of both 
targets.  
 
2.8.4.2. miRNA transfections 
The heterozygous assays were performed in a 2:1 ratio of target to effector 
using 6-well plates and a total of 6μg of DNA. The change in the ratio was 
performed to overcome problems of promoter occlusion of the target and 
effector CMV promoters. The combination of two CMV expressing targets as 
well as a CMV expressing effector (in contrast to the Pol II promoter-expressing 
shRNAs) likely led to a saturation of Pol III machinery recruited by the various 
vectors thus resulting in reduced levels of target expression. In order to 
accurately measure the effectors of the miRNAs, target plasmid DNA was 
increased to increase levels of reporter expression which could be read by the 










  Chapter 2: Materials and Methods 
 67
comparison in the heterozygous experiments, miR-NS was included to equate 
the total amount of DNA transfected to that in the co-transfections of both 
targets. In addition, the addition of miR-NS allowed for accurate measurement 
since it contains the same CMV promoter as the other miRNAs.   
 
 
2.9. Luciferase assay 
For the purpose of this experiment, the luciferase assay was used to identify 
changes in mRNA levels of short targets tagged to luciferase reporter genes by 
measuring changes in luciferase activity. Using the target constructs shown in 
Figure 2.7 (page 60), expression of renilla luciferase can used to identify 
knockdown of the target (Figure 2.12), as well as then normalised to levels of 
firefly luciferase, resulting in easily replicable r sults. The activities of Renilla 
and firefly luciferase were measured with the Dual-Glo™ Luciferase Assay 
System (Promega, Whitehead Scientific, South Africa) and using the Veritas 
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2.10. Fluorescence assay 
2.10.1. Protein quantification 
All quantitative experiments were performed by normalising to 100 μg/ml of 
protein using the Micro BCA Protein Kit (Pierce, USA).  
 
2.10.2. Fluorimeter quantification 
Fluorescence was quantified using the Optima software program on an Optima 
FLUOSTAR fluorimeter. Average values are shown from experiments in 
biological triplicate with values from indicated U6/shRNA expression plasmids 
normalized to a miss-targeted shRNA expression plasmid set at 1. Error bars 
indicate variation between experiments as the standard deviation of the mean. 
For the hemizygous experiments; equivalent quantities of mock-transfected cells 
seeded in 24-well plates were used to subtract the background fluorescence. 
Both eGFP and DsRed have an excitation wavelength 489 nm and 556 nm 
respectively; and emission of 508 nm and 586 nm respectively (Clontech, 
Takara Bio, USA). In measuring the fluorescence dual assay of eGFP and 
DsRed an overlap can occur and influence the fluorescent measurements of 
both. In order to avoid the overlap of green and red fluorescence in a dual 
hemizygous assay two modifications were performed. Firstly the excitation and 
emission wavelengths for both proteins were adjusted to create minimal overlap, 
such that eGFP and dsRed were read at excitation wavelengths of 485 nm and 
544 nm respectively; and emissions of 520 nm and 590 nm respectively. 
Secondly because the overlap cannot be completely removed, equivalent 
quantities of cells transfected with 0.5 μg atxn7-10-G-eGFP + 1.5 μg of 
pTZU6+1 were used as the background values whilst reading through the red 
channel. Conversely, equivalent quantities of cells transfected with 0.5 μg atxn7-
100-A-dsRED + 1.5μg of pTZU6+1 were used as the background values whilst 
reading through the green channel. Hemizygous assays were measured at 48 
hours, while heterozygous assays were measured at 72 hours in order to 
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2.11. Aggregate counting assay 
Aggregate-containing cells were counted as previously reported (201) with the 
following modifications. Cells were co-transfected in triplicate as described in the 
heterozygous assay. Non-overlapping frames of live cells from each well were 
captured on an AxioVision Inc. microscope using the AxioVision 4.6.3 software 
after 72 hours. The sum of the total number of cells in three frames was 
calculated using a 40x objective. Cells with aggregates and those with dispersed 
patterns of expression were counted as a total of the three different frames of 
live cells. This was performed in triplicate with the mean representing the 
average number of that biological triplicate. It is noted that previous studies 
using the tagged vectors had shown that the reporter genes had no effect on the 
localisation and expression pattern of the ATXN7 protein (42). 
 
2.12. Confocal microscopy 
A Zeiss LSM 510 laser scanning confocal microscope was used. Images were 
taken with the 40X and 63X oil immersion objective lenses. The following filter 
sets were used: MBS NT 80/20 or HFT UV 488/543/633 with DBS NFT 490 or 
NFT 545 or mirror or none. An Argon laser at 488nm was used to excite eGFP, 
emission collected using 505 -550 nm band pass filter. A Helium-Neon laser was 
used to excite dsRed at 543 nm, emission collected using band pass 560nm – 
615nm. Representative images shown were analysed by the ZEISS LSM 4.1 
software.  
 
2.13. Statistical analysis  
Statistical analysis utilized two-tailed t-tests, unless otherwise stated. Statistical 
differences were considered significant when the two-tailed p value < 0.05 using 














3.1. Luciferase assay  
3.1.1. Single mismatches 
In order to identify RNAi effectors targeting the atxn7 SNP, multiple shRNAs 
were designed to place the weak G:U mismatch created against the wild-type 
transcript successively in positions 10 to 16 from the 5’ end of the shRNA guide 
strand (Figure 2.1, page 53). These predicted shRNAs were screened in a dual 
luciferase reporter assay (section 2.9, page 67) incorporating a short stretch (60 
nt) of either the mutant or the wild-type target gene sequence (Figure 2.7, page 
60). Mismatches at positions P11-P16 showed statistically significant (p<0.05) 
discrimination (Figure 3.1). Of these shRNAs, shR-P15 showed the greatest 
discrimination with the wild-type minimally affected at 90% and the mutant 
knocked down to nearly 55%, relative to a non-specific control. Mismatches 
placed at position 12 and 14 also showed a significant degree of selectivity with 
20 – 25 % discrimination between knockdown of the mutant and wild-type, 
although this selectivity was achieved with strong knockdown against both the 
mutant and the target with more than 50% knockdown against both targets. This 
is in contrast to the selectivity obtained using shR-P15, where neither target was 
reduced to less than 50%. Finally, hairpins shR-P11, -P13 and -P16 showed 
significant but minimal discrimination of approximately 10 – 15 %. Selective 
target knockdown was the least efficient at the central shR-P10 position where 
no significant selectivity was obtained. Interestingly, shR-P16 which showed little 
mutant-specific discrimination dramatically knocked down both wild-type and 
mutant targets indicating that the shRNA was highly tolerant of a single 


















Figure 3.1. Analysis of series of mismatched shRNA guide sequences targeting the 
G>A SNP in atxn7 in a dual luciferase assay. Relative levels of Renilla luciferase 
(hRluc) expression normalised to firefly luciferase (hFluc) expression. Each experiment 
was performed in triplicate and the data is relative to that measured using a non-
specific shRNA, NS. Average ± standard deviation is shown. Statistically significant 
differences (p<0.05) between wild-type and mutant silencing are indicated by 
corresponding p values. Relative expression of wild-type and mutant targets is 
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3.1.2. Double mismatches 
Given the weak nature of the atxn7 G:U nucleotide mismatch, efforts were made 
to enhance the level of wild-type:mutant discrimination by incorporating a 
secondary mismatch 3’ to the primary mismatch (Figure 2.2, page 54). This 
resulted in a weak A:C mismatch against both the mutant and the wild-type 
targets in addition to the G:U mismatch against the mutant, thus creating a 
double mismatch against the mutant in comparison to the single mismatch 
against the wild-type. The results of the dual luciferase screen showed that 
discrimination could not be improved beyond that achieved using the single 
mismatch at shR-P15 (Figure 3.2). The greatest discrimination achieved 
occurred using the double mismatch shR-P13P14, where enhancement of the 
10% selectivity obtained using the single mismatch at position 13 was increased 
to 25% with the addition of the second mismatch. This was the only position to 
show an enhancement of selectivity. While significant levels of discrimination 
were obtained for almost all the other positions, the levels were reduced or 
remained the same in each case. Furthermore the inclusion of these secondary 
mismatches resulted in decreased levels of discrimination at almost all positions 
tested, such that only two hairpins (shR-P10P11 and -P16P17) showed greater 
than 50% knockdown against both targets. However this abrogation of 
knockdown was minimal in the case of the double shR-P16P17 mismatch, which 














Figure 3.2. Analysis of secondary mismatched shRNA guide sequences targeting the 
G>A SNP in atxn7 in a dual luciferase assay. Relative levels of Renilla luciferase 
(hRluc) expression normalized to firefly luciferase (hFluc) expression. Each experiment 
was performed in triplicate and the data is relative to that measured using a non-
specific shRNA, NS. Average ± standard deviation is shown. Statistically significant 
differences (p<0.05) between wild-type and mutant silencing are indicated by 
corresponding p values. Relative expression of wild-type and mutant targets is 
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3.1.3. Additional mismatches 
Since the introduction of a double mismatch had been less successful in 
enhancing the initial discrimination obtained, further modifications were 
attempted. A secondary mismatch was incorporated immediately 3’ to the initial 
primary mismatch at position 15 as before. However the mismatch itself was 
designed to create greater destabilisation than the previous A:C combination by 
yielding a U:C mismatch (shR-P15P16’). Two further modifications were made 
to the P15 hairpins which including changing the nucleotide at this position from 
a U to an A or G, changing the nature of the primary mismatch itself. This 
resulted in an A:G mismatch to the wild-type corresponding with a G:G 
mismatch to the mutant (shR-P15A:G); and a G:G mismatch against the wild-
type corresponding with an A:G mismatch against the mutant target (shR-
P15G:G). Although the level of discrimination remained significant for all three of 
these positions, none led to discrimination greater than 10% and appeared to 
reduce the ability of the hairpin structures to exert knockdown (Figure 3.3).  
Further investigation into the tolerance of the mismatch at position 16 was also 
attempted. A secondary mismatch was placed 5’ to the original shR-P16 
mismatch yielding a C:U mismatch against both the mutant and the wild-type 
(shr-P16P15); in addition, a second hairpin was generated by placing additional 
mismatches on both 3’ and 5’  to the primary mismatch (shR-P16P15P17) 
(Figure 2.3, page 55). The results showed that neither hairpin was able to create 
enhanced discrimination (Figure 3.3). Interestingly, however, both hairpins 
retained the ability to exert strong knockdown approaching 80% against both 

















Figure 3.3. Analysis additional mismatched shRNA guide sequences targeting the G>A 
SNP in atxn7 in a dual luciferase assay. Relative levels of Renilla luciferase (hRLuc) 
expression normalized to firefly luciferase (hFLuc) expression. Each experiment was 
performed in triplicate and the data is relative to that measured using a non-specific 
shRNA, NS. Average ± standard deviation is shown. Statistically significant differences 
(p<0.05) between wild-type and mutant silencing are indicated by corresponding p 
values. Relative expression of wild-type and mutant targets is represented by red and 
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3.2. Full-length assay  
3.2.1. Hemizygous assay 
3.2.1.1. Single mismatches 
To replicate the SCA7 disease state with greater precision, shRNAs were tested 
against the full-length atxn7 gene fused to eGFP in a hemizygous cell system. 
The assay was performed using the HEK293 cell line which had been validated 
for this study by confirming minimal levels of endogenous atxn7 transcript in 
comparison to the transfected full-length transcripts (Materials and Methods, 
Figure 2.9, page 63). The results of this assay indicated that target knockdown 
was reduced across the panel of shRNAs in comparison to the knockdown seen 
in the luciferase assay (Figure 3.4). Again, shRNAs mismatched at shR-P12 and 
-P14 showed some level of selectivity (although not significant). However shR-
P15 showed no ability to knockdown either the full-length mutant or wild-type 
gene, contrasting with the results which showed selectivity in the luciferase 
assay. Surprisingly shR-P16, which showed the most effective knockdown 
against both targets in the luciferase assay and thus minimal discrimination, 
demonstrated the most selectivity against the full-length targets with minimal 





















Figure 3.4: Single mismatched shRNAs targeting the atxn7 G>A SNP in a full-length 
hemizygous assay. Quantitation of fluorescence in HEK293 cells transfected with wild-
type (atx7-10-G-eGFP) or mutant (atx7-100-A-eGFP) expression plasmids and the 
indicated shRNA. Each experiment was performed in triplicate and the data is relative 
to that measured using a non-specific shRNA, NS. The anti-eGFP shRNA, used was 
pE19; a published U6/shRNA expression plasmid targeting eGFP (200). Average ± 
standard deviation is shown. Statistically significant differences (p<0.05) between wild-
type and mutant silencing are indicated by corresponding p values Wild-type and 
mutant targets are represented by red and blue bars respectively. 
 
3.2.1.2. Double mismatches 
In a similar manner to P16 the double mismatch P16P17 showed moderate 
selectivity in the full-length target assay (Figure 3.5). In general, as was the case 
with the luciferase assay, the level of knockdown across the screen was 
reduced in comparison to the single mismatches to the point where none of the 
effectors demonstrated any ability to knock down the targets. However, E19, the 
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knockdown in both assays indicating that the assay accurately reflected 




Figure 3.5: Double mismatched shRNAs targeting the atxn7 G>A SNP in a full-length 
hemizygous assay. Quantitation of fluorescence in HEK293 cells transfected with wild-
type (atx7-10-G-eGFP) or mutant (atx7-100-A-eGFP) expression plasmids and the 
indicated shRNA. Each experiment was performed in triplicate and the data is relative 
to that measured using a non-specific shRNA, NS. The anti-eGFP shRNA, used was 
pE19; a published U6/shRNA expression plasmid targeting eGFP (200). Average ± 
standard deviation is shown. Statistically significant differences (p<0.05) between wild-
type and mutant silencing are indicated by corresponding p values Wild-type and 
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3.2.1.3.  Additional mismatches 
Since P16 had been shown to be the most effective hairpin in this assay, the 
previously mentioned modified versions of the primary mismatch hairpin were 
assessed in this assay in the hope that discrimination might be enhanced. 
Neither P16P15 which included shifting of the position of the secondary 
mismatch, nor P16P15P17 which incorporated additional mismatches showed 
any ability to selectively knockdown the mutant target (Figure 3.6). Indeed 
neither of these hairpins showed any ability to knockdown either target 
reinforcing the data from the luciferase assay.  
 
Figure 3.6: Additional mismatched shRNAs targeting the atxn7 G>A SNP in a full-length 
hemizygous assay. Quantitation of fluorescence in HEK293 cells transfected with wild-
type (atx7-10-G-eGFP) or mutant (atx7-100-A-eGFP) expression plasmids and the 
indicated shRNA. Each experiment was performed in triplicate and the data is relative 
to that measured using a non-specific shRNA, NS. The anti-eGFP shRNA, used was 
pE19; a published U6/shRNA expression plasmid targeting eGFP (200). Average ± 
standard deviation is shown. Statistically significant differences (p<0.05) between wild-
type and mutant silencing are indicated by corresponding p values. Wild-type and 
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3.2.2. Heterozygous assay 
A significant test of RNAi-based single nucleotide discrimination is to use a 
heterozygous system (169). Therefore a full-length assay was designed to 
measure levels of knockdown following co-transfection of both full-length wild-
type and mutant DNA encoding transcripts into HEK293 cells tagged to GFP 
and dsRED respectively. The P16 shRNA was chosen for study based on its 
high degree of target selectivity in the full-length hemizygous assay. The 
discriminatory effects seen with this shRNA were comparable to those in the 
earlier hemizygous full-length assay (Figure 3.7). Indeed, shR-P16 showed 
strong selectivity for the mutant target, efficiently knocking down the mutant to 
7% whilst minimally affecting the wild-type with knockdown at only 74% of the 
control levels (p<0.05). shR-P15 again showed minimal selectivity and 
knockdown against both targets reinforcing the results of the full-length 
hemizygous assay. The eGFP-specific hairpin showed specific and consistent 
knockdown of the wild-type target tagged to eGFP, with no ability to recognise 
and therefore knock down the mutant transcript tagged to dsRED demonstrating 
the specificity of this assay. Finally, shR-P15 showed similar results to that 
















Figure 3.7. shRNA targeting the atxn7 G>A SNP in a full-length heterozygous assay. A. 
Quantitation of fluorescence in HEK293 cells co-transfected with wild-type atx7-10-G-
eGFP and mutant atx7-100-A-dsRED expression plasmids and the indicated shRNA. 
Each experiment was performed in triplicate and the data is relative to that measured 
using a non-specific shRNA, NS. Average ± standard deviation is shown. Statistically 
significant differences (p<0.05) between wild-type and mutant silencing are indicated by 
using the one-tailed t-test. Wild-t pe and mutant targets are represented by green and 
red bars respectively. 
 
3.3. Study of aggregate formation 
3.3.1. Confocal images 
It is well documented that mutant polyglutamine proteins form aggregates which 
are associated with, if not directly causative of disease pathogenesis (202). In 
addition, it has been shown that mutant ATXN7 recruits wild-type ATXN7 into 
intracellular inclusion-like aggregates (42). In the process of performing the 
heterozygous assay, live cells were viewed using fluorescence microscopy prior 
to protein extraction to confirm fluorescent gene expression. To obtain more 
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expression of the mutant and wild-type protein. As has previously been 
demonstrated (42) the wild-type protein indicates a dispersed pattern of 
expression with minimal aggregate formation, while in contrast the mutant 
protein appears in the form of inclusion bodies or large aggregates (Figure 3.8). 
Co-transfection of both wild-type and mutant atxn7 genes replicates previously 
reported results (42) in that the wild-type protein co-localizes to these 
aggregates of mutant protein indicating recruitment of the wild-type protein by 
the mutant protein into the inclusions (Figure 3.9). However, with the 
introduction of the P16 hairpin, the remaining wild-type protein was observed to 
revert to the normal pattern of expression, and the number of intracellular 


















Figure 3.8. Representative confocal images of HEK293 cells from the heterozygous 
assay. Confocal images of cells transfected with (i, ii) mutant (atx7-100-A-dsRED) alone 
(iii, iv) wild-type (atx7-10-G-eGFP) alone; (i) Image visualized under red fluorescence 
(ii) red fluorescence merged with the bright field, (iii) green fluorescence and (iv) green 
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Figure 3.9. Representative confocal images of HEK293 cells from the heterozygous assay. Confocal images of cells co-
transfected with wild-type and mutant expression plasmids in addition to (i - iii) shR-NS or (iv - vi) shR-P16. (i) and (iv) show 
images under green fluorescence to reveal wild-type protein, (180) and (v) show images under red fluorescence to reveal 











   
  Chapter 3: Results 
 86
3.3.2. Aggregate counting assay 
In order to quantify whether the level of wild-type release from aggregation to a 
normal dispersed pattern of expression was significant, the number of cells 
containing aggregates or presenting a normal pattern of expression was counted 
following shRNA treatment and compared to that of the non-specific control 
(Figure 3.10). This data shows a substantial decrease in the number of cells 
expressing mutant aggregates in the presence of shR-P16, corroborating data 
from the fluorescent heterozygous assay. More importantly, these results further 
support the original observation that, not only does the combination of mutant 
and wild-type protein result in a significantly increased percentage of aggregates 
containing wild-type protein (p<0.05), but that treatment with shR-P16 promotes 
release of the wild-type protein to the dispersed distribution seen in cells 
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Figure 3.10. shRNA P16 reduces wild-type atxn7 aggregates in a heterozygous assay. 
Cells expressing eGFP and/or dsRED were counted according to whether they 
contained aggregates or a dispersed pattern of expression of mutant and wild-type 
ATXN7. Cells were transfected with wild-type target (atx7-10-G-eGFP) alone; mutant 
target (atx7-100-A-dsRED) alone; mutant (atx7-100-A-dsRED), wild-type (atx-10-G-
eGFP) and NS (non-specific shRNA); mutant, wild-type and shR-P16. Cells were 
counted separately in the red and the green filter by collecting 3 representative images 
from each well and combining the total number. This was performed for each indicated 
combination in biological triplicate, yielding standard deviations. The bars comprise the 
total number of cells counted in each transfection; separated according to whether they 
contained aggregates (blue) or a dispersed pattern of expression (grey). Note that the 
decrease in expression from target vectors transfected alone to co-transfected cells is 
likely to be a result of the promoter occlusion effect of co-expression of targets and not 
due to the addition of the shR-NS which has no effect upon the target vectors (Figure 
2.10, page 64). Statistically significant differences in % of aggregate containing cells are 
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3.4. miRNA assay 
3.4.1. Hemizygous assay 
Given that shRNAs have been shown to be toxic in vivo, effectors were 
constructed in a pri-miRNA based structure and screened in a full-length assay 
in order to identify an equivalent allele-specific effector in a format predicted to 
be less toxic (Figure 2.6, page 60). Due to the possibility of alternative 
processing of the two different types of effectors, multiple miRNAs were 
designed to incorporate this potential variation in the hope that one would mimic 
the mature shR-P16 guide strand. Thus miRNAs were screened in the same 
manner as previously described in a full-length hemizygous assay and tested 
simultaneously with the shR-P16 effector. Results show that miR-P16 is capable 
of discriminating as efficiently as shR-P16 (Figure 3.11). Indeed, miR-P16 
shows almost exactly the same levels of knockdown against the mutant and 
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Figure 3.11: miRNAs targeting the atxn7 G>A SNP in a full-length hemizygous assay. Quantitation of fluorescence in 
HEK293 cells transfected with wild-type (atx7-10-G-eGFP) or mutant (atx7-100-A-eGFP) expression plasmids and the 
indicated miR/ shRNA. Each experiment was performed in triplicate and the data is relative to that measured using a non-
specific shRNA, shR-NS or non-specific miRNA, miR-NS. The anti-eGFP shRNA, used was pE19; a published U6/shRNA 
expression plasmid targeting eGFP (200). Average ± standard deviation is shown. Statistically significant differences 
(p<0.05) between wild-type and mutant silencing are indicated by corresponding p values Wild-type and mutant targets are 
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3.4.2. Heterozygous assay 
To compare the efficiency of the miRNAs with the selective shR-P16 in a 
heterozygous system, the miRNAs were screened as previously outlined. 
The results indicate similarities between the selectivity obtained between the 
shR-P16 (Figure 3.7, page 82) and the miR-P16 (Figure 3.12) with the latter 
demonstrating the same ability to show increased selectivity in a 
heterozygous system. Remarkably, miR-P16 results in almost complete 
ablation of the mutant target (to less than 10%) with minimal effect on the 
wild-type (retaining 75% expression).   
 
Figure 3.12. miRNAs targeting the atxn7 G>A SNP in a full-length heterozygous 
assay. Quantitation of fluorescence in HEK293 cells co-transfected with wild-type 
atx7-10-G-eGFP and mutant atx7-100-A-dsRED expression plasmids and the 
indicated shRNA. Each experiment was performed in triplicate and the data is 
relative to that measured using a non-specific miRNA, miR-NS. Average ± standard 
deviation is shown. Statistically significant differences (p<0.05) between wild-type 
and mutant silencing are indicated. Wild-type and mutant targets are represented by 
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3.4.3. Ratio assay 
Given that the miRNA screen performed using the heterozygous assay 
resulted in allele-specificity at a 2:1 ratio of target:effector, an attempt was 
made to ascertain whether lower ratios of target:effector might still be 
effective. The hairpin shR-P16 maintained the previously established high 
level of allele-specificity with the wild-type minimally affected to over 80% 
relative to the non-specific control; while the mutant target was reduced to 
less than 10% expression (Figure 3.13). In comparison, the selectivity of 
miR-P16 was significantly reduced (Figure 3.14). Interestingly, while the level 
of knockdown of the wild-type remained the same as that at a 2:1 ratio at 
70%, the ability of the pri-miRNA-based hairpin to knockdown the mutant was 
drastically reduced, to the extent that 30% of the mutant target remained in 
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Figure 3.13. shRNAs targeting the atxn7 G>A SNP in a full-length heterozygous 
assay with decreased effector. Quantitation of fluorescence in HEK293 cells co-
transfected with wild-type atx7-10-G-eGFP and mutant atx7-100-A-dsRED 
expression plasmids and the indicated shRNA. Each experiment was performed in 
triplicate and the data is relative to that measured using a non-specific shRNA, shR-
NS. Average ± standard deviation is shown. Statistically significant differences 
(p<0.05) between wild-type and mutant silencing are indicated. Wild-type and 
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Figure 3.14. miRNA targeting the atxn7 G>A SNP in a full-length heterozygous 
assay with decreased effector. Quantitation of fluorescence in HEK293 cells co-
transfected with wild-type atx7-10-G-eGFP and mutant atx7-100-A-dsRED 
expression plasmids and the indicated shRNA. Each experiment was performed 
in triplicate and the data is relative to that measured using a non-specific 
miRNA, miR-NS. Average ± standard deviation is shown. Statistically significant 
differences (p<0.05) between wild-type and mutant silencing are indicated. Wild-




















In this study, the efficacy of RNAi hairpins to target the mutant atxn7 
transcript using a linked SNP, with the intention of ameliorating the 
pathogenicity of SCA7 in a cellular model was investigated. Using an 
extensive screen of various designs of expressed hairpins, multiple cellular 
models of target knockdown were tested. Comparisons of the short luciferase 
and full-length eGFP reporter assays led to conclusions regarding secondary 
structure. While the luciferase assay may be useful for mechanistic 
investigations, the full-length assay more accurately represents the 
endogenous gene response. Full-length heterozygous assays indicate that 
an allele-specific effector has been identified, which has little knockdown 
effect on the wild-type, and strong silencing of the mutant. Structural 
modifications of this effector to resemble a pri-miRNA structure yielded 
remarkably similar selectivity, which has importance in future work in that in 
vivo studies would require a non-toxic effector. Finally, hairpin selectivity in 
the heterozygous system indicated a further benefit of allele-specific silencing 
due to the reduction of total mutant protein causing reduced aggregate 
formation. Consequently, he wild-type protein is released into the more 
dispersed pattern of expression indicative of that observed with the normal 
protein alone.  
 
 
4.1. Mechanistic implications 
Effectors used to screen multiple positions of the SNP in order to obtain 
selectivity were based on the shRNA structure. Despite possible toxic effects 
in vivo (135), they are easy to design. Since they have been more 
extensively studied than miR-based hairpins, the rules governing their 
construction yield fairly predictable outcomes in terms of guide sequence 
production. They require only a single processing step by Dicer, pre-empting 
the complications of the Drosha, exportin-5, and Dicer processing that the 
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be in-accurate, they may not be recognized by Drosha, or be cut in 
alternative positions.  
 
In designing guide sequences several issues were taken into account, 
reviewed in the introduction. These include the position of the mismatch 
within the guide strand, the strength of the mismatch, and target accessibility 
(Figure 4.1, page 96). Secondary structure of the target region and the 
strength of the mismatch cannot be controlled, as these are defined by the 
single nucleotide change itself; however they should be taken into 
consideration as they have significant effects on the discrimination. Mismatch 
placement, however, can be modified; thus we were able to address this 
issue extensively. 
 
4.1.1. Mismatch placement 
In order to achieve selective target knockdown, a sequence change must be 
amenable to exploitation. Given that the nature of the mutation in 
polyglutamine disorders is not suitable for discrimination by a short RNA 
guide sequence, an alternative approach is required. Highly heterozygous 
SNPs present in the targeted transcripts can be used as an alternative for the 
mutation itself. In SCA7 patients in South Africa, it has already been 
demonstrated that one such SNP exists such that over 50% of the patients 
have been genotyped with an A and G allele on the mutant and wild-type 
transcripts respectively. This single nucleotide change was investigated as a 
template for selective silencing in this study.  
 
The question of where to position this single base pair change within the 
guide sequence of a predicted shRNA effector to achieve optimal selectivity 
in allele-specific RNAi is debatable and has been examined in various 
studies (Table 1.2, page 43). Traditionally, it has been hypothesised that 
centrally placed mismatches i.e. those placed near position 10 or 11, with 
position 1 being the first nucleotide of the 5’ end of the guide strand, allow for 
the greatest discrimination because they would interrupt the site of Ago2 















Figure 4.1: Aspects to consider in allele-specific silencing 
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transcriptional suppression in perfectly complementary sequences (124, 125) 
knockdown of the mismatched target would be avoided. However, the 
comprehensive study by Schwarz and colleagues (183) showed extensive 
evidence suggesting that mismatches in the 3’ region of guide strands could 
allow greater selectivity than those placed centrally. In addition, the same 
study indicated that while mismatches placed in the seed region result in 
discrimination, they did not yield the most efficient selectivity in a full screen 
of two different genes, indicating that interfering with catalysis rather than 
binding, would lead to greater discrimination (183). With the view to 
screening as many likely discriminating sequences as efficaciously as 
possible, we screened mismatches placed at positions 10 to 16 of the 3’ end 
of the guide strand, which Schwarz and colleagues had shown to have 
greatest selectivity in their screen. In contrast to the siRNAs investigated in 
the Schwarz study, expressed hairpins were used as effectors in the data 
presented here. Expressed hairpins are inexpensive in comparison to the 
RNA oligomers of siRNAs. Placement of a Pol III promoter upstream of these 
hairpin sequences allows for stable expression of these short sequences with 
specific termination without the requirement for complex termination 
regulatory sequence elements. For the purpose of addressing mechanistic 
issues, the initial part of this discussion will focus on the data obtained from 
the luciferase assay due to the reduced impact of secondary structure. It is 
acknowledged that expressed hairpins predicted to place mismatches at 
specific positions may yield heterozygous heterogeneous species, with the 
major species not representing the predicted mismatch. Thus it is 
emphasized that the observations made are based on predicted structure 
and not necessarily definitive. However, it is likely that should there be 
alternative species, they will be at most one or two nucleotides up or 
downstream of what is predicted. Further, given the extensive published 
studies using this design and the similarity of the results presented in this 
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Results from the luciferase assay, in which a short target sequence of 50 
nucleotides is tagged to the luciferase reporter gene, indicated various single 
mismatches placed 3’ to the centrally placed shR-P10 appear to be the 
discriminatory, including those at positions 12, 14, and 15. The single 
mismatches placed at positions 10 and 11 showed minimal selectivity 
conflicting with the hypothesis that interfering with the site of Ago2 cleavage 
at these positions leads to the greatest discrimination. Indeed, the results 
reinforce the Schwarz study suggesting an important role for the 3’ region of 
the guide strand (183). To date, no such role has been proposed. Current 
theories on the regional structure of guide sequences indicate an important 
role for the 5’ nucleotides of the guide, known as the seed region. This region 
has been shown to be essential in binding and recognition of the target 
sequence and have been shown in structural studies of Ago2 in Pyrococcus 
furiosus to directly interact with the slicer protein (203). Studies have shown 
that anchoring of the 5’ nucleotide of the guide strand to a binding pocket in 
the PIWI domain of Ago2 in Archaeoglobus fulgidus (204) leads to direct 
interaction of the seed region within a small groove of the PIWI domain due 
to the conserved positive charges of the latter interacting with the negative 
phosphate backbone of the RNA (203). A possible reason for the importance 
of the 3’ end may lie in the requirement of an alpha helix for slicer activity. 
Studies of Ago2 suggest that the PAZ domain which recognises the 3’ end of 
the guide strand may provide additional constraints on the dsRNA helix 
formation (205). Nucleotide interactions have previously suggested that 
mismatches within nucleic acid duplexes can be more stable if surrounded by 
strong G:C pairings, whereas weaker adjacent pairs such as A:U allow the 
mismatch to maintain its maximum destabilisation (206). Similarly, since the 
seed region is maintained within a tight small groove within the Piwi domain 
of Ago2, destabilising effects may be minimised, while in comparison, it has 
been suggested that the 3’ region bound to the target may extend into a less 
constrained region of Ago2, possibly even into solvent (204). Thus enabling 
even weak mismatches to create maximum local widening of the duplex 
preventing Ago2 slicing (207), possibly due to disruption of alpha-helix 
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has been shown to be essential for binding stability of the PAZ domain (208) 
Furthermore thermodynamic destabilisation has been shown to be less 
important than distortion of the helix to the point where A:C mismatches are 
more tolerated by Ago2 than G:U mismatches (207). If this is the case, it may 
explain why traditionally weak mismatches correctly placed in a specific 
region have such a strong effect on slicer efficiency.  
 
4.1.2. Nature of the mismatch 
Most studies based on a single nucleotide change have exploited 
purine:purine or pyrimidine:pyrimidine mismatches. In this study, the nature 
of the SNP resulted in a weak G:U mismatch between the wild-type target 
and the guide strand. As such, complete discrimination was unlikely to occur, 
although minimal selectivity has been demonstrated in other studies (Table 
1.2, page 43). The surprising selectivity of shR-P16, indicates that G:U 
wobbles can be used to discriminate, even though it is not considered a true 
mismatch due to the formation of a single hydrogen bond. This is likely in part 
due to the sequence context of the mismatch. It has been well established, 
from the complex nearest neighbour model used to identify thermodynamic 
differences within RNA hybrids, that different sequences surrounding the 
same mismatch significantly change the thermodynamic profile of the 
mismatch. Thus it is unlikely that every G:U mismatch will be amenable to 
selectivity. Only a few studies have looked at using G:U mismatches across 
different positions with varying degrees of success (Table 1.2, page 43). 
However, most acknowledge that some modifications of the guide sequence 
may be required to enhance selectivity. Not all of these studies have clearly 
defined positions, while they label a mismatch as being “central”, some have 
used alternative nomenclature such that a position 9 is in fact equivalent to 
position 12 from the 5’ end. One study has shown that a G:U mismatch at 
position 10 from the 5’ end of the guide strand leads to minimal selectivity 
(183). This corroborates the data presented in our study. However the same 
study did show significant selectivity at position 10 using a strong 
purine:purine mismatch. The notion of relaxed conformation leading to 
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selectivity obtained even with a G:U wobble. It is possible that strong 
mismatches lead to strong destabilisation even in tight small grooves, such 
as that where cleavage occurs thus resulting in the strong selectivity obtained 
both at positions 10 and 16. However, a weaker mismatch may be more 
easily constrained at the tight cleavage junction, minimising local widening of 
the duplex, and thus allowing slicing of the target.  
 
4.1.3. Modifications 
Given the nature of the weak mismatch, several attempts were made to 
enhance the level of selectivity identified in the 3’ region. Initial modifications 
included introducing a second mismatch immediately 3’ to the primary 
mismatch. This resulted in a single weak purine:pyrimidine (A:C) mismatch 
against the mutant, with two mismatches the A:C mismatch and the initial 
G:U mismatch against the mutant. Surprisingly, only one of the double 
mismatches resulted in selectivity greater than that achieved using the 
corresponding single mismatch; that of shR-P13P14. Other studies using 
weak (and strong) mismatches have shown that the addition of a secondary 
mismatch may enhance the selectivity by increasing the difference in 
destabilisation  (169, 170) (Table 1.2, page 43). Indeed a double mismatch at 
position 14 has previously been shown to enhance mismatch specificity with 
a weak G:U wobble against the normal tau transcript (169). The data 
presented in this thesis suggest that this is not always the case, and may 
reinforce the role of sequence context. The general abrogation of knockdown 
against both targets is not surprising given that additional mismatches are 
expected to hamper alpha helix formation, and therefore cleavage efficiency. 
However, further attempts to enhance selectivity were made by changing the 
position of the secondary mismatch in shR-P15 which had shown the 
greatest selectivity in the luciferase assay. The changes that were tested 
included, 
o shR-P15P16’: changing the nature of the secondary mismatch 
from a weak A:C to a stronger pyrimidine:pyrimidine U:C to 











  Chapter 4: Discussion 
 101
o shR-P15A:G: changing the nature of the primary mismatch. 
According to thermodynamics one of the most destabilizing 
mismatches possible is a purine:purine mismatch, in particular, 
A:G. Purine:purine mismatches are considered the strongest, 
because the strength of these bonds is decreased by 
incompatible hydrogen bonding positions (209, 210). 
Furthermore different purine: purine mismatches show different 
destabilisation, thus it may be possible to increase the 
difference in destabilisation such that, although there are single 
mismatches to both mutant and wild-type targets, the A:A 
mismatch to the mutant is less destabilizing than the A:G 
against the wild-type. The hypothesis is that the difference in 
destabilization between A:A and A:G may be greater than U:A 
and U:G and therefore possibly more discriminatory. 
o shR-P15G:G: changing the nature of the primary mismatch. 
Although the above rules are true stereotypically, mismatch 
destabilisation is sequence specific. However, it has been 
suggested that G:A mismatches might form ionic bonds and 
that tandem G:A pairs could well in fact stabilize RNA duplex 
structure (211, 212). As a result, it may be possible that G:A 
mismatches are more stable than A:A, or G:G mismatches. 
With that in mind another hairpin was created to yield a G:G 
mismatch with the wild-type, and a G:A with the mutant.  
 
Unfortunately, none of the modifications showed increased specificity for the 
wild-type. As was expected, the general level of knockdown against the 
mutant in all three hairpins was less than that of the perfectly complementary 
shR-P15 hairpin.   
 
While investigating the modifications of the selective shR-P15, an attempt 
was made to modify the strong shR-p16 effector in the hope that weakening 
the efficacy may lead to enhanced selectivity since this effector had 
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Placing the second mismatch on the 5’ side of the primary mismatch had no 
effect; while the introduction of a triple mismatch (shR-P16P15P17) released 
knockdown by less than 5%. The tolerance for a triple mismatch at this 
position is surprising given that two of these mismatches overlap with shR-
P15P16 which showed minimal knockdown efficiency in contrast to the lack 
of tolerance to a mismatch at this position in plant genes such as 
PHABULOSA  (79). However, it does reinforce the previous observation that 
a shift in a single base pair may have significant repercussions for allele-
specific knockdown.  
 
The use of the tagged reporter genes which may or may not confer 
differential secondary structure to the target region that are not present in 
endogenous atxn7 transcripts, as well as the use of expressed hairpins as 
opposed to siRNAs, may limit the ability to draw specific conclusions about 
the mechanisms involved in single nucleotide mismatch design. Short targets 
are more likely to yield accurate information regarding base by base rules, in 
that they negate the effects of secondary structure. Therefore most of the 
conclusions drawn in this study regarding mechanistic rules are taken from 
the luciferase assay. Comparisons of similar types of effectors are required to 
make assumptions regarding specific selective positions. Here, expressed 
hairpins which showed selectivity were identified at positions similar to the 
data presented in the Schwarz et al. 2006 study, i.e. positions 12, 14, and 15 
(183). These may not hold true for every sequence, given the nature of the 
mismatch and sequence context. Furthermore, expressed hairpins predicted 
to place the mismatch at each position may not be as specific as siRNAs 
used in the Schwarz et al 2006 screen. While every effort was made in the 
design of these hairpins to place the mismatches, studies have indicated that 
a heterogeneous species of guide strands may result from Dicer cleavage of 
the hairpin, such that shR-P15 may result in the presence of P13. P14, P15 
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4.1.4. Comparisons of short verses full-length 
hemizygous assays 
Given that the luciferase tagged assay had yielded results demonstrating 
successful allele-specificity, full-length targets were constructed to more 
accurately represent the effect on endogenous atxn7.  Comparisons of the 
short target luciferase and full-length assays indicated that the former failed 
to identify or predict the specific guide sequence with the highest degree of 
selectivity in the full-length assay. Knockdown was generally diminished from 
the luciferase assay to the full-length assay. Since full-length mRNA 
secondary structure can affect the efficiency of RISC-associated cleavage 
(213) these results are not surprising. Significant energy may be required to 
disrupt the target region in order to accommodate RISC binding resulting in 
decreased knockdown efficiency (213). Given this effect of secondary 
structure, it was still unexpected to observe th  distinct changes in efficient 
effectors, such as that of shR-P15. This hairpin had resulted in strong 
discrimination in the luciferase assay, while in the full-length assay, 
demonstrated no ability to knockdown either the mutant or the wild-type. A 
possible reason for this is that while shR-P15 had shown the highest 
selectivity, the levels of knockdown had been less efficient (remaining levels 
of expression at 90% for the wild-type and 55% for the mutant) than all the 
other single mismatch hairpins, most of which were able to show less than 
50% of remaining levels of both targets. The effect of secondary structure 
would thus i terfere with target binding to such an extent that knockdown of 
either the mutant or the wild-type was no longer possible, hence abolishing 
the resultant selectivity. The observation that all but one of the double 
mismatched hairpins, which had shown decreased knockdown but still limited 
selectivity, in the luciferase assay, now demonstrated no ability to knockdown 
either target in the full-length assay reinforces this theory. The converse of 
this hypothesis could be used to explain the resultant selectivity obtained 
using shR-P16 in the full-length assay. This hairpin had previously shown 
strong levels of knockdown against both targets in the luciferase assay, but 
became selective in the full-length assay. Secondary structure could reduce 
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mismatched wild-type target, while the perfectly matched mutant target 
duplex retained knockdown ability to a greater degree. Interestingly, the 
double mismatch, shR-P16P17, which had also shown strong knockdown of 
both targets in the luciferase assay, showed limited (although statistically 
insignificant) selectivity against the full-length targets and may represent a 
subtle replication of this hypothesis. 
 
Although the full-length target assay is likely to represent more accurately the 
endogenous system, the question of the repeat size should be taken into 
account. In this study, the wild-type allele contained 10 CAG repeats – the 
most common normal size in most populations (12, 22). The size of the 
expansion in SCA7 patients varies from over 39 to 406; in this study, only 
one mutant allele size was examined – at 100 repeats. To place this in 
context, as of 2003, the largest repeat size of SCA7 in South Africa was 
reported to be 92 repeats (90). Thus it could be argued that given the 
extensive evidence of an effect of target structure, a large change in the 
repeat size of the expanded allele may confer significant secondary structure 
alterations from one mutant allele to another, thus effecting selectivity. This 
may be the case with the SNP used to selectively target atxn3, located 
immediately 3’ to the SCA3 CAG repeat, (169). Furthermore, it may confer 
improved target accessibility to the wild-type allele, leading to unwanted 
selective knockdown of the wild-type, although this has yet to be shown. 
However, an advantage of the SNP used here, is the significant distance 
between the expansion and the SNP, with the former in exon 3 and the latter 
in exon 12, over 2.5kb away. Therefore, local secondary structure around the 
SNP is less likely to be affected by a change in the size of the expansion, 
and almost certainly not by a small change in the size of the normal allele.  
 
With reference to the full-length assays, It is noted that a lower than expected 
transfection efficiency of the full-length targets was observed as seen in 
Figure 3.8 and 3.9, page 84 and 85. One of the main reasons for this was 
thought to be the introduction of a fusion protein in cells which express the 
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transfection, several transfection reagents were tested. Only jetPEI (Polyplus, 
UK) showed reasonable levels of transfection efficiency. In addition, half of 
the total amount of DNA introduced into the cells included a non-specific 
shRNA expressing plasmid to ensure that the same amount of DNA, and 
ratio of target to transfection reagent was added to each well. Despite the low 
level of transfection, good standard deviations were achieved by using 
normalising to protein levels, thus validating the reliability of the assay.   
 
4.1.5. Strand bias 
In designing any effector, the aspect of strand bias should be taken into 
account. RISC has been shown to have the ability to incorporate both 
passenger and guide strands of a small RNA duplex. As a result, those 
effectors which lack the ability to knockdown both the mutant and the wild-
type target may not represent inefficient selectivity, but rather be due to the 
preferential incorporation of RISC of the passenger strand (117, 118). This 
could explain the lack of selectivity of some of the double mismatch hairpins, 
in particular shR-P11P12 and –P13P14. Both hairpins showed a significant 
decrease in knockdown of the wild-type gene to the point where silencing 
was completely removed. It is therefore possible that improved design 
incorporating enhanced duplex instability may result in increased 
incorporation of the guide, with an improvement in mutant knockdown, 
without significant effects on the wild-type. However, while the introduction of 
double mismatches at positions 12 and 14 (shR-P12P13 and –P14P15) 
resulted in decreased knockdown as well as decreased selectivity, silencing 
was not completely removed indicating that this is a true reflection of double 
mismatches unable to enhance selectivity. As such, it is likely that strand bias 
would reduce/ enhance levels of knockdown of both targets, and have little 
effect on the selectivity obtained. Furthermore, each hairpin in this 
investigation was designed with the intention of incorporating a 
thermodynamic signature, such that the duplex would be significantly 
destabilised using G:U wobble pairs in the 3’ end of the passenger strand, 
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4.1.6. Heterozygous assay 
In an attempt to replicate the cellular system, the knockdown efficiency of 
each of the effectors was investigated. In order to distinguish between levels 
of knockdown of mutant verses wild-type, the eGFP reporter from the full-
length mutant target was replaced with the dsRED reporter gene. The results 
of this assay corroborated well with that of the full-length hemizygous assay 
in that both shR-P16 and shR-P15 demonstrated either the ability or lack 
thereof to selectively knockdown the mutant target. Indeed shR-P16 showed 
significantly decreased levels of mutant relative to wild-type protein indicating 
strong silencing of the toxic protein with a difference of nearly 80% in 
selectivity. This was greater even than that observed in the hemizygous 
assays.  
 
The reasons for this increase in selectivity of the mutant are perplexing. 
Before suggesting mechanistic reasons for this enhancement the alteration in 
the assay itself should be addressed. Changes in levels of discrimination 
over short periods of time hours (1-2 hours (183)) and days (24 hours 
through to 72 hours; personal communication C. Sibley) have been 
observed. Although the heterozygous assay was performed at 72 hours in 
comparison to the hemizygous assay which was performed after 48 hours of 
transfection, 72 hour incubation of the hemizygous assay showed no 
increase in selectivity excluding the extended incubation as a possible 
reason for increased selectivity (comparison between shR-P16 in Figure 3.4, 
page 78 and 3.11, page 89; measured at 48 and 72 hours respectively).  
 
In addition, the possibility of a difference in mutant verses wild-type 
expression from the full-length targets has been examined. While the level of 
knockdown against the wild-type target remains the same from hemizygous 
to heterozygous conditions, it is the level of mutant expression which 
changes significantly from approximately 40% to 10%. Thus, the expression 
of the two different types of mutant target vectors could vary, with greater 
levels of expression with the eGFP tagged target, and lower levels with the 
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expression would significantly affect knockdown by a hairpin, since the 
eGFP-specific hairpin shows equal levels of knockdown against both mutant 
and wild-type targets in the hemizygous assay. Furthermore, a significant 
reduction is unlikely to be the cause in the heterozygous assay, since shR-
P15 shows the same effect on the hemi- and heterozygous assays. Although 
the same amount of target plasmid was added in each transfection, 
quantitative PCR indicates that there are some changes in the levels of target 
expression (A6, Appendix, page 138). The data indicates that the levels of 
expression of the mutant target tagged to eGFP are greater than the 
equivalent target tagged to dsRED in the heterozygous assay. Thus 
increased levels of mutant target in the hemizygous assay may contribute to 
the difference in hairpin selectivity of the mutant target. This indicates that the 
actual level of discrimination is likely to be greater than that indicated in the 
hemizygous assay. 
 
A second argument is that of altered secondary structure due to the dsRED 
in comparison with tagged eGFP, which were tagged to the 3’ end of the full-
length construct, thus less than 100 nucleotides from the SNP. That there is 
limited sequence homology between dsRED and eGFP (approximately 50%) 
suggests that this may contribute to altered selectivity in this assay. However, 
without knowing which reporter confers greater inaccessibility, if at all, little 
can be drawn from this theory. A possible way in which to test this hypothesis 
would be to switch reporter genes in the hemizygous assays. This may clarify 
whether the secondary structure effect proposed to cause changes in allele-
specific positions is created by the reporter tags or the length of the repeat. 
Additionally, it may be worthwhile to widen the target sequence from 60 nt in 
the luciferase assay, to assess the importance of proximity of local secondary 
structure. This would significantly add to the importance of this work by the 
creation of a predictable in vitro system. These surprising results do further 
reiterate the importance of choice of reporter genes.  
 
It is tempting to tentatively suggest that the reason for enhanced 
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the targets. To the best of our knowledge, no data has been produced to 
substantiate this hypothesis. Although the exact mechanism by which mature 
RISC finds the complementary target is not completely understood, this 
theory of competition is unlikely to be explained by active recruitment of the 
target for the shRNA. A model for target recognition has been proposed by 
Ameres and colleagues whereby activated RISC binds to single stranded 
RNA non-specifically, and cleavage depends on the thermodynamics of the 
complementary base pairing, where unfavourable base pairing results in 
dissociation of RISC (124). Indeed it is even suggested that this may facilitate 
the coming together of potential target sites for testing with the guide strand. 
Whatever the mechanism, if competition were the reason for the enhanced 
knockdown, it is likely that rather than the level of mutant knockdown 
increasing, the level of wild-type knockdown would be expected to decrease, 
such that guide strands in a heterozygous system would be preferentially 
bound to the mutant, and therefore less likely to act against the wild-type.  
 
It is possible that promoter occlusion has some effect in this matter. Given 
the strong nature of the CMV promoter expressing the targets, co-expression 
leads to reduced levels of both targets, resulting in an optimal threshold ratio 
of target to effector for selectivity. No matter what the explanation, it is clear 
that this effector has the ability to result in significant selectivity in 
heterozygous assay.  
 
4.1.7. miRNA formatted effectors 
It is now well established that shRNA effectors can lead to toxicity in vivo by 
the saturation of the endogenous miRNA pathway (135). However, pri-miR 
structured hairpins have been shown not to result in this toxic effect, due to 
their more endogenous structure, resulting in more efficient processing (214, 
215). In particular, the miR-122 shuttle has been shown to produce highly 
homogenous mature sequences of 21 bases in length as opposed to the 
heterogeneous products identified using the equivalent miR-31 shuttle (196). 
In designing a pri-miRNA, alternative processing by Drosha and Dicer was 
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place the mismatch against the wild-type at the same position as shR-P16 
showed the greatest selectivity in a full-length hemizygous assay. Indeed in 
an assay in which both shR-P16 and miR-P16 were tested simultaneously, 
the degree of knockdown of the mutant and wild-type targets is to all intent 
and purposes, exactly the same. Furthermore, the results of miR-P16 in a 
heterozygous assay reveal the same level of knockdown as shR-P16 with 
70% of the wild-type remaining and less than 10% of the mutant target. None 
of the other pri-miR hairpins demonstrated a similar reduction in mutant 
targeting, although the selectivity using miR-p14 became significant, albeit 
minimal. This suggests that the enhanced selectivity identified using both 
these effectors may be specific to the guide sequence used, rather than the 
solely due to the difference between the hemi- and heterozygous assays.  
 
In the absence of the use of a primer extension sequencing method of the 
guides themselves, the remarkable similarity of the data from heterozygous 
assays may indicate that the design of both hairpins is accurate in predicting 
the placement of the mismatch. At the very least, they are predicted to result 
in the same mismatch position. As has been discussed, the anchoring of the 
first nucleotide of the 5’ end of the guide defines the position of the guide 
strand within the groove between the Piwi and PAZ domains of Ago2, while 
the 3’ end is more loosely bound. This would allow for two effectors of 
approximately the same length (~21 nucleotides) to contain a mismatch at 
the same stereotypic position within the mature RISC complex. Thus, it is 
likely that the mismatch of these two effectors, which result in exactly the 
same selectivity in two different transfection conditions, must be placed in the 
same position relative to the first 5’ nucleotide in order to create the same 
destabilisation. Furthermore, observations of shR-P15 and miR-P15 in both 
full-length hemi- and heterozygous assays indicate that the pri-miR formatted 
hairpin performs better, with stronger knockdown efficiencies in both cases. 
This is in agreement with recent studies indicating that miRNAs are 
processed more efficiently, thus resulting in stronger knockdown; and further, 
that the use of a Pol II promoter prevents saturation of the endogenous 
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4.1.8. Reduced ratios of target to effectors 
Due to the issue of promoter occlusion created by the combination of three 
Pol II promoters in the pri-miRNA assay in a heterozygous state, the assay 
was performed using a ratio of 2:1 of target:effector, in contrast to all the 
other assays which had been performed at a 1:1 ratio. This allowed 
increased levels of target, in order to maximise the low level of target 
expression already discussed to obtain reliable data. Given that selectivity 
was achieved using less effector, an attempt was made to identify whether a 
lower ratio could result in the same specificity. It was hoped that this may 
indicate that reduced amounts of effector could maintain discrimination, 
translating into reduced amounts required in vivo. These experiments 
indicated that while shR-P16 maintained a high level of selectivity, miR-P16 
selectivity was moderately reduced. While this is not the result hoped for, it is 
not unexpected. shRNAs result in significantly higher levels of guide 
sequences in part due to the expression off a Pol III promoter. Thus, there 
may be excess guide, at a 1:1 ratio, such that at 5:1, enough effector 
remains. However, pri-miRNAs are already more economically regulated by 
expression from a Pol II promoter. Thus, the lower ratio may be below the 
threshold for optimal selectivity. In any event, these various conditions are 
more likely to be informative in vivo.  
 
 
4.2. Therapeutic implications of successful allele-
specific knockdown: aggregate removal  
The benefits of allele-specific knockdown in SCA7 are for the most part, 
conjectures. It is assumed that the function of the wild-type is required at the 
very least for retinal specific genes, such that additional loss of the one 
remaining wild-type allele even without the toxic gain of function of the 
expanded polyglutamine protein would result in a more severe retinal 
phenotype i.e. a full knockout model would be expected to have a retinal 
phenotype. Without data from in vivo investigations of loss-of-function of this 
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mutant aggregates (42) causes a loss-of-function contributing to 
pathogenesis and been discussed in the Introduction of this thesis. This was 
reiterated in the data presented here using confocal microscopy, where co-
expression of the mutant and wild-type targets indicated co-localisation of the 
mutant and wild-type protein. In the normal state, wild-type protein shows a 
dispersed pattern of expression, while the mutant protein aggregates into 
large inclusion-like bodies. It was observed that the introduction of an allele-
specific hairpin (shR-P16) resulted in decreased mutant aggregates, due to 
the reduced levels of mutant expression. As a result, the numbers of cells 
containing wild-type aggregates were also reduced. The protein however, 
appeared to retain the normal dispersed expression pattern seen when the 
wild-type was expressed alone, thus not as a result of decreased wild-type 
protein. This was quantified as being significant by counting the cells showing 
aggregate formation in comparison to those with dispersed expression. In the 
wild-type state, the ratio of aggregates to dis ersed cells is minimal. However 
with the addition of the mutant protein, the ratio shifts to a majority of cells 
showing aggregates of wild-type protein. The addition of the shRNA results in 
a significant change back to the normal state, such that the ratio of cells 
containing aggregates to dispersed expression in this condition is not 
significantly different from that in the normal state.  
 
Some studies suggest that inclusion formation is protective and thus 
inhibition of these aggregates may lead to detrimental effects (216). In our 
study it is important to note that the removal of large aggregates correlates 
with the associated removal of toxic mutant protein and thus is very likely to 
be beneficial. Furthermore we observed as a consequence of the reduction 
of mutant aggregate protein, the release of wild-type ATXN7 from aggregates 
to a distribution of expression resembling the pattern seen in the normal 
state. The importance of this lies in the fact that the function of the wild-type 
protein in transcription (50, 54, 55) may be retarded by this sequestration into 
aggregate formation. One of the advantages of the full-length assay used in 
this experiment is that eGFP has been shown not to interfere with the 
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dsRED reporter gene used in our investigation prevents formation of dsRED 
aggregates. Thus, localisation of the tagged wild-type protein is likely, even in 
this artificial system, to be representative of that occurring in the natural 
state, and that the aggregates that do form can only be as a result of the 
mutant ATXN7 protein, not the tagged reporter gene. As has been discussed, 
there are questions that remain regarding the contributing secondary 
structure of these reporter genes to atxn7 mRNA. It may be necessary to 
also investigate untagged ATXN7 levels, using Western blot analysis with an 
anti ATXN7 antibody indicating levels of total ATXN7 (both mutant and wild-
type) and a 1C1 antibody (specific for expanded polyglutamine tracts) to 
reveal levels of remaining mutant ATXN7. However this may not allow 
accurate comparisons of wild-type knockdown, which the fluorescent tags 
have accomplished.  
 
Given the striking change in the cellular distribution of wild-type ATXN7, it is 
expected to have a significant impact on the ability of the protein to perform 
its function. The in vivo implications could be quite extensive. One of the 
issues to consider is when an RNAi based allele-specific therapy should be 
started. Some studies of SCA7 mouse and drosophila models suggest that 
initiation of therapeutic intervention in the form of suppression of mutant 
protein must take place as early as possible; in order to precede what is likely 
to be a threshold point of irreversible damage. The question is therefore 
raised as to how early this is required, and importantly, what follows is the 
issue of what the effects of a long-term gene therapy would be? These 
questions will no doubt be answered eventually, but in the interim, can 
assumptions be made regarding the benefits of retaining the wild-type allele?  
The SCA7 models studied removed only the mutant protein, leaving the wild-
type for the most part intact, yet still, they indicated an early threshold level of 
toxicity. However, these studies used extreme expansion sizes with truncated 
mutant proteins and significantly high levels of expression of the mutant 
protein, thus creating drastic phenotypes unlikely to be representative of 
SCA7 patients with lower expanded repeat sizes – constituting the majority of 
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later in the human SCA7 condition, and that retaining the wild-type allele may 
lead to significant beneficial effects. A further argument for an allele-specific 
approach stems from the mild neurological phenotypes noted in knockout 
models, which may not accurately reflect the equivalent in humans, such that 
‘mild’ phenotypes may correlate to highly undesirable side-effects in human 
patients. Thus, as is the case with SCA1 (154), this may depend upon the 
severity of the symptoms, in that even mild symptoms that are apparently 
well-tolerated in a murine model may be undesirable in the human condition. 
  
As with the example of the redistribution of wild-type expression shown here, 
any therapy that can remove the mutant allele of a disease-causing dominant 
gene while retaining the endogenous functional allele would be ideal. 
However, finding a SNP linked to the disease in the polyglutamine disorders 
could prove difficult as is the case with HD. Interestingly, this difficulty is 
partly due to the heterogeneous populations studied. This is not the case in 
South Africa where the presence founder effects provide a more 
homogeneous patient cohort, and an increased opportunity of finding a single 
SNP that may be useful for a significant proportion of the group. Without this 
advantage, the mechanistic complexity involved in assembling an allele-
specific therapy may be too great. Therefore, it is noted that where not 
possible, general knockdown of the target gene, both wild-type and mutant, 
may delay onset of the disease to such a time, that significant quality of life 
may be allowed for those patients who have inherited the expansion. This is 
especially the case when taking into account the polyglutamine disorders, for 
which a significant delay and not necessarily total elimination of disease 
pathogenesis, may push the disease onset to beyond a natural life 
expectancy. Incomplete knockdown of both alleles may lead to sufficient wild-
type protein remaining to perform its function, and little enough mutant to 
delay the onset of progression to beyond the normal life expectancy resulting 
in a significant phenotypic benefit, originally suggested by Harper and 
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Although our data has not been tested in vivo, the release of the wild-type 
protein suggests that allele-specificity may show significant phenotypic 
advantages over a general knockdown approach of both alleles.  
 
 
4.3. Concluding remarks 
In summary, this study has identified an RNAi effector sequence that can 
selectively knockdown the expression of the disease-causing gene in SCA7 
patients. Extensive modifications to the design of the effector, as well as the 
various assays tested, indicate that allele-specific silencing using a weak G:U 
mismatch is attainable, but careful consideration must be made in this design 
and in the types of assays performed. While many hypotheses regarding the 
exploitation of single base pair changes can be drawn from the short target 
luciferase assay, it is likely that for the purposes of therapeutic approaches, 
full-length target assays should be tested to more accurately replicate the 
effects of the endogenous expression and sequence context. Further 
investigations of the effects of allele-specific silencing suggest that the 
additional benefit of removal of aggregates will release the wild-type protein 
to its normal expression pattern. It is likely that this reversal of a 
characteristic cellular polyglutamine phenotype will confer a significant 
advantage to allele-specific silencing in comparison to a general knockdown 
gene therapy approach. It is important to note that the unique macular 
degeneratio  phenotype of SCA7 model would provide an ideal model for 
studying the principle of allele-specific knockdown in patients with 
neurodegenerative disease. Given the data reported here, showing that even 
a moderate degree of mutant selectivity may have beneficial phenotypic 
effects through decreasing mutant aggregates and restoring wild-type protein 
to its native distribution pattern; such a study may have implications for 
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4.4. Future studies 
 
Many of the questions regarding the mechanistics of single nucleotide 
discrimination effector design have yet to be answered. Although these have 
less impact on the major direction of this work, they would none-the-less be 
of great value to the study of guide strand structure and RISC function and 
requirements.  Firstly, what other, if any, modifications could be incorporated 
to produce greater selectivity? Although extensive modifications were made 
in this study, screening the 5’ region may show additional selectivity. No 
screen of mismatches in the 5’ region of the guide strand has yet been 
performed using shRNAs, in particular targeting a G:U mismatch. Data from 
such an experiment would test the hypothesis that stronger structural 
constraints around the seed region transfer increased stability to mismatches 
by reducing local widening of the RNA duplex.   
 
Determining the exact species of the guide strand produced by the shRNAs 
and miRNAs would also contribute to a better understanding of expressed 
hairpin design. While primer extension may serve to identify these 
sequences, given the remarkably similar success with shR-P16 and miR-
P16, it is likely that our predictions are correct.  
 
A further aspect to consider would be the biological consequences of 
introduction of such effectors. There are multiple avenues to investigate here, 
including the effect of the vector, the presence of modified hairpin constructs 
on the endogenous RNAi machinery, and the off-target effects of the guide 
sequence on the expression of other genes. The ideal way in which to test 
these would be to look at gene expression changes within patient cell lines 
using expression based micro-arrays, though thorough consideration of 
interpretations of this type of experiment would be required given the plethora 
of changes that could be identified.  
 
The main focus of this study will now turn towards the therapeutic 
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advantages conferred by this approach. This is likely to require two different 
branches of investigation. Firstly, testing a primary cell line such as 
transformed lymphoblasts can be relatively easily obtained from SCA7 
patients with the correct heterozygous G>A genotype, thus, the effects of 
these effectors can be measured in patient cell lines. It is likely that this will 
require the construction of viral vector mediated transductions given the 
difficulty in transfecting this cell line. Western blot analysis would enable a 
clear evaluation of the level specific knockdown. In addition, levels of heat 
shock proteins could be investigated, given that these have been shown to 
be reduced in SCA7 lymphoblast cell lines (78). A return to normal levels 
may not necessarily indicate the direct involvement of these proteins in 
pathogenesis, but may be an indicator of a return to the normal state, as 
seen with the release of the wild-type protein from aggregates.  
 
More recently, the development of induced pluripotent stem (iPS) cell 
technology should allow for significantly improved patient-specific ex vivo 
cell-based investigations (217, 218). These and other studies indicate that 
fibroblasts from patients could be re-programmed into embryonic stem cells, 
differentiated into different cell types such as neurons, and investigated both 
for pathogenic mechanisms of disease, but also assessed for different 
therapeutic strategies. This would be particularly useful for polyglutamine 
disorders in that several aspects previously mentioned could be addressed, 
such as assessing the effect of different sizes of repeats as well as 
investigating the very cell types that degenerate.  
 
Finally, the acme of gene therapy investigations would be to investigate the 
amelioration of pathogenic phenotypes using in vivo mouse models of SCA7. 
An ideal model would include the use of the transgenic SCA7 mouse which 
has an expanded repeat sequence within one of the endogenous mouse 
alleles, such that the effects of general knockdown versus allele-specific 
knockdown could be investigated. Improved delivery using viral vectors such 
as lentivirus and AAV would need to be investigated. Extensive phenotypic 
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reference to the macular phenotype. Intra-ocular delivery of an efficient 
vector would be more conducive to assessment, given the well-established 
method of gene therapy to this organ, and the natural presence of an internal 
control in the untreated eye.  
 
In summary, the data from this study should pave the way for an ideal model 
system of investigating allele-specific silencing for the polyglutamine 
disorders. Although this has been applied to other polyglutamine disease 
models, the work described here represents the only study on SCA7 to date. 
Given the unique ocular involvement of SCA7, investigation of an allele-
specific approach for this disorder holds the greatest potential for the 












  References 
 118
References 
References have been listed in the format of Human Molecular Genetics journal.  
 
1. Menken, M., Munsat, T.L. and Toole, J.F. (2000) The global burden of disease 
study: implications for neurology. Arch Neurol, 57, 418-20. 
2. Bergen, D.C. and Silberberg, D. (2002) Nervous system disorders: a global 
epidemic. Arch Neurol, 59, 1194-6. 
3. Orr, H.T. and Zoghbi, H.Y. (2007) Trinucleotide repeat disorders. Annu Rev 
Neurosci, 30, 575-621. 
4. Lindblad, K., Savontaus, M.L., Stevanin, G., Holmberg, M., Digre, K., Zander, 
C., Ehrsson, H., David, G., Benomar, A., Nikoskelainen, E. et al. (1996) An 
expanded CAG repeat sequence in spinocerebellar ataxia type 7. Genome Res, 6, 
965-71. 
5. Rosenblatt, A., Brinkman, R.R., Liang, K.Y., Almqvist, E.W., Margolis, R.L., 
Huang, C.Y., Sherr, M., Franz, M.L., Abbott, M.H., Hayden, M.R. et al. (2001) 
Familial influence on age of onset among siblings with Huntington disease. Am J 
Med Genet, 105, 399-403. 
6. Shao, J. and Diamond, M.I. (2007) Polyglutamine diseases: emerging concepts in 
pathogenesis and therapy. Hum Mol Genet, 16 Spec No. 2, R115-23. 
7. Harding, A.E. (1993) Clinical features and classification of inherited ataxias. Adv 
Neurol, 61, 1-14. 
8. Duenas, A.M., Goold, R. and Giunti, P. (2006) Molecular pathogenesis of 
spinocerebellar ataxias. Brain, 129, 1357-70. 
9. Giunti, P., Stevanin, G., Worth, P.F., David, G., Brice, A. and Wood, N.W. 
(1999) Molecular and clinical study of 18 families with ADCA type II: evidence 
for genetic heterogeneity and de novo mutation. Am J Hum Genet, 64, 1594-603. 
10. Aleman, T.S., Cideciyan, A.V., Volpe, N.J., Stevanin, G., Brice, A. and 
Jacobson, S.G. (2002) Spinocerebellar ataxia type 7 (SCA7) shows a cone-rod 
dystrophy phenotype. Exp Eye Res, 74, 737-45. 
11. Garden, G.A. and La Spada, A.R. (2007) Molecular pathogenesis and cellular 
pathology of spinocerebellar ataxia type 7 neurodegeneration. Cerebellum, 1-12. 
12. Johansson, J., Forsgren, L., Sandgren, O., Brice, A., Holmgren, G. and 
Holmberg, M. (1998) Expanded CAG repeats in Swedish spinocerebellar ataxia 
type 7 (SCA7) patients: effect of CAG repeat length on the clinical 
manifestation. Hum Mol Genet, 7, 171-6. 
13. Benton, C.S., de Silva, R., Rutledge, S.L., Bohlega, S., Ashizawa, T. and Zoghbi, 
H.Y. (1998) Molecular and clinical studies in SCA-7 define a broad clinical 
spectrum and the infantile phenotype. Neurology, 51, 1081-6. 
14. Whitney, A., Lim, M., Kanabar, D. and Lin, J.P. (2007) Massive SCA7 
expansion detected in a 7-month-old male with hypotonia, cardiomegaly, and 











  References 
 119
15. van de Warrenburg, B.P., Frenken, C.W., Ausems, M.G., Kleefstra, T., Sinke, 
R.J., Knoers, N.V. and Kremer, H.P. (2001) Striking anticipation in 
spinocerebellar ataxia type 7: the infantile phenotype. J Neurol, 248, 911-4. 
16. Benomar, A., Krols, L., Stevanin, G., Cancel, G., LeGuern, E., David, G., 
Ouhabi, H., Martin, J.J., Durr, A., Zaim, A. et al. (1995) The gene for autosomal 
dominant cerebellar ataxia with pigmentary macular dystrophy maps to 
chromosome 3p12-p21.1. Nat Genet, 10, 84-8. 
17. David, G., Giunti, P., Abbas, N., Coullin, P., Stevanin, G., Horta, W., Gemmill, 
R., Weissenbach, J., Wood, N., Cunha, S. et al. (1996) The gene for autosomal 
dominant cerebellar ataxia type II is located in a 5-cM region in 3p12-p13: 
genetic and physical mapping of the SCA7 locus. Am J Hum Genet, 59, 1328-36. 
18. David, G., Abbas, N., Stevanin, G., Durr, A., Yvert, G., Cancel, G., Weber, C., 
Imbert, G., Saudou, F., Antoniou, E. et al. (1997) Cloning of the SCA7 gene 
reveals a highly unstable CAG repeat expansion. Nat Genet, 17, 65-70. 
19. Michalik, A., Del-Favero, J., Mauger, C., Lofgren, A. and Van Broeckhoven, C. 
(1999) Genomic organisation of the spinocerebellar ataxia type 7 (SCA7) gene 
responsible for autosomal dominant cerebellar ataxia with retinal degeneration. 
Hum Genet, 105, 410-7. 
20. Einum, D.D., Clark, A.M., Townsend, J.J., Ptacek, L.J. and Fu, Y.H. (2003) A 
novel central nervous system-enriched spinocerebellar ataxia type 7 gene 
product. Arch Neurol, 60, 97-103. 
21. Strom, A.L., Forsgren, L. and Holmberg, M. (2005) A role for both wild-type 
and expanded ataxin-7 in transcriptional regulation. Neurobiol Dis, 20, 646-55. 
22. David, G., Durr, A., Stevanin, G., Cancel, G., Abbas, N., Benomar, A., Belal, S., 
Lebre, A.S., Abada-Bendib, M., Grid, D. et al. (1998) Molecular and clinical 
correlations in autosomal dominant cerebellar ataxia with progressive macular 
dystrophy (SCA7). Hum Mol Genet, 7, 165-70. 
23. Alluri, R.V., Komandur, S., Wagheray, A., Chaudhuri, J.R., Sitajayalakshmi, 
Meena, A.K., Jabeen, A., Chawda, K., Subhash, K., Krishnaveni, A. et al. (2007) 
Molecular analysis of CAG repeats at five different spinocerebellar ataxia loci: 
correlation and alternative explanations for disease pathogenesis. Mol Cells, 24, 
338-42. 
24. Stevanin, G., David, G., Durr, A., Giunti, P., Benomar, A., Abada-Bendib, M., 
Lee, M.S., Agid, Y. and Brice, A. (1999) Multiple origins of the spinocerebellar 
ataxia 7 (SCA7) mutation revealed by linkage disequilibrium studies with closely 
flanking markers, including an intragenic polymorphism (G3145TG/A3145TG). 
Eur J Hum Genet, 7, 889-96. 
25. Nardacchione, A., Orsi, L., Brusco, A., Franco, A., Grosso, E., Dragone, E., 
Mortara, P., Schiffer, D. and De Marchi, M. (1999) Definition of the smallest 
pathological CAG expansion in SCA7. Clin Genet, 56, 232-4. 
26. Monckton, D.G., Cayuela, M.L., Gould, F.K., Brock, G.J., Silva, R. and 
Ashizawa, T. (1999) Very large (CAG)(n) DNA repeat expansions in the sperm 
of two spinocerebellar ataxia type 7 males. Hum Mol Genet, 8, 2473-8. 











  References 
 120
28. Trottier, Y., Biancalana, V. and Mandel, J.L. (1994) Instability of CAG repeats 
in Huntington's disease: relation to parental transmission and age of onset. J Med 
Genet, 31, 377-82. 
29. Yoon, S.R., Dubeau, L., de Young, M., Wexler, N.S. and Arnheim, N. (2003) 
Huntington disease expansion mutations in humans can occur before meiosis is 
completed. Proc Natl Acad Sci U S A, 100, 8834-8. 
30. Libby, R.T., Monckton, D.G., Fu, Y.H., Martinez, R.A., McAbney, J.P., Lau, R., 
Einum, D.D., Nichol, K., Ware, C.B., Ptacek, L.J. et al. (2003) Genomic context 
drives SCA7 CAG repeat instability, while expressed SCA7 cDNAs are 
intergenerationally and somatically stable in transgenic mice. Hum Mol Genet, 
12, 41-50. 
31. Hayden, M.R. (1981) Huntington's Chorea. Springer-Verlag, Berlin Heidelberg. 
32. La Spada, A.R., Roling, D.B., Harding, A.E., Warner, C.L., Spiegel, R., 
Hausmanowa-Petrusewicz, I., Yee, W.C. and Fischbeck, K.H. (1992) Meiotic 
stability and genotype-phenotype correlation of the trinucleotide repeat in X-
linked spinal and bulbar muscular atrophy. Nat Genet, 2, 301-4. 
33. Rub, U., Brunt, E.R., Gierga, K., Seidel, K., Schultz, C., Schols, L., Auburger, 
G., Heinsen, H., Ippel, P.F., Glimmerveen, W.F. et al. (2005) Spinocerebellar 
ataxia type 7 (SCA7): first report of a systematic neuropathological study of the 
brain of a patient with a very short expanded CAG-repeat. Brain Pathol, 15, 287-
95. 
34. Yamada, M., Sato, T., Tsuji, S. and Takahashi, H. (2008) CAG repeat disorder 
models and human neuropathology: similarities and differences. Acta 
Neuropathol, 115, 71-86. 
35. Holmberg, M., Duyckaerts, C., Durr, A., Cancel, G., Gourfinkel-An, I., Damier, 
P., Faucheux, B., Trottier, Y., Hirsch, E.C., Agid, Y. et al. (1998) 
Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with 
neuronal intranuclear inclusions. Hum Mol Genet, 7, 913-8. 
36. Chen, S., Peng, G.H., Wang, X., Smith, A.C., Grote, S.K., Sopher, B.L. and La 
Spada, A.R. (2004) Interference of Crx-dependent transcription by ataxin-7 
involves interaction between the glutamine regions and requires the ataxin-7 
carboxy-terminal region for nuclear localization. Hum Mol Genet, 13, 53-67. 
37. To, K.W., Adamian, M., Jakobiec, F.A. and Berson, E.L. (1993) 
Olivopontocerebellar atrophy with retinal degeneration. An electroretinographic 
and histopathologic investigation. Ophthalmology, 100, 15-23. 
38. Gouw, L.G., Digre, K.B., Harris, C.P., Haines, J.H. and Ptacek, L.J. (1994) 
Autosomal dominant cerebellar ataxia with retinal degeneration: clinical, 
neuropathologic, and genetic analysis of a large kindred. Neurology, 44, 1441-7. 
39. Kaytor, M.D., Duvick, L.A., Skinner, P.J., Koob, M.D., Ranum, L.P. and Orr, 
H.T. (1999) Nuclear localization of the spinocerebellar ataxia type 7 protein, 
ataxin-7. Hum Mol Genet, 8, 1657-64. 
40. Mushegian, A.R., Vishnivetskiy, S.A. and Gurevich, V.V. (2000) Conserved 
phosphoprotein interaction motif is functionally interchangeable between ataxin-











  References 
 121
41. Strom, A.L., Jonasson, J., Hart, P., Brannstrom, T., Forsgren, L. and Holmberg, 
M. (2002) Cloning and expression analysis of the murine homolog of the 
spinocerebellar ataxia type 7 (SCA7) gene. Gene, 285, 91-9. 
42. Zander, C., Takahashi, J., El Hachimi, K.H., Fujigasaki, H., Albanese, V., Lebre, 
A.S., Stevanin, G., Duyckaerts, C. and Brice, A. (2001) Similarities between 
spinocerebellar ataxia type 7 (SCA7) cell models and human brain: proteins 
recruited in inclusions and activation of caspase-3. Hum Mol Genet, 10, 2569-79. 
43. Taylor, J., Grote, S.K., Xia, J., Vandelft, M., Graczyk, J., Ellerby, L.M., La 
Spada, A.R. and Truant, R. (2006) Ataxin-7 can export from the nucleus via a 
conserved exportin-dependent signal. J Biol Chem, 281, 2730-9. 
44. Einum, D.D., Townsend, J.J., Ptacek, L.J. and Fu, Y.H. (2001) Ataxin-7 
expression analysis in controls and spinocerebellar ataxia type 7 patients. 
Neurogenetics, 3, 83-90. 
45. Cancel, G., Duyckaerts, C., Holmberg, M., Zander, C., Yvert, G., Lebre, A.S., 
Ruberg, M., Faucheux, B., Agid, Y., Hirsch, E. et al. (2000) Distribution of 
ataxin-7 in normal human brain and retina. Brain, 123 Pt 12, 2519-30. 
46. Jonasson, J., Strom, A.L., Hart, P., Brannstrom, T., Forsgren, L. and Holmberg, 
M. (2002) Expression of ataxin-7 in CNS and non-CNS tissue of normal and 
SCA7 individuals. Acta Neuropathol, 104, 29-37. 
47. Lebre, A.S., Jamot, L., Takahashi, J., Spassky, N., Leprince, C., Ravise, N., 
Zander, C., Fujigasaki, H., Kussel-Andermann, P., Duyckaerts, C. et al. (2001) 
Ataxin-7 interacts with a Cbl-associated protein that it recruits into neuronal 
intranuclear inclusions. Hum Mol Genet, 10, 1201-13. 
48. Matilla, A., Gorbea, C., Einum, D.D., Townsend, J., Michalik, A., van 
Broeckhoven, C., Jensen, C.C., Murphy, K.J., Ptacek, L.J. and Fu, Y.H. (2001) 
Association of ataxin-7 with the proteasome subunit S4 of the 19S regulatory 
complex. Hum Mol Genet, 10, 2821-31. 
49. Chai, Y., Koppenhafer, S.L., Shoesmith, S.J., Perez, M.K. and Paulson, H.L. 
(1999) Evidence for proteasome involvement in polyglutamine disease: 
localization to nuclear inclusions in SCA3/MJD and suppression of 
polyglutamine aggregation in vitro. Hum Mol Genet, 8, 673-82. 
50. La Spada, A.R., Fu, Y.H., Sopher, B.L., Libby, R.T., Wang, X., Li, L.Y., Einum, 
D.D., Huang, J., Possin, D.E., Smith, A.C. et al. (2001) Polyglutamine-expanded 
ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse 
model of SCA7. Neuron, 31, 913-27. 
51. Sohocki, M.M., Sullivan, L.S., Mintz-Hittner, H.A., Birch, D., Heckenlively, 
J.R., Freund, C.L., McInnes, R.R. and Daiger, S.P. (1998) A range of clinical 
phenotypes associated with mutations in CRX, a photoreceptor transcription-
factor gene. Am J Hum Genet, 63, 1307-15. 
52. Furukawa, T., Morrow, E.M., Li, T., Davis, F.C. and Cepko, C.L. (1999) 
Retinopathy and attenuated circadian entrainment in Crx-deficient mice. Nat 
Genet, 23, 466-70. 
53. Scheel, H., Tomiuk, S. and Hofmann, K. (2003) Elucidation of ataxin-3 and 
ataxin-7 function by integrative bioinformatics. Hum Mol Genet, 12, 2845-52. 
54. Helmlinger, D., Hardy, S., Sasorith, S., Klein, F., Robert, F., Weber, C., Miguet, 











  References 
 122
of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet, 13, 
1257-65. 
55. Palhan, V.B., Chen, S., Peng, G.H., Tjernberg, A., Gamper, A.M., Fan, Y., Chait, 
B.T., La Spada, A.R. and Roeder, R.G. (2005) Polyglutamine-expanded ataxin-7 
inhibits STAGA histone acetyltransferase activity to produce retinal 
degeneration. Proc Natl Acad Sci U S A, 102, 8472-7. 
56. Mauger, C., Del-Favero, J., Ceuterick, C., Lubke, U., van Broeckhoven, C. and 
Martin, J. (1999) Identification and localization of ataxin-7 in brain and retina of 
a patient with cerebellar ataxia type II using anti-peptide antibody. Brain Res 
Mol Brain Res, 74, 35-43. 
57. Latouche, M., Fragner, P., Martin, E., El Hachimi, K.H., Zander, C., Sittler, A., 
Ruberg, M., Brice, A. and Stevanin, G. (2006) Polyglutamine and polyalanine 
expansions in ataxin7 result in different types of aggregation and levels of 
toxicity. Mol Cell Neurosci, 31, 438-45. 
58. Ansorge, O., Giunti, P., Michalik, A., Van Broeckhoven, C., Harding, B., Wood, 
N. and Scaravilli, F. (2004) Ataxin-7 aggregation and ubiquitination in infantile 
SCA7 with 180 CAG repeats. Ann Neurol, 56, 448-52. 
59. Takahashi, J., Fujigasaki, H., Zander, C., El Hachimi, K.H., Stevanin, G., Durr, 
A., Lebre, A.S., Yvert, G., Trottier, Y., de The, H. et al. (2002) Two populations 
of neuronal intranuclear inclusions in SCA7 differ in size and promyelocytic 
leukaemia protein content. Brain, 125, 1534-43. 
60. Bowman, A.B., Yoo, S.Y., Dantuma, N.P. and Zoghbi, H.Y. (2005) Neuronal 
dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-
proteasome system impairment and inversely correlates with the degree of 
nuclear inclusion formation. Hum Mol Genet, 14, 679-91. 
61. Wheeler, V.C., White, J.K., Gutekunst, C.A., Vrbanac, V., Weaver, M., Li, X.J., 
Li, S.H., Yi, H., Vonsattel, J.P., Gusella, J.F. et al. (2000) Long glutamine tracts 
cause nuclear localization of a novel form of huntingtin in medium spiny striatal 
neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet, 9, 503-13. 
62. Wang, H.L., Yeh, T.H., Chou, A.H., Kuo, Y.L., Luo, L.J., He, C.Y., Huang, P.C. 
and Li, A.H. (2006) Polyglutamine-expanded ataxin-7 activates mitochondrial 
apoptotic pathway of cerebellar neurons by upregulating Bax and 
downregulating Bcl-x(L). Cell Signal, 18, 541-52. 
63. McMahon, S.J., Pray-Grant, M.G., Schieltz, D., Yates, J.R., 3rd and Grant, P.A. 
(2005) Polyglutamine-expanded spinocerebellar ataxia-7 protein disrupts normal 
SAGA and SLIK histone acetyltransferase activity. Proc Natl Acad Sci U S A, 
102, 8478-82. 
64. Riley, B.E., Zoghbi, H.Y. and Orr, H.T. (2005) SUMOylation of the 
polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear 
localization signal. J Biol Chem, 280, 21942-8. 
65. Xia, J., Lee, D.H., Taylor, J., Vandelft, M. and Truant, R. (2003) Huntingtin 
contains a highly conserved nuclear export signal. Hum Mol Genet, 12, 1393-
403. 
66. Ellerby, L.M., Andrusiak, R.L., Wellington, C.L., Hackam, A.S., Propp, S.S., 











  References 
 123
Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J 
Biol Chem, 274, 8730-6. 
67. Ellerby, L.M., Hackam, A.S., Propp, S.S., Ellerby, H.M., Rabizadeh, S., 
Cashman, N.R., Trifiro, M.A., Pinsky, L., Wellington, C.L., Salvesen, G.S. et al. 
(1999) Kennedy's disease: caspase cleavage of the androgen receptor is a crucial 
event in cytotoxicity. J Neurochem, 72, 185-95. 
68. Gafni, J., Hermel, E., Young, J.E., Wellington, C.L., Hayden, M.R. and Ellerby, 
L.M. (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: 
accumulation of calpain/caspase fragments in the nucleus. J Biol Chem, 279, 
20211-20. 
69. Kim, Y.J., Yi, Y., Sapp, E., Wang, Y., Cuiffo, B., Kegel, K.B., Qin, Z.H., 
Aronin, N. and DiFiglia, M. (2001) Caspase 3-cleaved N-terminal fragments of 
wild-type and mutant huntingtin are present in normal and Huntington's disease 
brains, associate with membranes, and undergo calpain-dependent proteolysis. 
Proc Natl Acad Sci U S A, 98, 12784-9. 
70. Garden, G.A., Libby, R.T., Fu, Y.H., Kinoshita, Y., Huang, J., Possin, D.E., 
Smith, A.C., Martinez, R.A., Fine, G.C., Grote, S.K. et al. (2002) Polyglutamine-
expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and 
displays proteolytic cleavage in ataxic transgenic mice. J Neurosci, 22, 4897-
905. 
71. Young, J.E., Gouw, L., Propp, S., Sopher, B.L., Taylor, J., Lin, A., Hermel, E., 
Logvinova, A., Chen, S.F., Chen, S. et al. (2007) Proteolytic cleavage of ataxin-7 
by caspase-7 modulates cellular toxicity and transcriptional dysregulation. J Biol 
Chem, 282, 30150-60. 
72. Helmlinger, D., Abou-Sleymane, G., Yvert, G., Rousseau, S., Weber, C., 
Trottier, Y., Mandel, J.L. and Devys, D. (2004) Disease progression despite early 
loss of polyglutamine protein expression in SCA7 mouse model. J Neurosci, 24, 
1881-7. 
73. Yvert, G., Lindenberg, K.S., Picaud, S., Landwehrmeyer, G.B., Sahel, J.A. and 
Mandel, J.L. (2000) Expanded polyglutamines induce neurodegeneration and 
trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. 
Hum Mol Genet, 9, 2491-506. 
74. Yvert, G., Lindenberg, K.S., Devys, D., Helmlinger, D., Landwehrmeyer, G.B. 
and Mandel, J.L. (2001) SCA7 mouse models show selective stabilization of 
mutant ataxin-7 and similar cellular responses in different neuronal cell types. 
Hum Mol Genet, 10, 1679-92. 
75. Opal, P. and Zoghbi, H.Y. (2002) The role of chaperones in polyglutamine 
disease. Trends Mol Med, 8, 232-6. 
76. Sakahira, H., Breuer, P., Hayer-Hartl, M.K. and Hartl, F.U. (2002) Molecular 
chaperones as modulators of polyglutamine protein aggregation and toxicity. 
Proc Natl Acad Sci U S A, 99 Suppl 4, 16412-8. 
77. Helmlinger, D., Bonnet, J., Mandel, J.L., Trottier, Y. and Devys, D. (2004) 
Hsp70 and Hsp40 chaperones do not modulate retinal phenotype in SCA7 mice. 











  References 
 124
78. Tsai, H.F., Lin, S.J., Li, C. and Hsieh, M. (2005) Decreased expression of Hsp27 
and Hsp70 in transformed lymphoblastoid cells from patients with 
spinocerebellar ataxia type 7. Biochem Biophys Res Commun, 334, 1279-86. 
79. Mallory, A.C., Reinhart, B.J., Jones-Rhoades, M.W., Tang, G., Zamore, P.D., 
Barton, M.K. and Bartel, D.P. (2004) MicroRNA control of PHABULOSA in 
leaf development: importance of pairing to the microRNA 5' region. Embo J, 23, 
3356-64. 
80. Abou-Sleymane, G., Chalmel, F., Helmlinger, D., Lardenois, A., Thibault, C., 
Weber, C., Merienne, K., Mandel, J.L., Poch, O., Devys, D. et al. (2006) 
Polyglutamine expansion causes neurodegeneration by altering the neuronal 
differentiation program. Hum Mol Genet, 15, 691-703. 
81. Merienne, K., Friedman, J., Akimoto, M., Abou-Sleymane, G., Weber, C., 
Swaroop, A. and Trottier, Y. (2007) Preventing polyglutamine-induced 
activation of c-Jun delays neuronal dysfunction in a mouse model of SCA7 
retinopathy. Neurobiol Dis, 25, 571-81. 
82. Gatchel, J.R., Watase, K., Thaller, C., Carson, J.P., Jafar-Nejad, P., Shaw, C., Zu, 
T., Orr, H.T. and Zoghbi, H.Y. (2008) The insulin-like growth factor pathway is 
altered in spinocerebellar ataxia type 1 and type 7. Proc Natl Acad Sci U S A, 
105, 1291-6. 
83. Custer, S.K., Garden, G.A., Gill, N., Rueb, U., Libby, R.T., Schultz, C., Guyenet, 
S.J., Deller, T., Westrum, L.E., Sopher, B.L. et al. (2006) Bergmann glia 
expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by 
impairing glutamate transport. Nat Neurosci, 9, 1302-11. 
84. Yoo, S.Y., Pennesi, M.E., Weeber, E.J., Xu, B., Atkinson, R., Chen, S., 
Armstrong, D.L., Wu, S.M., Sweatt, J.D. and Zoghbi, H.Y. (2003) SCA7 
knockin mice model human SCA7 and reveal gradual accumulation of mutant 
ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron, 37, 383-
401. 
85. Humphries, M.M., Rancourt, D., Farrar, G.J., Kenna, P., Hazel, M., Bush, R.A., 
Sieving, P.A., Sheils, D.M., McNally, N., Creighton, P. et al. (1997) Retinopathy 
induced in mice by targeted disruption of the rhodopsin gene. Nat Genet, 15, 
216-9. 
86. Latouche, M., Lasbleiz, C., Martin, E., Monnier, V., Debeir, T., Mouatt-Prigent, 
A., Muriel, M.P., Morel, L., Ruberg, M., Brice, A. et al. (2007) A conditional 
pan-neuronal Drosophila model of spinocerebellar ataxia 7 with a reversible 
adult phenotype suitable for identifying modifier genes. J Neurosci, 27, 2483-92. 
87. Storey, E., du Sart, D., Shaw, J.H., Lorentzos, P., Kelly, L., McKinley Gardner, 
R.J., Forrest, S.M., Biros, I. and Nicholson, G.A. (2000) Frequency of 
spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Australian patients with 
spinocerebellar ataxia. Am J Med Genet, 95, 351-7. 
88. Bird, T.D. (1998) Hereditary Ataxia Overview  
89. Jonasson, J., Juvonen, V., Sistonen, P., Ignatius, J., Johansson, D., Bjorck, E.J., 
Wahlstrom, J., Melberg, A., Holmgren, G., Forsgren, L. et al. (2000) Evidence 
for a common Spinocerebellar ataxia type 7 (SCA7) founder mutation in 











  References 
 125
90. Bryer, A., Krause, A., Bill, P., Davids, V., Bryant, D., Butler, J., Heckmann, J., 
Ramesar, R. and Greenberg, J. (2003) The hereditary adult-onset ataxias in South 
Africa. Journal of the neurological sciences, 216, 47-54. 
91. Greenberg, J., Solomon, G.A., Vorster, A.A., Heckmann, J. and Bryer, A. (2006) 
Origin of the SCA7 gene mutation in South Africa: implications for molecular 
diagnostics. Clin Genet, 70, 415-7. 
92. Meissner, P.N., Dailey, T.A., Hift, R.J., Ziman, M., Corrigall, A.V., Roberts, 
A.G., Meissner, D.M., Kirsch, R.E. and Dailey, H.A. (1996) A R59W mutation 
in human protoporphyrinogen oxidase results in decreased enzyme activity and is 
prevalent in South Africans with variegate porphyria. Nat Genet, 13, 95-7. 
93. Scholefield, J. and Greenberg, J. (2007) A common SNP haplotype provides 
molecular proof of a founder effect of Huntington disease linking two South 
African populations. Eur J Hum Genet, 15, 590-5. 
94. Napoli, C., Lemieux, C. and Jorgensen, R. (1990) Introduction of a Chimeric 
Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of 
Homologous Genes in trans. Plant Cell, 2, 279-289. 
95. van der Krol, A.R., Mur, L.A., Beld, M., Mol, J.N. and Stuitje, A.R. (1990) 
Flavonoid genes in petunia: addition of a limited number of gene copies may 
lead to a suppression of gene expression. Plant Cell, 2, 291-9. 
96. Pal-Bhadra, M., Bhadra, U. and Birchler, J.A. (1997) Cosuppression in 
Drosophila: gene silencing of Alcohol dehydrogenase by white-Adh transgenes 
is Polycomb dependent. Cell, 90, 479-90. 
97. Ratcliff, F., Harrison, B.D. and Baulcombe, D.C. (1997) A similarity between 
viral defense and gene silencing in plants. Science, 276, 1558-60. 
98. Fire, A., Albertson, D., Harrison, S.W. and Moerman, D.G. (1991) Production of 
antisense RNA leads to effective and specific inhibition of gene expression in C. 
elegans muscle. Development, 113, 503-14. 
99. Guo, S. and Kemphues, K.J. (1995) par-1, a gene required for establishing 
polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is 
asymmetrically distributed. Cell, 81, 611-20. 
100. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E. and Mello, C.C. 
(1998) Potent and specific genetic interference by double-stranded RNA in 
Caenorhabditis elegans. Nature, 391, 806-11. 
101. Clemens, M.J. (1997) PKR--a protein kinase regulated by double-stranded RNA. 
Int J Biochem Cell Biol, 29, 945-9. 
102. Hamilton, A.J. and Baulcombe, D.C. (1999) A species of small antisense RNA in 
posttranscriptional gene silencing in plants. Science, 286, 950-2. 
103. Caplen, N.J., Parrish, S., Imani, F., Fire, A. and Morgan, R.A. (2001) Specific 
inhibition of gene expression by small double-stranded RNAs in invertebrate and 
vertebrate systems. Proc Natl Acad Sci U S A, 98, 9742-7. 
104. Elbashir, S.M., Lendeckel, W. and Tuschl, T. (2001) RNA interference is 
mediated by 21- and 22-nucleotide RNAs. Genes Dev, 15, 188-200. 
105. Rana, T.M. (2007) Illuminating the silence: understanding the structure and 
function of small RNAs. Nat Rev Mol Cell Biol, 8, 23-36. 
106. Borchert, G.M., Lanier, W. and Davidson, B.L. (2006) RNA polymerase III 











  References 
 126
107. Han, J., Lee, Y., Yeom, K.H., Nam, J.W., Heo, I., Rhee, J.K., Sohn, S.Y., Cho, 
Y., Zhang, B.T. and Kim, V.N. (2006) Molecular basis for the recognition of 
primary microRNAs by the Drosha-DGCR8 complex. Cell, 125, 887-901. 
108. Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., 
Radmark, O., Kim, S. et al. (2003) The nuclear RNase III Drosha initiates 
microRNA processing. Nature, 425, 415-9. 
109. Lund, E., Guttinger, S., Calado, A., Dahlberg, J.E. and Kutay, U. (2004) Nuclear 
export of microRNA precursors. Science, 303, 95-8. 
110. Yi, R., Qin, Y., Macara, I.G. and Cullen, B.R. (2003) Exportin-5 mediates the 
nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev, 17, 3011-
6. 
111. Bernstein, E., Caudy, A.A., Hammond, S.M. and Hannon, G.J. (2001) Role for a 
bidentate ribonuclease in the initiation step of RNA interference. Nature, 409, 
363-6. 
112. Gonzalez-Alegre, P. and Paulson, H.L. (2007) Technology insight: therapeutic 
RNA interference--how far from the neurology clinic? Nat Clin Pract Neurol, 3, 
394-404. 
113. Macrae, I.J., Zhou, K., Li, F., Repic, A., Brooks, A.N., Cande, W.Z., Adams, 
P.D. and Doudna, J.A. (2006) Structural basis for double-stranded RNA 
processing by Dicer. Science, 311, 195-8. 
114. Hammond, S.M., Bernstein, E., Beach, D. and Hannon, G.J. (2000) An RNA-
directed nuclease mediates post-transcriptional gene silencing in Drosophila 
cells. Nature, 404, 293-6. 
115. Nykanen, A., Haley, B. and Zamore, P.D. (2001) ATP requirements and small 
interfering RNA structure in the RNA interference pathway. Cell, 107, 309-21. 
116. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. and Tuschl, T. (2002) 
Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell, 
110, 563-74. 
117. Khvorova, A., Reynolds, A. and Jayasena, S.D. (2003) Functional siRNAs and 
miRNAs exhibit strand bias. Cell, 115, 209-16. 
118. Schwarz, D.S., Hutvagner, G., Du, T., Xu, Z., Aronin, N. and Zamore, P.D. 
(2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell, 115, 
199-208. 
119. Matranga, C., Tomari, Y., Shin, C., Bartel, D.P. and Zamore, P.D. (2005) 
Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing 
RNAi enzyme complexes. Cell, 123, 607-20. 
120. Rand, T.A., Petersen, S., Du, F. and Wang, X. (2005) Argonaute2 cleaves the 
anti-guide strand of siRNA during RISC activation. Cell, 123, 621-9. 
121. Leuschner, P.J., Ameres, S.L., Kueng, S. and Martinez, J. (2006) Cleavage of the 
siRNA passenger strand during RISC assembly in human cells. EMBO Rep, 7, 
314-20. 
122. Valencia-Sanchez, M.A., Liu, J., Hannon, G.J. and Parker, R. (2006) Control of 
translation and mRNA degradation by miRNAs and siRNAs. Genes Dev, 20, 
515-24. 
123. Doench, J.G. and Sharp, P.A. (2004) Specificity of microRNA target selection in 











  References 
 127
124. Ameres, S.L., Martinez, J. and Schroeder, R. (2007) Molecular basis for target 
RNA recognition and cleavage by human RISC. Cell, 130, 101-12. 
125. Liu, J., Carmell, M.A., Rivas, F.V., Marsden, C.G., Thomson, J.M., Song, J.J., 
Hammond, S.M., Joshua-Tor, L. and Hannon, G.J. (2004) Argonaute2 is the 
catalytic engine of mammalian RNAi. Science, 305, 1437-41. 
126. Zeng, Y., Yi, R. and Cullen, B.R. (2003) MicroRNAs and small interfering 
RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci 
U S A, 100, 9779-84. 
127. Yekta, S., Shih, I.H. and Bartel, D.P. (2004) MicroRNA-directed cleavage of 
HOXB8 mRNA. Science, 304, 594-6. 
128. Brummelkamp, T.R., Bernards, R. and Agami, R. (2002) A system for stable 
expression of short interfering RNAs in mammalian cells. Science, 296, 550-3. 
129. Paddison, P.J., Caudy, A.A. and Hannon, G.J. (2002) Stable suppression of gene 
expression by RNAi in mammalian cells. Proc Natl Acad Sci U S A, 99, 1443-8. 
130. Zeng, Y. and Cullen, B.R. (2003) Sequence requirements for micro RNA 
processing and function in human cells. Rna, 9, 112-23. 
131. Zeng, Y., Wagner, E.J. and Cullen, B.R. (2002) Both natural and designed micro 
RNAs can inhibit the expression of cognate mRNAs when expressed in human 
cells. Mol Cell, 9, 1327-33. 
132. Zhou, H., Xia, X.G. and Xu, Z. (2005) An RNA polymerase II construct 
synthesizes short-hairpin RNA with a quantitative indicator and mediates highly 
efficient RNAi. Nucleic Acids Res, 33, e62. 
133. Silva, J.M., Li, M.Z., Chang, K., Ge, W., Golding, M.C., Rickles, R.J., Siolas, 
D., Hu, G., Paddison, P.J., Schlabach, M.R. et al. (2005) Second-generation 
shRNA libraries covering the mouse and human genomes. Nat Genet, 37, 1281-
8. 
134. Dickins, R.A., Hemann, M.T., Zilfou, J.T., Simpson, D.R., Ibarra, I., Hannon, 
G.J. and Lowe, S.W. (2005) Probing tumor phenotypes using stable and 
regulated synthetic microRNA precursors. Nat Genet, 37, 1289-95. 
135. Grimm, D., Streetz, K.L., Jopling, C.L., Storm, T.A., Pandey, K., Davis, C.R., 
Marion, P., Salazar, F. and Kay, M.A. (2006) Fatality in mice due to 
oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 441, 
537-41. 
136. Snove, O., Jr. and Rossi, J.J. (2006) Toxicity in mice expressing short hairpin 
RNAs gives new insight into RNAi. Genome Biol, 7, 231. 
137. Kay, M. (2008) Functional Evidence for Restricting MicroRNA Targets to the 3' 
Untranslated Region of mRNAs RNAi, MicroRNA, and Non-Coding RNA 
Whistler Resort, British Columbia, Canada. 
138. Caplen, N.J. (1998) Gene therapy: different strategies for different applications. 
American Society of Gene Therapy: First Annual Meeting, Seattle, Washington, 
USA, 28-31 May 1998. Mol Med Today, 4, 374-5. 
139. Smith, R.A., Miller, T.M., Yamanaka, K., Monia, B.P., Condon, T.P., Hung, G., 
Lobsiger, C.S., Ward, C.M., McAlonis-Downes, M., Wei, H. et al. (2006) 
Antisense oligonucleotide therapy for neurodegenerative disease. The Journal of 











  References 
 128
140. Hayashita-Kinoh, H., Yamada, M., Yokota, T., Mizuno, Y. and Mochizuki, H. 
(2006) Down-regulation of alpha-synuclein expression can rescue dopaminergic 
cells from cell death in the substantia nigra of Parkinson's disease rat model. 
Biochemical and biophysical research communications, 341, 1088-95. 
141. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. and Tuschl, 
T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in 
cultured mammalian cells. Nature, 411, 494-8. 
142. Hannon, G.J. and Rossi, J.J. (2004) Unlocking the potential of the human 
genome with RNA interference. Nature, 431, 371-8. 
143. Kim, D.H. and Rossi, J.J. (2007) Strategies for silencing human disease using 
RNA interference. Nat Rev Genet, 8, 173-84. 
144. Lingor, P. and Bahr, M. (2007) Targeting neurological disease with RNAi. Mol 
Biosyst, 3, 773-80. 
145. Rodriguez-Lebron, E. and Paulson, H.L. (2006) Allele-specific RNA interference 
for neurological disease. Gene Ther, 13, 576-81. 
146. Wood, M.J., Trulzsch, B., Abdelgany, A. and Beeson, D. (2003) Therapeutic 
gene silencing in the nervous system. Hum Mol Genet, 12 Spec No 2, R279-84. 
147. Saegusa, H., Wakamori, M., Matsuda, Y., Wang, J., Mori, Y., Zong, S. and 
Tanabe, T. (2007) Properties of human Cav2.1 channel with a spinocerebellar 
ataxia type 6 mutation expressed in Purkinje cells. Mol Cell Neurosci, 34, 261-
70. 
148. Jun, K., Piedras-Renteria, E.S., Smith, S.M., Wheeler, D.B., Lee, S.B., Lee, T.G., 
Chin, H., Adams, M.E., Scheller, R.H., Tsien, R.W. et al. (1999) Ablation of 
P/Q-type Ca(2+) channel currents, altered synaptic transmission, and progressive 
ataxia in mice lacking the alpha(1A)-subunit. Proc Natl Acad Sci U S A, 96, 
15245-50. 
149. Li, S.H. and Li, X.J. (2004) Huntingtin-protein interactions and the pathogenesis 
of Huntington's disease. Trends Genet, 20, 146-54. 
150. del Toro, D., Canals, J.M., Gines, S., Kojima, M., Egea, G. and Alberch, J. 
(2006) Mutant huntingtin impairs the post-Golgi trafficking of brain-derived 
neurotrophic factor but not its Val66Met polymorphism. J Neurosci, 26, 12748-
57. 
151. Nasir, J., Floresco, S.B., O'Kusky, J.R., Diewert, V.M., Richman, J.M., Zeisler, 
J., Borowski, A., Marth, J.D., Phillips, A.G. and Hayden, M.R. (1995) Targeted 
disruption of the Huntington's disease gene results in embryonic lethality and 
behavioral and morphological changes in heterozygotes. Cell, 81, 811-23. 
152. Dragatsis, I., Levine, M.S. and Zeitlin, S. (2000) Inactivation of Hdh in the brain 
and testis results in progressive neurodegeneration and sterility in mice. Nat 
Genet, 26, 300-6. 
153. Schmitt, I., Linden, M., Khazneh, H., Evert, B.O., Breuer, P., Klockgether, T. 
and Wuellner, U. (2007) Inactivation of the mouse Atxn3 (ataxin-3) gene 
increases protein ubiquitination. Biochem Biophys Res Commun, 362, 734-9. 
154. Matilla, A., Roberson, E.D., Banfi, S., Morales, J., Armstrong, D.L., Burright, 
E.N., Orr, H.T., Sweatt, J.D., Zoghbi, H.Y. and Matzuk, M.M. (1998) Mice 
lacking ataxin-1 display learning deficits and decreased hippocampal paired-











  References 
 129
155. van Roon-Mom, W.M., Reid, S.J., Faull, R.L. and Snell, R.G. (2005) TATA-
binding protein in neurodegenerative disease. Neuroscience, 133, 863-72. 
156. Ralser, M., Albrecht, M., Nonhoff, U., Lengauer, T., Lehrach, H. and Krobitsch, 
S. (2005) An integrative approach to gain insights into the cellular function of 
human ataxin-2. J Mol Biol, 346, 203-14. 
157. Kiehl, T.R., Nechiporuk, A., Figueroa, K.P., Keating, M.T., Huynh, D.P. and 
Pulst, S.M. (2006) Generation and characterization of Sca2 (ataxin-2) knockout 
mice. Biochem Biophys Res Commun, 339, 17-24. 
158. Thomas, P.S., Jr., Fraley, G.S., Damian, V., Woodke, L.B., Zapata, F., Sopher, 
B.L., Plymate, S.R. and La Spada, A.R. (2006) Loss of endogenous androgen 
receptor protein accelerates motor neuron degeneration and accentuates androgen 
insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy. 
Human molecular genetics, 15, 2225-38. 
159. Ambrose, C.M., Duyao, M.P., Barnes, G., Bates, G.P., Lin, C.S., Srinidhi, J., 
Baxendale, S., Hummerich, H., Lehrach, H., Altherr, M. et al. (1994) Structure 
and expression of the Huntington's disease gene: evidence against simple 
inactivation due to an expanded CAG repeat. Somat Cell Mol Genet, 20, 27-38. 
160. Fujigasaki, H., Uchihara, T., Koyano, S., Iwabuchi, K., Yagishita, S., Makifuchi, 
T., Nakamura, A., Ishida, K., Toru, S., Hirai, S. et al. (2000) Ataxin-3 is 
translocated into the nucleus for the formation of intranuclear inclusions in 
normal and Machado-Joseph disease brains. Exp Neurol, 165, 248-56. 
161. Uchihara, T., Fujigasaki, H., Koyano, S., Nakamura, A., Yagishita, S. and 
Iwabuchi, K. (2001) Non-expanded polyglutamine proteins in intranuclear 
inclusions of hereditary ataxias--triple-labeling immunofluorescence study. Acta 
Neuropathol, 102, 149-52. 
162. Lim, J., Crespo-Barreto, J., Jafar-Nejad, P., Bowman, A.B., Richman, R., Hill, 
D.E., Orr, H.T. and Zoghbi, H.Y. (2008) Opposing effects of polyglutamine 
expansion on native protein complexes contribute to SCA1. Nature, 452, 713-8. 
163. Kornberg, R.D. (2007) The molecular basis of eucaryotic transcription. Cell 
Death Differ, 14, 1989-97. 
164. Figueroa, K.P. and Pulst, S.M. (2003) Identification and expression of the gene 
for huma  ataxin-2-related protein on chromosome 16. Exp Neurol, 184, 669-78. 
165. Caplen, N.J., Taylor, J.P., Statham, V.S., Tanaka, F., Fire, A. and Morgan, R.A. 
(2002) Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-
mediated RNA interference. Hum Mol Genet, 11, 175-84. 
166. Harper, S.Q., Staber, P.D., He, X., Eliason, S.L., Martins, I.H., Mao, Q., Yang, 
L., Kotin, R.M., Paulson, H.L. and Davidson, B.L. (2005) RNA interference 
improves motor and neuropathological abnormalities in a Huntington's disease 
mouse model. Proc Natl Acad Sci U S A, 102, 5820-5. 
167. Xia, H., Mao, Q., Eliason, S.L., Harper, S.Q., Martins, I.H., Orr, H.T., Paulson, 
H.L., Yang, L., Kotin, R.M. and Davidson, B.L. (2004) RNAi suppresses 
polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. 
Nat Med, 10, 816-20. 
168. Davidson, B.L. (2008) RNAi and Neurodegenerative Diseases Keystone 












  References 
 130
169. Miller, V.M., Xia, H., Marrs, G.L., Gouvion, C.M., Lee, G., Davidson, B.L. and 
Paulson, H.L. (2003) Allele-specific silencing of dominant disease genes. Proc 
Natl Acad Sci U S A, 100, 7195-200. 
170. Feng, X., Zhao, P., He, Y. and Zuo, Z. (2006) Allele-specific silencing of 
Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or 
London mutations. Gene, 371, 68-74. 
171. Gonzalez-Alegre, P., Bode, N., Davidson, B.L. and Paulson, H.L. (2005) 
Silencing primary dystonia: lentiviral-mediated RNA interference therapy for 
DYT1 dystonia. J Neurosci, 25, 10502-9. 
172. Gonzalez-Alegre, P., Miller, V.M., Davidson, B.L. and Paulson, H.L. (2003) 
Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA. 
Ann Neurol, 53, 781-7. 
173. Li, Y., Yokota, T., Matsumura, R., Taira, K. and Mizusawa, H. (2004) Sequence-
dependent and independent inhibition specific for mutant ataxin-3 by small 
interfering RNA. Ann Neurol, 56, 124-9. 
174. Xia, X., Zhou, H., Huang, Y. and Xu, Z. (2006) Allele-specific RNAi selectively 
silences mutant SOD1 and achieves significant therapeutic benefit in vivo. 
Neurobiol Dis, 23, 578-86. 
175. Kubodera, T., Yokota, T., Ishikawa, K. and Mizusawa, H. (2005) New RNAi 
strategy for selective suppression of a mutant allele in polyglutamine disease. 
Oligonucleotides, 15, 298-302. 
176. O'Reilly, M., Millington-Ward, S., Palfi, A., Chadderton, N., Cronin, T., 
McNally, N., Humphries, M.M., Humphries, P., Kenna, P.F. and Farrar, G.J. 
(2008) A transgenic mouse model for gene therapy of rhodopsin-linked Retinitis 
Pigmentosa. Vision Res, 48, 386-91. 
177. Boutla, A., Delidakis, C., Livadaras, I., Tsagris, M. and Tabler, M. (2001) Short 
5'-phosphorylated double-stranded RNAs induce RNA interference in 
Drosophila. Curr Biol, 11, 1776-80. 
178. Elbashir, S.M., Martinez, J., Patkaniowska, A., Lendeckel, W. and Tuschl, T. 
(2001) Functional anatomy of siRNAs for mediating efficient RNAi in 
Drosophila melanogaster embryo lysate. Embo J, 20, 6877-88. 
179. Yu, J.Y., DeRuiter, S.L. and Turner, D.L. (2002) RNA interference by 
expression of short-interfering RNAs and hairpin RNAs in mammalian cells. 
Proc Natl Acad Sci U S A, 99, 6047-52. 
180. Holen, T., Amarzguioui, M., Wiiger, M.T., Babaie, E. and Prydz, H. (2002) 
Positional effects of short interfering RNAs targeting the human coagulation 
trigger Tissue Factor. Nucleic Acids Res, 30, 1757-66. 
181. Abdelgany, A., Wood, M. and Beeson, D. (2003) Allele-specific silencing of a 
pathogenic mutant acetylcholine receptor subunit by RNA interference. Hum 
Mol Genet, 12, 2637-44. 
182. Ding, H., Schwarz, D.S., Keene, A., Affar el, B., Fenton, L., Xia, X., Shi, Y., 
Zamore, P.D. and Xu, Z. (2003) Selective silencing by RNAi of a dominant 
allele that causes amyotrophic lateral sclerosis. Aging Cell, 2, 209-17. 
183. Schwarz, D.S., Ding, H., Kennington, L., Moore, J.T., Schelter, J., Burchard, J., 











  References 
 131
distinguish between genes that differ by a single nucleotide. PLoS Genet, 2, 
e140. 
184. Jackson, A.L., Bartz, S.R., Schelter, J., Kobayashi, S.V., Burchard, J., Mao, M., 
Li, B., Cavet, G. and Linsley, P.S. (2003) Expression profiling reveals off-target 
gene regulation by RNAi. Nat Biotechnol, 21, 635-7. 
185. Dahlgren, C., Zhang, H.Y., Du, Q., Grahn, M., Norstedt, G., Wahlestedt, C. and 
Liang, Z. (2008) Analysis of siRNA specificity on targets with double-nucleotide 
mismatches. Nucleic Acids Res, 36, e53. 
186. Martinez, L.A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchenio, T., 
Lozano, G. and Harel-Bellan, A. (2002) Synthetic small inhibiting RNAs: 
efficient tools to inactivate oncogenic mutations and restore p53 pathways. 
Proceedings of the National Academy of Sciences of the United States of 
America, 99, 14849-54. 
187. Brummelkamp, T.R., Bernards, R. and Agami, R. (2002) Stable suppression of 
tumorigenicity by virus-mediated RNA interference. Cancer Cell, 2, 243-7. 
188. Miller, V.M., Gouvion, C.M., Davidson, B.L. and Paulson, H.L. (2004) 
Targeting Alzheimer's disease genes with RNA interference: an efficient strategy 
for silencing mutant alleles. Nucleic Acids Res, 32, 661-8. 
189. Du, Q., Thonberg, H., Wang, J., Wahlestedt, C. and Liang, Z. (2005) A 
systematic analysis of the silencing effects of an active siRNA at all single-
nucleotide mismatched target sites. Nucleic Acids Res, 33, 1671-7. 
190. Dykxhoorn, D.M., Schlehuber, L.D., London, I.M. and Lieberman, J. (2006) 
Determinants of specific RNA interference-mediated silencing of human beta-
globin alleles differing by a single nucleotide polymorphism. Proc Natl Acad Sci 
U S A, 103, 5953-8. 
191. Hickerson, R.P., Smith, F.J., Reeves, R.E., Contag, C.H., Leake, D., Leachman, 
S.A., Milstone, L.M., McLean, W.H. and Kaspar, R.L. (2008) Single-nucleotide-
specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol, 
128, 594-605. 
192. Leung, R.K. and Whittaker, P.A. (2005) RNA interference: from gene silencing 
to gene-specific therapeutics. Pharmacol Ther, 107, 222-39. 
193. Bainbridge, J.W., Smith, A.J., Barker, S.S., Robbie, S., Henderson, R., Balaggan, 
K., Viswanathan, A., Holder, G.E., Stockman, A., Tyler, N. et al. (2008) Effect 
of gene therapy on visual function in Leber's congenital amaurosis. N Engl J 
Med, 358, 2231-9. 
194. Lee, N.S., Dohjima, T., Bauer, G., Li, H., Li, M.J., Ehsani, A., Salvaterra, P. and 
Rossi, J. (2002) Expression of small interfering RNAs targeted against HIV-1 rev 
transcripts in human cells. Nat Biotechnol, 20, 500-5. 
195. Baer, M., Nilsen, T.W., Costigan, C. and Altman, S. (1990) Structure and 
transcription of a human gene for H1 RNA, the RNA component of human 
RNase P. Nucleic Acids Res, 18, 97-103. 
196. Ely, A., Naidoo, T., Mufamadi, S., Crowther, C. and Arbuthnot, P. (2008) 
Expressed anti-HBV primary microRNA shuttles inhibit viral replication 
efficiently in vitro and in vivo. Mol Ther, 16, 1105-12. 
197. Castanotto, D., Li, H. and Rossi, J.J. (2002) Functional siRNA expression from 











  References 
 132
198. Campbell, R.E., Tour, O., Palmer, A.E., Steinbach, P.A., Baird, G.S., Zacharias, 
D.A. and Tsien, R.Y. (2002) A monomeric red fluorescent protein. Proc Natl 
Acad Sci U S A, 99, 7877-82. 
199. Graham, F.L., Smiley, J., Russell, W.C. and Nairn, R. (1977) Characteristics of a 
human cell line transformed by DNA from human adenovirus type 5. J Gen 
Virol, 36, 59-74. 
200. An, C.I., Trinh, V.B. and Yokobayashi, Y. (2006) Artificial control of gene 
expression in mammalian cells by modulating RNA interference through 
aptamer-small molecule interaction. Rna, 12, 710-6. 
201. Stenoien, D.L., Cummings, C.J., Adams, H.P., Mancini, M.G., Patel, K., 
DeMartino, G.N., Marcelli, M., Weigel, N.L. and Mancini, M.A. (1999) 
Polyglutamine-expanded androgen receptors form aggregates that sequester heat 
shock proteins, proteasome components and SRC-1, and are suppressed by the 
HDJ-2 chaperone. Hum Mol Genet, 8, 731-41. 
202. Janer, A., Martin, E., Muriel, M.P., Latouche, M., Fujigasaki, H., Ruberg, M., 
Brice, A., Trottier, Y. and Sittler, A. (2006) PML clastosomes prevent nuclear 
accumulation of mutant ataxin-7 and other polyglutamine proteins. J Cell Biol, 
174, 65-76. 
203. Song, J.J., Smith, S.K., Hannon, G.J. and Joshua-Tor, L. (2004) Crystal structure 
of Argonaute and its implications for RISC slicer activity. Science, 305, 1434-7. 
204. Parker, J.S., Roe, S.M. and Barford, D. (2005) Structural insights into mRNA 
recognition from a PIWI domain-siRNA guide complex. Nature, 434, 663-6. 
205. Heale, B.S., Soifer, H.S., Bowers, C. and Rossi, J.J. (2005) siRNA target site 
secondary structure predictions using local stable substructures. Nucleic Acids 
Res, 33, e30. 
206. Kierzek, R., Burkard, M.E. and Turner, D.H. (1999) Thermodynamics of single 
mismatches in RNA duplexes. Biochemistry, 38, 14214-23. 
207. Li, F., Pallan, P.S., Maier, M.A., Rajeev, K.G., Mathieu, S.L., Kreutz, C., Fan, 
Y., Sanghvi, J., Micura, R., Rozners, E. et al. (2007) Crystal structure, stability 
and in vitro RNAi activity of oligoribonucleotides containing the ribo-
difluorotoluyl nucleotide: insights into substrate requirements by the human 
RISC Ago2 enzyme. Nucleic Acids Res, 35, 6424-38. 
208. Ma, J.B., Ye, K. and Patel, D.J. (2004) Structural basis for overhang-specific 
small interfering RNA recognition by the PAZ domain. Nature, 429, 318-22. 
209. Miles, K., McAuliffe, L., Ayling, R.D. and Nicholas, R.A. (2004) Rapid 
detection of Mycoplasma dispar and M. bovirhinis using allele specific 
polymerase chain reaction protocols. FEMS Microbiol Lett, 241, 103-7. 
210. Ye, S., Dhillon, S., Ke, X., Collins, A.R. and Day, I.N. (2001) An efficient 
procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res, 
29, E88-8. 
211. Morse, S.E. and Draper, D.E. (1995) Purine-purine mismatches in RNA helices: 
evidence for protonated G.A pairs and next-nearest neighbor effects. Nucleic 
Acids Res, 23, 302-6. 
212. Tolbert, B.S., Kennedy, S.D., Schroeder, S.J., Krugh, T.R. and Turner, D.H. 











  References 
 133
the structural features that shape the thermodynamic stability of GA pairs. 
Biochemistry, 46, 1511-22. 
213. Shao, Y., Chan, C.Y., Maliyekkel, A., Lawrence, C.E., Roninson, I.B. and Ding, 
Y. (2007) Effect of target secondary structure on RNAi efficiency. Rna, 13, 
1631-40. 
214. McBride, J.L., Boudreau, R.L., Harper, S.Q., Staber, P.D., Monteys, A.M., 
Martins, I., Gilmore, B.L., Burstein, H., Peluso, R.W., Polisky, B. et al. (2008) 
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications 
for the therapeutic development of RNAi. Proceedings of the National Academy 
of Sciences of the United States of America, 105, 5868-73. 
215. Boudreau, R.L., Monteys, A.M. and Davidson, B.L. (2008) Minimizing variables 
among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA (New 
York, N.Y, 14, 1834-44. 
216. Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. and Finkbeiner, S. (2004) 
Inclusion body formation reduces levels of mutant huntingtin and the risk of 
neuronal death. Nature, 431, 805-10. 
217. Park, I.H., Zhao, R., West, J.A., Yabuuchi, A., Huo, H., Ince, T.A., Lerou, P.H., 
Lensch, M.W. and Daley, G.Q. (2008) Reprogramming of human somatic cells 
to pluripotency with defined factors. Nature, 451, 141-6. 
218. Dimos, J.T., Rodolfa, K.T., Niakan, K.K., Weisenthal, L.M., Mitsumoto, H., 
Chung, W., Croft, G.F., Saphier, G., Leibel, R., Goland, R. et al. (2008) Induced 
pluripotent stem cells generated from patients with ALS can be differentiated 
















A1. Basic PCR Cocktail and cycling conditions 
PCR was performed in 0.2ml tubes (Eppendorf, Merck) in a total volume of 25 μl 
containing 200 ng of DNA; 10 pmol of each primer; 0.2mM of each of the 4 
dNTPs (Bioline, Celtic Molecular Diagnostics, SA), 1 x PCR Buffer (Promega, 
Whitehead Scientific, SA); 0.5 Unit of Taq polymerase (Promega GoTaq, 
Whitehead Scientific, SA), made up with H2O. PCR was carried out on a Perkin 
Elmer DNA thermal cycler as follows: 
• 1 cycle of   95oC – 5 min 
• 30 cycles of   95oC – 30 sec 
50oC – 30 sec 
72oC – 40 sec 
• 1 cycle of   72oC – 7 min 
 
A2. Table of primers used for PCR 
Primer Sequence (5’ – 3’) 
G>A SNP_F TCCAATGAACTGCCTGTCAA 
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A3. Long reverse oligonucleotides required for cloning shRNAs 
Primer Sequence 5’ – 3’  
U6+1 GATCGTCGACAAGGTCGGGCAGGAAGAGGGCCT 
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A4. Long reverse oligonucleotides required for cloning miRNAs 
Primer Sequence 5’ – 3’  
miR-122 universal F GATACACTCGAGTGGAGGTGAAGTTAACACCTTCGTGGCTACAGAGTTTCCTTAGCAGAGCTG 
miR-122 universal R TGTATCGCGGCCGCAAGCAAACGATGCCAAGACATTTATCGAGGGAAGGATTGCCTAGCAGTAGCTA
miR-P14 F GTTTCCTTAGCAGAGCTGTGGACATTGTTCATGGCTGGCATGTCTAAACTATTG 
miR-P14 R CTAACGGATCGTCATCGATAGATGTAACACGTACCGACCGTTATCAAATCTGTAC 
miR-P15 F GTTTCCTTAGCAGAGCTGGTGGACATTGTTCATGGCTGGCTGTCTAAACTATGC 
miR-P15 R CTAACGGATCGTCATCGATCCGCTGTAACCAGTACCGACCGTATCAAATCTGTCG 
miR-P16 F GTTTCCTTAGCAGAGCTGTGTGGACATTGTTCATGGCTGGTGTCTAAACTATCC 
miR-P16 R CTAACGGATCGTCATCGATAACCCTGTAAGAAGTACCGACCTATCAAATCTGTGG 
miR-P17 F GTTTCCTTAGCAGAGCTGATGTGGACATTGTTCATGGCTGTGTCTAAACTATCA 
miR-P17 R CTAACGGATCGTCATCGATTCGACCTGTACCAAGTACCGACTATCAAATCTGTGT 
miR-P18 F GTTTCCTTAGCAGAGCTGCATGTGGACATTGTTCATGGCTTGTCTAAACTATAG 























A5. Oligonucleotides required for cloning target plasmids 







Oligonucleotide sequences used for 









Oligonucleotide sequences used for 










CTTGTGCCCCTGGGATGGTGCCTGTGTGTTTCATGTG   
Atx-A-s-F-p GATACAACTCGAGCAGCATC  
Atx-A-as-R-p TTGTATAAAGCTTGGGACGT  
Oligonucleotide sequences required 
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Figure A6: Levels of mutant atxn7 mRNA relative to wild-type. The top graph 
indicates an increased fold change of mutant target expression relative to the 
wild-type when the target is tagged to the eGFP. The bottom graph indicates 
that the level of mutant target when tagged to dsRED is slightly less relative 
to the levels of wild-type target. These experiments were performed in 

























“There is no medicine like hope. No incentive so great and no tonic so 
powerful as expectation of something new tomorrow. Janine, in your research, 
expect something new every day”  































“It is not enough that we do our best; 
sometimes we have to do what is required.” 
- Winston hurchill. 
 
